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Abstract 
With the rise of multi-drug resistant bacteria, there has been an increasing need 
for the development of novel antibacterials. A family of molecules that have 
consistently proved effective against bacteria are Cationic Antimicrobial 
Peptides. These peptides are found extensively in nature, unfortunately, except 
a few like Polymyxin B, are unsuitable for mass production and commercial use. 
Polymyxin B, one of the few CAMPs administered commercially is exceedingly 
toxic causing as much damage as the principal infection. 
This research project involved the design of small molecules that mimicked the 
essential characteristics of Cationic Antimicrobial Peptides. Previous research 
showed that the norbornane scaffold was an excellent motif as the rigidity of the 
structure ensured the segregation of hydrophobic and hydrophilic residues, a 
characteristic necessary for the amphiphilicity of a molecule. Furthermore, the 
norbornane scaffold proved easy to functionalise. The acetal was used to attach 
different hydrophobic residues and amides links the necessary hydrophilic 
functionality. 
 
Figure 1 – General structure of norbornane based CAMP mimics. 
The main goal of the current project was to synthesise two libraries of 
norbornane based mimics and have them tested for antibacterial activity. This 
was completed successfully and a selection of compounds was further evaluated 
using fluorescence spectroscopy, dynamic light scattering and isothermal 
titration calorimetry to elucidate a potential mode of action. 
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Plain English Summary 
In recent years, society has been increasingly concerned with bacteria that are 
no longer susceptible to commercial antibiotics. Faced with a lack of tools, 
medical practitioners today are forced to prescribe medicines that, although 
effective, cause as much harm to the patient as the principal infection. The 
purpose of this research project is to develop novel antibacterials that remain 
potent against bacterial infections without being toxic to the patient. 
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Chapter 1 
Introduction 
In this chapter, there is a brief discussion regarding the concerning issue of 
antibiotic resistance. The bacterial membrane is selected as an appropriate 
antibiotic target and a description of its important molecular features is 
provided. Cationic Antimicrobial Peptides (CAMPs), their different 
classifications and modes of action are elaborated. Polymyxin B is utilised as a 
case study to convey how CAMPs potentially act when targeting the bacterial 
membrane. From there, a suitable pharmacophore is identified and examples 
of synthetically derived CAMP mimics highlighted. Finally, the aims of the 
current project are outlined.  
1.1 Antibiotic pipeline 
When antibiotics were first discovered, they were heralded as ‘miracle drugs’.1 
However as Alexander Fleming himself warned  
“The time may come when penicillin can be bought by 
anyone in the shops. Then, there is the danger that the 
ignorant man may easily underdose himself and by 
exposing his microbes to non-lethal quantities of the drug 
make them resistant” (Alexander Fleming, Nobel lecture, 
1945).2  
With uncanny foresight, he predicted a scenario that has now come to fruition. 
Decades of overuse and misuse have caused a global epidemic where bacteria 
have become resistant to most antibiotics.1, 3, 4  
 
2 
 
 
 
 
Figure 2 – A graph comparing the increasing resistance of Methicillin-resistant 
Staphylococcus Aureus (MRSA), Vancomycin Resistant Enteroccoci (VRE) and 
Fluoroquinolone-Resistant Pseudomonas Aeruginosa (FQRP) against the 
decreasing number of antibiotics approved over 30 years. Also highlighted is 
the decreasing numbers of companies researching antibiotics.5, 6 
Antibacterial resistance typically occurs within hospitals where antibiotics are 
administered as a preventative measure against post-surgery bacterial 
infections.4, 7, 8 Such medical practices have led to the evolution of Multiple Drug 
Resistant (MDR) bacteria, also known as ‘superbugs’. Examples of MDR bacteria 
and their growing resistance are documented in Figure 2. The prevalence of 
Methicillin-Resistant Staphylococcus Aureus (MRSA) has grown to more than 
60% of clinical isolates. Hospital patients who contract infections from MDR 
bacteria (nosocomial infections) are difficult to treat and consequently, there 
has been a rise in morbidity.5, 9-15 In 1995, an estimated two million people in 
the United States acquired nosocomial infections and ninety thousand died as a 
result.4, 16-18 MDR bacterial infections are no longer confined to hospitals as 
incidences are now being detected within the wider community.16 
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Figure 3 – Compounds under clinical evaluation in 2011 divided into different 
development phases.19  
Contrary to the current health emergency and the obvious need for new 
antibiotics, pharmaceutical companies have decreased their efforts in the search 
for novel antibacterials.5, 6 The number of companies researching antibiotics has 
decreased from eighteen in 1993 to four in 2010 (Figure 2).6 There has also 
been a high attrition rate of compounds undergoing clinical evaluation (Figure 
3). In 2011, there were twenty-two compounds in phase II, five compounds in 
Phase III and only one compound where a New Drug Application was filed (last 
step before commercialisation).19 - 
With a dwindling number of therapeutic options, medical practitioners are 
being forced to reconsider the viability of drugs such as Polymyxin B and 
Colistin (Polymyxin E). Although effective, these fell out of use decades ago due 
to toxicity concerns.7, 20 Both Polymyxin B and Colistin have been known to 
cause neurotoxicity, nephrotoxicity and respiratory failure.9, 21, 22 Unfortunately, 
medical practitioners have to ignore side effects and follow strict guidelines for 
administering these antibiotics in an effort to treat patients suffering from life 
threatening bacterial infections.8, 14, 23 
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1 2 
In summary, there is a very real need for the development of novel antibacterial 
agents.20, 24, 25 A more detailed examination of antibiotics and the current 
antibiotic ‘crisis’ is needed before elaborating on the goal of the current project. 
1.2 Antibiotics 
1.2.1 Definitions 
Antimicrobial is a general term for any substance that either kills or slow the 
growth of microbes.12 An antibiotic is a type of antimicrobial that is effective 
against bacteria and fungi but not against viruses.12 If classified as 
bacteriostatic, the antibiotic stops bacteria from growing. If classified as 
bactericidal, it causes bacteria death.24 Antibiotics can be natural products or 
the result of synthesis. More commonly, they are produced through the 
synthetic alterations of natural products.12 
1.2.2 History 
World War One had a profound influence on the field of medicinal chemistry. 
With bacterial infections a cause of large numbers of fatalities amongst 
wounded soldiers, the search for treatment was accelerated.  
 
Figure 4 – (a) Prontosil (1). (b) Penicillin G (2).26, 27 
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In 1932, Gerhard Johannes Paul Domagk, Fritz Mietzsch and Josef Klarer were 
credited for the discovery of Prontosil 1, a synthetic antibacterial developed by 
a pharmaceutical research program under the Friedrich Bayer Company (Figure 
4a).26  
Alexander Fleming’s discovery of penicillin was somewhat serendipitous. In 
1928, he noticed that a mould growing on a laboratory plate was surrounded by 
a large zone of inhibition repelling staphylococcal bacteria growing alongside.2, 
12 Fleming found that the mould was of the genus Penicillium. He proceeded to 
then test it against other bacterial strains such as streptococcus, Bacillus 
diphtherice and Bacillus typhosus and the mould repelled some bacteria but not 
all. His most important deduction was the mould was effective against microbes 
that were responsible for many of the common infections in society back then. 
Ten years after publishing his findings, Fleming provided his strain of 
Penicillium notatum to Ernst Chain and Howard Florey who succeeded in 
isolating the substance known as penicillin G (2) from the mould (Figure 4b).2 
The discovery of these antibiotics (Prontosil and penicillin) is widely accepted 
as one of modern medicine’s greatest achievements.1, 12 
1.2.3 Resistance 
When a new antimicrobial begins clinical use, the manifestation of resistance is 
imminent. Cases of resistance against antibiotics such Erythromycin and 
Linezolid were reported after only one year of being prescribed in clinics (Table 
1).4, 28 Vancomycin was used commercially for almost fifteen years before the 
first case of resistance emerged. Although the effective life time of antibiotics 
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may vary, one thing is certain: once used in clinics, bacterial isolates exhibiting 
resistance against the antibiotic will emerge.4 
Table 1 – A comparison of when an antibiotic is discovered, introduced into 
clinical circulation and when resistant bacteria are first detected.4 
Antibiotic Discovered Introduced in clinic 
Emergence of 
resistance 
Penicillin 1940 1943 1940 (methicillin, 1965) 
Streptomycin 1944 1947 1947, 1956 
Chloramphenicol 1947 1949 1970 
Tetracycline 1948 1952 1956 
Erythromycin 1952 1955 1956 
Gentamicin 1963 1967 1970 
Vancomycin 1956 1972 1987 
TMP/SMX 1969 1973 1979 
Ciprofloxacin 1980 1987 1992 
Linezolid 1990 2000 2001 
Telithromycin 1997 2001 2003 
Quinupristin/Dalfopristin 1999 2000 2000 
Daptomycin 1980 2003 2004 
Antibiotic resistance exhibited by Gram-positive bacteria began in the 1950s 
when penicillin G (2) proved ineffective against some Staphylococcus aureus 
infections.29 Since then, penicillin-resistant Staphylococcus aureus has become 
the most common Gram-positive pathogen in clinics and is the leading cause of 
skin, bloodstream and bone and joint infections (Figure 5).29, 30 Each year in the 
USA, four hundred thousand people are admitted to hospital for Staphylococcus 
aureus infections with nineteen thousand people dying in hospital.29, 31  
 
 
Figure 5 – Number of antibiotic resistant bacterial isolates collected from 
clinical specimens from January 1998 to June 2003.5, 30 
Although receiving much less attention than Gram-positive bacteria, experts 
now agree that Gram-negative bacteria are of more concern being responsible 
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for more than half of all bacterial infections and acquiring resistance at much 
faster rates.32 The faster rate at which Gram-negative bacteria develop 
resistance is demonstrated by the percentage of cephalosporin-resistant 
Klebsiella pneumonia isolates increasing dramatically from 3% in 1989 to 22% 
in 1991, a period of only two years.33 Figure 5 shows that the number of 
antibiotic resistant Gram-negative bacterial isolates is almost equal to that of 
Gram-positive bacteria.5, 30, 34, 35 According to a report released by the European 
Centre for Disease Prevention and Control, Gram-negative bacterial infections 
were responsible for 67% of twenty-five thousand deaths in 2009.16, 34  
The scale of antibiotic resistance emphasises the need to develop novel 
antimicrobials targeting Gram-positive and Gram-negative bacteria. 
1.3 Antibiotic target 
When developing novel antibiotics, it is necessary to first select a target.36 Most 
current antibiotics fall within four classes: cell wall biosynthesis inhibitors, 
ribosome inhibitors, DNA and RNA synthesis inhibitors and membrane 
disruptors.37 The first three classes refer to compounds that interfere with 
critical functions within the bacteria cell inhibiting cell growth and eventually 
leading to cell death.   
Membrane disruptors however are membrane-damaging agents; they disrupt 
the stability of the cell membrane immediately leading to cell death.37 As 
membrane disruptors cause rapid cell death, instances of bacteria developing 
resistance to these compounds is rare.38 Developing a novel antibiotic that 
targets bacterial membranes in such a way would therefore be ideal. Before 
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(a) (b) 
discussing how a compound may be tailored to ‘attack’ the bacterial membrane, 
an examination of the composition and structure of bacterial membranes is 
necessary.  
1.4 Bacteria 
1.4.1 Classifications of bacteria 
Bacteria are prokaryotic pathogenic cells which are further classified into Gram-
positive and Gram-negative bacteria based on the structural differences in their 
cell walls.39  Gram-positive bacteria have cell membranes encased in a thick 
peptidoglycan layer (Figure 6a).40 Gram-negative bacteria have a much thinner 
peptidoglycan layer encasing the cell membrane which is further surrounded by 
an outer membrane (Figure 6b).40  
 
Figure 6 – (a) Artistic depiction of the cell walls of Gram-positive and (b) Gram-
negative bacteria.40 
Bacterial membranes contain one-third of the proteins found in the cell and are 
important in many processes, such as transport of nutrients, necessary for 
survival.37, 41, 42  
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1.4.2 Gram-positive bacteria outer membrane 
 
Figure 7 – Schematic representation of the outer membrane of Gram-
positive bacteria.43 
Bacteria often live in harsh environments like the digestive systems of humans. 
In order to withstand such conditions, the outer membranes of Gram-positive 
bacteria can be up to 100 nm thick.44 Although there are variations in the 
structure of the outer membrane across all the species of Gram-positive 
bacteria, there are common entities present in most: the peptidoglycan layer, 
teichoic acids and lipoteichoic acids.  
The peptidoglycan layer is comprised of a series of glycan chains cross-linked by 
peptides which form the mesh-like framework seen in Figure 7. The basic 
disaccharide consists of a β-1,4-linked N-acetylglucosamine and N-
acetylmuramic acid units (Figure 8). The carboxyl group of the N-acetylmuramic 
acid unit is always substituted with a peptide. However, not all of these peptides 
are cross linked. The proportion of cross-linkages in peptidoglycan differs for 
each species of bacteria. Starting the scale is peptidoglycan from Escherichia coli 
which only have 50% of the peptides cross-linked. The other extreme is the 
peptidoglycan from Staphylococci in which all peptides are cross-linked.45   
Lipoteichoic acids 
Peptidoglycan layer 
Cell Membrane 
Teichoic acids 
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Figure 8 – Cross-linked glycan strands.45-49 
Threaded through the peptidoglycan layer are teichoic acids and lipoteichoic 
acids. A difference between the two acids is that teichoic acids are covalently 
bonded to the peptidoglycan layer whereas lipoteichoic acids are anchored in 
the cell membrane with large portions extending through the peptidoglycan 
(Figure 9a).41, 44  
 
 
Figure 9 – (a) Schematic of the different sections in teichoic acids and lipoteichoic acids. (b) 
Structures of repeating polymer units that are commonly found in teichoic acids and 
lipoteichoic acids.41, 44 
Common to both teichoic acids and lipoteichoic acids are repeating units of 
anionic polymers known as poly(Gro-P) 3 and poly(Rbo-P) 4 (Figure 9b). 
Covalently linked phosphate anions are a feature in the anionic polymers and 
(b) 
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contribute to a ‘continuum of anionic charge’ that pervades the outer membrane 
of Gram-positive bacteria.44  
1.4.3 Gram-negative bacteria outer membrane 
The outer membrane in Gram-negative bacteria is an asymmetric lipid bilayer 
interspersed with porins (protein channels) (Figure 10). The inner monolayer is 
composed of phospholipids and lipoproteins whilst the outer monolayer is a 
mixture of phospholipids and lipopolysaccharide (LPS) molecules.50 As 
lipopolysaccharides (LPSs) comprise about 45% of the outer monolayer and is 
the major constituent, the layer is often referred to as the LPS layer.51, 52 
 
Figure 10 – Schematic representation of outer membrane of Gram-
negative bacteria.43 
Lipopolysaccharides are known as the endotoxin of Gram-negative bacteria and 
are released whenever cells grow, divide or lyses.53 When LPS is released, it 
causes a cascade of responses from the host body which can result in sepsis and 
in some cases, death.54-58 The LPS molecule has three main sections (Figure 11): 
the O-antigen, the core oligosaccharide and the lipid A (5) moiety.51, 59-62 Of the 
three sections, it is the lipid A (5) moiety that is the most conserved across the 
different species of Gram-negative bacteria. 
Lipopolysaccharide 
Peptidoglycan 
Inner Membrane 
Porins 
Inner monolayer 
Outer monolayer 
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Figure 11 – General structure of LPS found in E. coli. Structure of Lipid A 
(5) has been elaborated.63-65 
 The O-antigen section of the LPS molecule varies considerably between the 
different strains of bacteria and is composed of repeating units of five to eight 
monosaccharides.20, 51, 54, 62 The core oligosaccharide is divided into an inner 
core and an outer core. The structure of the outer core differs but the inner core 
is always composed of 2-keto-3-deoxyoctonoic acid (KDO).20, 61 Studies have 
shown that in order for a bacterial cell to live, at a minimum there must be a 
single molecule of KDO present in the LPS molecules.51 
The Lipid A (5) is a hydrophobic and lipid rich moiety comprised of a β-(2’-4)-
linked D-glucosamine disaccharide phosphorylated at the 1- and 4’- positions 
respectively. Six acyl chains are connected to the disaccharide, four β-
hydroxyacyl chains are directly attached to the glucosamine sugars (5-, 6-, 5’- 
and 6’ positions) with two secondary chains attached to the β-hydroxy group.20, 
58, 59, 66, 67  The amide-linked chains are both 3-hydroxymyristate whilst the 
ester-linked chains vary between myristate, laurate or palmitate.51 The Lipid A 
(5) molecule anchors the LPS within the outermost layer of the outer membrane 
forming ionic bridges with alternating calcium and magnesium cations (Figure 
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11). The ionic bridges contribute significantly to the stability of the outer 
membrane. 
Table 2 – Chemical composition of lipid A (5) derived from different 
bacterial groups.65 
Lipid A Disaccharide backbone Phosphates 
Fatty 
Acids 
AraN* 
Escherichia 
coli Yes Yes Yes No 
     
Salmonella Yes Yes Yes Yes 
     
Chromobacterium 
violaceum Yes Yes Yes Yes 
     
Rhodospirillum 
tenue Yes Yes Yes Yes 
     
Rhodopseudomonas 
viridis No No Yes No 
     
* AraN = 4-amino-L-arabinose; Ara = D-arabinose; FA = fatty acids; EtN = 
ethanolamine; P = phosphate 
Although it is the most conserved section of LPS, the chemical composition of 
Lipid A (5) can still vary. Table 2 features eight species of Gram-negative 
bacteria and highlights the differences between the chemical structures of their 
respective lipid A (5). Common to most bacteria is the D-glucosamine 
disaccharide that forms the backbone. In Rhodopseudomonas viridis, there is no 
disaccharide; instead there is a single unit of 2,3-diamino-D-glucose that forms 
the backbone. The presence of phosphate on the lipid A (5) backbone is not 
guaranteed either with Rhodopseudomonas viridis also not having any. Another 
common variation is the substituents on the D-glucosamine disaccharide. These 
may vary between 4-amino-L-arabinosa, D-arabinose and ethanolamine (Table 
2).  
In the current project, cationic antimicrobial peptides (CAMPs), natural 
products already deemed effective against the bacterial membrane, were closely 
examined.36 Using natural products as lead compounds is an established 
approach in medicinal chemistry with 50% of current commercial medicines 
originating from natural products isolated from plant, animal or fungal 
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sources.36 Furthermore, CAMPs have broad spectrum activity against bacteria, 
fungi and some viruses and as such are investigated extensively in the pursuit of 
novel antibacterials.68 A detailed examination of CAMPs follows.  
1.5 Cationic Antimicrobial Peptides 
Cationic Antimicrobial Peptides (CAMPs) are found widely distributed amongst 
plants and animals and form part of nature’s defence mechanisms against 
bacteria serving a fundamental protective role in evolution.38, 69, 70 Despite being 
present in nature for such a long time, CAMPs have remained effective. Their 
potency is attributed to their mode of action: disruption of the bacterial outer 
membrane.38 Cationic Antimicrobial Peptides cause rapid disorganisation of the 
bacterial outer membrane which quickly facilitates the death of the cell.38 
A common feature, regardless of classification is the amphipathic structure 
CAMPs adopt before or during the interaction with outer membranes of 
bacteria. Amphipathicity is the three-dimensional shape in which hydrophobic 
and hydrophilic residues are positioned on opposite sides of the molecule.25, 38, 
71  
CAMPs vary extensively in composition. They contain a number of amino acids 
and have different positively charged residues (e.g. arginine, lysine).35, 71 The 
peptides can be classified into three broad structural groups: β-sheet peptides 
with disulfide bridges, α-helical peptides and extended peptides.72, 73 Besides 
the main groups, there are a number of other smaller families of CAMPs, one of 
which are the lipopeptides. These classes are discussed in some detail below. 
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1.5.1 β-sheet CAMPs 
The β-sheet CAMPs are peptides with two to four disulfide bridges of which an 
example are the defensins. Defensins are CAMPs found in rabbits, guinea pigs, 
rats and humans.74 They exhibit activity against both Gram-positive and Gram-
negative bacteria as well as fungi and viruses.75-77 There are currently fifty 
known defensins.69 
 
Figure 12 –Structure of HNP3-defensin (6) solved by aqueous solution NMR 
studies in the presence of detergent micelles. β-sheet structures are indicated 
by flat ribbons and arrows. Cationic residues highlighted in blue, anionic 
residues highlighted in red and hydrophobic residues highlighted in grey. 72, 78 
Defensins found in humans are called Human Neutrophil Peptides (HNP). The 
three human defensins identified are named HNP1, HNP2 and HNP3 (6) (Figure 
12) and exhibit activity against bacteria, fungi and viruses.79  Although they are 
classified as small amphipathic peptides, HNPs still contain up to thirty amino 
acids. The human defensins are rich in arginine and cysteine and possess a net 
charge of either +3 or +2.80 Each human defensin contains a triple-stranded β-
sheet and its amphipathicity is ensured with three disulfide linkages between 
cysteine residues ensuring a high degree of conformational rigidity.78, 81  
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1.5.2 α-helical CAMPs 
One of the most famous examples of the α-helical peptides is magainin (7) 
(Figure 13). Magainin (7) was the first CAMP isolated from the skin of the 
African clawed frog Xenopus laevis.82, 83 Magainin (7) is comprised of twenty-
three amino acids with a highly basic with a net charge of +4 at a pH of 7.84 
 
Figure 13 – Active conformation of magainin (7). Hydrophobic amino 
acids are green, cationic residues are blue and anionic residues are 
red.83, 84 
Generally, α-helical CAMPs are flexible and will only assume the characteristic 
α-helix upon contact with bacterial membranes.83 Hence, to determine the α-
helical structure of magainin (7), Opella et. al. observed the interactions of the 
peptide (7) with anionic micelles in solution using two-dimensional NMR.83, 84 
By interpreting interactions, the α-helix of magainin (7) was constructed clearly 
showing the amphipathicity of the peptide. From the structure detailed in 
Figure 13, amphipathicity is clear; hydrophobic residues (coloured in green) 
occupy one side of the helix and cationic residues (coloured in blue) the other.83 
1.5.3 Extended CAMPs 
Extended CAMPs are a group of antimicrobial peptides that do not form a 
regular secondary structure when interacting with the bacterial membrane.85, 86 
Extended peptides commonly comprise of high percentages of arginine, 
7 
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tryptophan, proline and histidine and the most common example is indolicidin 
(8) (Figure 14).72. 
 
Figure 14 – Structure of Indolicidin (8) solved by solution NMR 
spectroscopy in the presence of detergent micelles. Cationic residues 
are highlighted blue and hydrophobic residues are highlighted grey.72 
Indolicidin (8) is found in cows, is comprised of thirteen amino acids and has 
the highest fraction of tryptophan (39%) observed in a natural peptide.87-89 
Indolicidin (8) has a net charge of +4 and exhibits broad spectrum activity 
against Gram-positive and Gram-negative bacteria as well as protozoa, fungi and 
viruses.86, 89 
1.5.4 Lipopeptides 
The last group of CAMPs to be discussed are lipopeptides. Lipopeptides feature 
a peptide with a fatty acid chain. A well studied and clinically used example are 
the Polymyxins. The polymyxins are a family of five related compounds: 
Polymyxin A to E.21, 86, 88 They were discovered in the late 1940s and are 
secondary metabolite nonribosomal peptides isolated from Bacillus polymyxa.20, 
21, 90, 91 All exhibit potent activity against Gram-negative and, to a lesser extent, 
against Gram-positive bacteria.92, 93 The Polymyxin family share the same 
general structure: a polypeptide ring with a fatty acid chain extending from it 
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(Figure 15).22, 93-96 Only Polymyxin B (9) and E have been commercially 
marketed as antibiotics for humans.21, 97, 98  
 
 
 
Figure 15 – (a) Structure of Polymyxin B1 and B2.9, 99 Cationic residues 
highlighted in blue and hydrophobic residues highlighted in orange. (b) NMR 
structure of Polymyxin B1 when bound to LPS.  
Polymyxin B (9) was discovered in 1950s and is a mixture of Polymyxin B1 and 
B2 differing in the fatty acid side chain (Figure 15a).9, 90 When Polymyxin B (9) is 
bound to LPS, it assumes an amphipathic structure where the hydrophobic 
residues occupy one side of the structure and the cationic residues occupy the 
other (Figure 15b). 
In all examples of CAMPs, there is the common motif of amphipathicity. The 
amphipathic characteristic is integral in the mode of action of CAMPs leading to 
the rapid disorganisation of the outer membrane of bacteria. 
9 
(a) 
(b) 
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1.6 CAMP Mode of Action 
The detergent-like mechanisms by which CAMPs attack bacterial membranes 
rely on a combination of hydrophobic and electrostatic interactions.38, 71, 100 
There are numerous theories as to the mode by which CAMPs completely 
disorganise the outer membranes of Gram-positive and Gram-negative bacteria. 
Each theory shares a common beginning; the initial electrostatic attraction 
between the anionic outer membranes of bacteria and the positively charged 
CAMPs which result in the adsorption of the peptide to the membrane (Figure 
16). 
 
Figure 16 – Events occurring after the initial electrostatic interaction between the 
negative outer membrane of bacteria and CAMPs.72, 101 The three main theories 
are highlighted with an orange border. 
The many theories by which CAMPs disorganise the outer membranes of 
bacteria are illustrated in Figure 16. The exact mechanism of a particular CAMP 
may involves aspects of these. The three main theories are the Barrel-Stave 
model, the Carpet-Like model and the Membrane-thinning model and details of 
each follow. 
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1.6.1 The Barrel-Stave Model 
 
Figure 17 – Cartoon illustrating the ‘Barrel-Stave’ model. (a) 
Peptides first assemble on the surface of the outer membrane. 
(b) Peptides insert into membrane.102 (c) Structure of ceratoxin 
1 (10).  
In the Barrel-Stave model, CAMPs aggregate to form ‘bundles’ of peptides before 
interaction and adsorption to the outer membrane. These aggregates proceed to 
embed themselves into the membrane forming transmembrane channels 
(Figure 16).103 The channels facilitate the leaking of cellular contents and the 
entry of molecules otherwise excluded by a stable membrane. Most importantly, 
the transmembrane channels promote the entry of CAMPs themselves where 
they may elicit further antibacterial action.9, 20, 68, 104-106 With the destabilisation 
of the outer membrane, cell lysis soon follows.21 Ceratotoxins are an example of 
a family of CAMPs that have been proven to disrupt the membranes of bacteria 
according to the Barrel-Stave model (Figure 17c). Ceratotoxins are α-helical 
peptides found in insects and spiders.103, 107 
(a) 
(b) 
(c) 
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1.6.2 The Carpet-Like Model 
 
Figure 18 – Cartoon illustrating ‘carpet’ model. (a) Peptides 
‘carpet’ the surface of the membrane. (b and c) When a critical 
local concentration is reached, destabilisation and disintegration 
of membrane occurs.102 (d) Structure of Indolicidin (8)72 
The Carpet-like Model proposes that individual CAMP molecules interact with 
the LPS. When enough peptides have ‘carpeted’ the surface of the outer 
membrane and a critical local concentration has been reached, the hydrophobic 
residues of CAMPs penetrate the membrane. The resulting destabilisation and 
disintegration of the membrane eventually leads to cell lysis (Figure 16).103 
Indolicidin (8) is an example of a CAMP that is proposed to act via the Carpet-
Like model.108 
1.6.3 The Membrane-Thinning Model 
The Membrane-Thinning model is a derivative of the Carpet-like model and 
similarly proposes that CAMP molecules ‘carpet’ the membrane. However, a 
localised electrostatic disturbance of the outer membrane is proposed. The LPS 
molecules in the outer membrane then rearrange to accommodate the 
electrostatic disturbance and a thinning of the membrane develops (Figure 16). 
The CAMPs are believed to then aggregate on the surface of the outer 
(a) 
(b) 
(c) 
(d) 
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membrane. With a thinned membrane and a reduced local surface tension, the 
CAMP aggregates insert into the membrane which becomes further disordered 
and cell lysis ensues.20 Magainin (7) is an example of a CAMP that disorganises 
bacterial membranes via the Membrane-Thinning model.109, 110   
 
 
 
Figure 19 – Cartoon illustrating ‘membrane-thinning’ model. (a) Peptides ‘carpet’ 
membrane surface. (b) Membrane rearranges to accommodate electrostatic 
disturbance and thinning of membrane results. (c) Peptides insert into membrane 
which disrupts further causing cell lysis.111 (d) Structure of magainin (7). 
The theories of membrane disruption provide a brief explanation of how CAMPs 
may act against bacteria, many theories are idiosyncratic to a particular family 
of peptides.112 To further illustrate how CAMPs interact with the outer 
membranes of bacteria, a case study using the well studied Polymyxin against 
Gram-negative bacteria is presented in the following section.  
1.6.4 Polymyxin against Gram-negative bacteria 
NMR spectroscopy and molecular modelling studies on the solution structures 
of Polymyxin B (9) show a three-dimensional conformation which is 
structurally amphipathic.9, 20, 54 In this structure, the fatty acid chain and 
hydrophobic residues (Phenylalanine-6 and Leucine-7) are distinctly separated 
from the Diaminobutyric residues 1, 4, 5, 8 and 9 (Figure 20).54 When 
interacting with the Lipid A (5) molecule, the Diaminobutyric residues displace 
(a) 
(b) 
(c) 
(d) 
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the calcium and magnesium ions and bind to the phosphate anions.71, 113, 114 The 
hydrophobic residues then insert into the LPS layer further destabilising the 
membrane. Cell lysis then follows. 
 
Figure 20 – A representation of the structure of a Polymyxin B (9) molecule 
interacting with LPS. Derived from NMR and molecular modelling studies.20, 54 
Extensive studies using structurally modified Polymyxins have proven that the 
cyclic peptide ring is integral in the binding of Lipid A (5) and the neutralisation 
of LPS. The presence of the fatty acid chain however is necessary for 
antibacterial activity.94 The group of Sakura synthesised various analogues of 
Polymyxin B (9) testing the role of each amino acid by systematically 
substituting each residue (Figure 21).115  
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Figure 21 – Synthetic Polymyxin B analogues used in study by Sakura et. al.115 (a) 
Analogue 11 where Diaminobutyric-3 replaced by alanine. (b) Analogue 12 where 
Diaminobutyric-5 replaced by alanine. (c) Analgoue 13 where Phenylalanine-6 and 
Leucine-7 replaced by glycine. Replacements highlighted in orange. 
Tested by Sakura et. al., Polymyxin B (9) exhibited MIC values of 0.5-1 nmol/ml 
against various Gram-negative bacteria. The absence of Diaminobutyric-3 in 
analogue 11 (Figure 21a, MIC: 1-2 nmol/ml) had no noticeable effect however 
without Diaminobutyric-5 in analogue 12, (Figure 21b, MIC: 16 nmol/ml), there 
was was a substantial decrease of potency. Variation of the hydrophobic chains, 
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Phenylalanine-6 and Leucine-7, had little effect on activity, however when both 
were replaced in analogue 13 (Figure 21c), a loss of activity was observed.  
 
Figure 22 – Structure of Polymyxin B Nonapeptide 14(PMBN).116 
Polymyxin B Nonapeptide (14) (PMBN) clearly illustrates the importance of the 
fatty acid chain for the antibacterial activity of the Polymyxin family (Figure 22). 
With reduced hydrophobicity, PMBN 14 has a lower potency than Polymyxin B 
(9) and requires higher concentrations to be effective. Although antibacterial 
activity is markedly less than Polymyxin B (9), PMBN 14 has the advantage of 
being 150 times less neurotoxic than either Polymyxin B (9).22, 99, 117 However, 
PMBN 14 still causes nephrotoxicity and as higher doses are needed, it can 
cause as much damage as the parent molecule.93, 117, 118 Polymyxin B 
Nonapeptide 14 still binds to Lipid A (5) and disorganises the LPS layer 
rendering Gram-negative bacteria sensitive to other hydrophobic antibiotics, 
such as Daptomycin, that would otherwise be excluded by a stable outer 
membrane.62, 119 
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1.7 Resistance against CAMPs 
1.7.1 Resistance in Gram-positive bacteria 
A thorough discussion of CAMPs is not complete without mentioning resistance. 
One of the most common resistance mechanisms seen in Gram-positive bacteria 
is the incorporation of D-Alanine into the teichoic acids of the cell wall.68, 120, 121 
By esterifying the carbohydrate polymers with D-Alanine, the positive charges 
from the free amines work to neutralise the ‘continuum of anionic charge’ 
associated with the outer membrane of Gram-positive bacteria (Figure 23).120, 
121 A decrease of anionic charge results in the consequential decrease of the 
initial electrostatic interactions between CAMPs and the bacterial outer 
membrane. 
 
Figure 23 – Esterification carbohydrate groups with D-Alanine which results in 
the introduction of more positive charges thereby neutralising the overall 
negative teichoic acids.120 
Other Gram-positive antibiotic resistance mechanisms involve the use of ABC 
transporters and protection proteins (bacterial cellular peptides). ABC 
transporters are designed to expel CAMPs once they have inserted into the cell 
and protection proteins are proposed to repel CAMPs from the surface of the 
cell membrane.121  
Susceptible 
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1.7.2 Resistance in Gram-negative bacteria 
The most common form of resistance in Gram-negative bacteria against CAMPs 
is the replacement of phosphate groups on the Lipid A moiety. A substitution 
with 4-amino-arabinose (Figure 24a) or phosphoethanolamine (Figure 24b) is 
effective in reducing the initial electrostatic interaction between CAMPs and the 
outer membrane.9, 13, 62, 68, 96, 97, 122-125 As the substitutions contain free amino 
groups, there is also a repulsion of the CAMP molecule. Another form of Lipid A 
alteration involves the addition of a fatty acid chain (Figure 24c) which reduces 
the permeability of the outer membrane by decreasing fluidity of the LPS 
layer.67, 123, 124 
 
Figure 24 – Examples of modifications to Lipid A that result in antibiotic 
resistant bacteria. (a) Substitution with 4-amino-arabinose (L-Ara4N). 
(b) Substitution with phosphoethanolamine. (c) Addition of fatty acid 
chain.123, 126 
Besides altering the chemical structure of Lipid A, Gram-negative bacteria have 
evolved a resistance mechanism which involves the production of a 
polysaccharide capsule (also known as a cell envelope) which encases the entire 
cell. This prevents the approach of CAMPs. 9, 92, 122, 124  
(a) 
(b) 
(c) 
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1.7.3 Resistance is rare 
Although a number of resistance mechanisms were outlined above, the 
incidence of resistance against CAMPs is still comparatively low. A reason for 
the lower rate of resistance is the target chosen by CAMPs: the bacterial 
membrane. For bacteria to develop resistance, a cell must change the structure, 
composition and organisation of its outer membrane which is a ‘costly 
solution’.38, 106 Also, CAMPs are composed of amino acids and have no unique 
sequence that bacteria can recognise and specifically target.38 Most importantly, 
there is difficulty in developing resistance against a mode of action (detailed 
above) based on hydrophobic and ionic interactions that causes cell death so 
quickly.90, 105 
1.8 Peptidomimetics 
1.8.1 Why develop a CAMP mimic 
The previous discussion emphasises the effectiveness of CAMPs in targeting 
bacteria. However, outside a select few (e.g. Polymyxin B), these peptides are 
not suitable for clinical use.127 There are toxicities associated with current 
medicinal peptides.101 Patients injected intravenously with Polymyxins suffer 
many side effects such as dizziness, weakness, numbing, peripheral neuropathy 
and vertigo. Extreme effects like respiratory failure, nephrotoxicity (toxic to 
kidneys) and neurotoxicity (toxic to the human brain) have been reported.9, 20-22, 
122, 128, 129  Other peptides such as magainin (7) require high doses to be effective 
in animal models of infection and unfortunately, the effective concentration of 
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magainin (7) is close to the toxic dose of the peptide making it unsuitable for 
therapeutic purposes.130  
 
Scheme 1 – Solid phase synthesis of Polymyxin B (9).131 
Another reason CAMPs are not suited for clinical use is the high cost of 
production due to their structural complexity. For example, the synthesis of 
Polymyxin B (9) has twenty-four synthetic steps. Each synthetic step is efficient 
(>95% yields) however the overall yield is only 20% (Scheme 1).131 As such, 
fermentation is the method of manufacture. Fermentation itself has many 
disadvantages. It requires large amounts of biological material which does not 
directly translate into the production of equal amounts of the desired product. 
Extensive processing involving multiple extraction and filtration steps is 
required to remove all traces of unwanted biomaterial. The complex process of 
21 
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fermentation results in products that typically cost ten to twenty times the 
amount of synthetically produced pharmaceuticals.132 
Unfortunately, CAMPs also suffer sensitivity to physiological pH and salt 
concentrations. Human defensins, for example, lose all activity against E. coli at 
physiological salt levels.133, 134 The antibacterial activity of  β-sheet CAMPs 
decreases drastically when subject to physiologic concentrations of sodium and 
potassium.135 Effects of pH are idiosyncratic to a particular class of peptides. For 
example, β-sheet CAMPs perform well in neutral or slightly basic environments 
however α-helical CAMPs perform better in acidic media.135 
The last reason why CAMPs are unsuitable for clinical use is due to the 
degradation faced when to subjected proteolysis (digestion by enzymes). Often 
CAMPs suffer a reduction of activity ranging from 50% to 94% (10 min to 24 
hours) with proteases capable of rendering CAMPs completely useless. 136-138  
1.8.2  Pharmacophore of CAMPs 
A CAMP mimic would be based on a simpler scaffold whilst still embodying the 
essential characteristics which are: cationic functional groups, hydrophobic 
residues and a scaffold that ensures structural amphiphilicity (Figure 25). 
 
 
 
Figure 25 – Essential characteristics of CAMPS. 
Scaffold 
Hydrophobic 
residues 
Cationic 
residues 
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Cholic acid scaffold 22 
Mimics should be cheaper to synthesis and be tailored to combat the 
disadvantages CAMPs currently suffer (toxicity, salt and pH sensitivity, 
proteolysis). Developing CAMP mimics using a simple scaffold is not a novel 
concept and the following section introduces some synthetic CAMP mimics.  
1.9 CAMP mimics 
1.9.1  Mimics based on Cholic Acid 
The CAMP mimics based on a cholic acid scaffold have been synthesised by the 
group of Savage et. al. (Figure 26).139 Each cholic acid based mimic had a 
hydrophobic residue, multiple cationic groups and a scaffold (cholic acid) that 
ensured structural amphiphilicity.  
 
Figure 26 – Structure of cholic acid based mimic, Ceragenin CSA-13 (21).139, 140  
Ceragenin CSA-13 (22) is currently in pre-clinical testing. It has comparable 
activity to Polymyxin B (9) with respect to Gram-negative bacteria. However, 
Ceragenin CSA-13 (22) is much more potent against Gram-positive bacteria. For 
example against Staphylococcus aureus, it has an MIC of only 0.40 μg/mL 
whereas Polymyxin B (9) has an MIC of 26 μg/mL.139 In the course of developing 
Ceragenin CSA-13 (22), Savage explored the effect that different cationic groups 
could have an antibacterial activity by synthesising mimics containing either 
amines or guanidines. Determinations of minimum inhibitory concentrations 
Hydrophobic group 
Cationic groups 
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showed that guanidine functionalised cholic acid based CAMP mimics were 
effective at lower concentrations than amine functionalised counterparts.  
1.9.2  Mimics based on a Triaryl Scaffold 
 
Figure 27 – Structure of triaryl based mimics.141  
In 2011, Tew et. al. synthesised triaryl based CAMP mimics (Figure 27) that 
exhibited comparable antibacterial activity with magainin (7).141 The triaryl 
based CAMP mimics contained two cationic groups and a triaryl scaffold. The 
analogues showed that the segregation of hydrophilic and hydrophobic groups 
were necessary for antibacterial activity. Moreover, Tew showed that the use of 
a rigid scaffold, here the triaryl scaffold, would ensure that hydrophilic and 
hydrophobic sections remained separated from each other, i.e. structural 
amphiphilicity. For the triaryl scaffold, there were no differences in MIC values 
between either guanidine 24 or amine 23 functionalised compounds against 
Escherichia coli and Klebsiella pneumoniae (6.25 μg/mL and 12.5 μg/mL 
respectively).  
1.9.3 Mimics based on Calixarene 
Mayo et. al. was responsible for the development of calixarene based CAMP 
mimics (Figure 28). Amphipathicity of mimics were maintained by ensuring 
Cationic groups 
Scaffold 
23 
33 
 
25 26 
large groups composed the lower section of the molecule thereby preventing 
rotation and isomerisation.  
 
Figure 28 – Structures of calixarene CAMP mimics.59  
Once again, the key requirements are present in the calixarene based mimics; 
the hydrophobic groups, multiple cationic groups and a scaffold ensuring 
structural amphiphilicity. Guanidine 26 performed as well as amine 25 showing 
excellent activity against several bacterial strains such as E. coli, Pseudomonas 
aeruginosa and Klebsiella pneumoniae with MICs ranging from 0.1 to 1.5 μg/mL.  
1.9.4  Lipopolyamines 
 
Figure 29 – Structure of lipopolyamine: 1,3-dioleoyl-oxy-2-(6-
carboxyspermyl)-propylamide (DOSPER) 27.142 
Lipopolyamines were originally designed to facilitate the transfection of DNA 
into eukaryotic cells. They proved to be of interest as antibacterials because of 
low toxicity to humans and approval by the FDA for other medicinal uses.142 The 
structure of 1,3-dioleoyl-oxy-2-(6-carboxyspermyl)-propylamide (DOSPER) 
(27) has the essential characteristics of a CAMP mimic; namely a hydrophobic 
27 Cationic groups 
Hydrophobic section 
Cationic groups 
Hydrophobic groups 
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section and multiple cationic groups. DOSPER 27 was found to bind to LPS at 
only one-tenth of the affinity of polymyxins. Nonetheless, lipopolyamine based 
CAMP mimics show great promise in the development of mimics with low 
toxicity to humans. 
1.9.5 Mimics based on Norbornanes  
Research into anion recognition by Pfeffer et. al. led to anion host 28, a 
compound proven to bind to two phosphate anions (Figure 30a). As Lipid A (5) 
contains two phosphate groups, anion host 28 was used for the development of 
norbornane based CAMP mimics (Figure 30b).143, 144 The norbornane scaffold 
was ideal due to a high degree of structural rigidity, ease of synthesis by the well 
known Diels-Alder cycloaddition and easily functionalised at multiple points.143, 
144 
 
Figure 30 – (a) Previously synthesised host 28. (b) General structure of first 
generation norbornane based CAMP mimic 29. (c) Structure of first generation 
norbornane based CAMP mimic 30.145 
Pfeffer et. al. incorporated an alkyl chain onto the norbornane scaffold using an 
acetal and substituted guanidines in place of urea as the cationic groups. Whilst 
a di-ether was initially more attractive than an acetal, extensive attempts using 
the Williamson ether approach failed entirely. Furthermore, the synthesised 
Cationic groups 
(a) 
(c) 
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norbornanes were synthesised as racemates and tested as such. This led to di-
guanidine TFA salt 30 which had activity comparable to Polymyxin E.145 The 
synthesis and evaluation of future generations of norbornane based CAMP 
mimics form the basis of the current project.  
1.10 Project Aims 
The norbornane based CAMP mimics proved that novel antimicrobials could be 
developed using the norbornane scaffold. However, in the original study, only 
two hydrophobic regions and guanidines were explored. Therefore,  the overall 
purpose of this project was to conduct a systematic exploration of the effect that 
variations in (i) hydrophobic and (ii) cationic groups would have on 
antibacterial activity.  
 
Figure 31 – General structure of norbornane based CAMP mimics. Choices for 
some hydrophobic groups (orange) and choices for cationic groups (blue). 
Many researchers have demonstrated that the potency of an antibiotic may be 
significantly influenced by the composition of the molecule’s hydrophobic 
region or lack thereof.99-101, 104, 115, 146 As such, the first aim of this project was to 
generate a library of functionalised norbornane based CAMP mimics with a 
range of hydrophobic ‘regions’ (Chapters 2 and 3). A number of hydrophobic 
(a) 
(b) (c) 
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groups comprising of alkyl, aryl and aryl substituted moieties were chosen 
(Figure 31b).  
The second aim of this project was to investigate the influence that different 
cationic groups exert on antibacterial activity. The two cationic residues 
employed were primary amines and guanidines (Chapter 2 and 3).  
The general structure in Figure 31 was similar to compound 30 synthesised by 
Pfeffer et. al. as a product of a ‘convergent’ methodology. The next aim of this 
project therefore was to optimise the ‘convergent’ methodology to allow for the 
easy variation of compound 30 (Chapter 4). 
The libraries of norbornane based CAMP mimics will be in the form of chloride 
salts which is more biologically relevant form than the TFA salt 30. The salts 
produced as a result of this project will be subject to antibacterial and 
physicochemical testing (Chapters 5 and 6). 
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Chapter 2 
Synthesis of Amines 
In Chapter 2, first the linear synthesis of amine functionalised 
norbornane based CAMP mimics was attempted. Inefficiencies and 
purification problems associated with this approach are highlighted. 
New methodology explored the late introduction of hydrophobic 
regions and allowed for the successfully synthesis of a library of 
protected amines. Problems with deprotection and salt formation 
identified for certain compounds were discussed. 
2.1 Retrosynthesis 
2.1.1 Disconnections 
In the synthesis of the target compound, key disconnections were identified 
(Figure 32): acetal formation, Diels-Alder cycloaddition, amide coupling, and the 
formation of the amine salt which was automatically selected as the final step. 
 
Figure 32 – Target amine with key disconnections identified. 
The acetal link allows for the easy attachment of a hydrophobic moiety to a cis 
diol. The acetal functional group was selected in light of many previous failed 
attempts at di-ether synthesis using the Williamson method.147 The Diels-Alder 
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cycloaddition forms the bicyclic norbornane scaffold. Amide couplings can be 
used to attach the hydrophilic regions to the main scaffold. Salt formation 
prepares the molecules in a pharmacologically relevant form ready for further 
assessment.148, 149  
2.1.2 Retrosynthetic analysis 
Salt formation and deprotection would be conducted last. Before that, di-amide 
couplings would attach the hydrophilic region to the main scaffold. Thus, the 
scaffold required di-carboxylic acids which can be prepared from esters. 
Aldehydes and ketones were to be attached to the main scaffold through the 
formation of an acetal; hence a diol must be present. The diol can be formed 
through the dihydroxylation of the unsaturated norbornene obtained from the 
Diels-Alder cycloaddition. Scheme 2 details the retrosynthesis. 
 
Scheme 2 – Retrosynthesis of amine functionalised norbornane based mimic.145 
Based on the retrosynthesis stated in Scheme 2, the sequence of planned 
reactions were as follows: 
x Diels-Alder cycloaddition between cyclopentadiene 31 and dimethyl 
fumarate 32. 
x Upjohn dihydroxylation of the unsaturated di-ester 33. 
x Synthesis of any necessary aldehydes. 
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x The formation of acetals between the diol 34 and any number of 
aldehydes or ketones. 
x Saponification to form the library of di-carboxylic acids. 
x Synthesis of mono-protected ethylene di-amine (EDA). 
x Di-amide couplings between di-carboxylic acids and mono-protected 
EDA. 
x The deprotection of protecting groups and the formation of salts. 
Having determined a course of action, attention turned to the Diels-Alder 
cycloaddition. 
2.2 Diels-Alder cycloaddition 
Otto Diels and Kurt Alder first published their findings on cycloadditions in 
1929.150 Their work is considered as one of the most useful carbon-carbon bond 
forming reactions.151-153 For such a significant contribution, both chemists 
shared the Nobel Prize for Chemistry in 1950. 
“It is perhaps surprising that this reaction, which is extremely 
elegant from the chemical point of view, should not have been 
discovered earlier, for cyclic structures had in fact been known 
since the sixties of last century. Individual observations had been 
made but they had been misunderstood or overlooked. The 
correct interpretation was so simple and yet – a mere twenty 
years ago – so bold, so like a chemist’s utopian dream, that it was 
beyond reach.”152 (by Professor A. Fredga in the Presentation 
Speech for the Nobel Prize in Chemistry 1950) 
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The Diels-Alder cycloaddition involves a reaction between two molecules, a 
diene and dienophile (Figure 33). The diene, as the name suggests, has a set of 
conjugated double bonds. The dienophile (diene-loving) has one double 
bond.152, 153 Figure 33 shows an example of a diene, cyclopentadiene (31) and a 
dienophile, maleic anhydride (35). 
 
Figure 33 – Structures of cyclopentadiene (32) and maleic anhydride 
(35). 
The Diels-Alder cycloaddition is a concerted pericyclic reaction.153, 154 In the 
transition state, the Highest Occupied Molecular Orbital of diene 34 interacts 
with the Lowest Unoccupied Molecular Orbital of dienophile 35 resulting in the 
unsaturated polycyclic compound 36 (Scheme 3). The Diels-Alder cycloaddition 
forms multiple rings in one step with defined stereochemistry.154  
 
Scheme 3 – The Diels-Alder cycloaddition between cyclopentadiene (31) and 
maleic anhydride (35).153 
Scheme 3 details a classic example of a diene and dienophile undergoing the 
Diels-Alder cycloaddition where the endo adduct 36 is formed. Although less 
stable than the exo version, compound 36 is preferred due to the interactions 
between the carbonyl groups in maleic anhydride (35) and the π bond that 
forms. Even after more than eighty years, the Diels-Alder cycloaddition remains 
relevant to the modern chemist. One recent example (in 2013) was the total 
synthesis of protoilludane aryl ester (+)-armillarivin (40) where a Diels-Alder 
cycloaddition began the assembly of the framework (Scheme 4).155 High 
31 
41 
 
31 32 33 
37 39 40 
pressures promoted the cycloaddition of cis-1,2,-dihydrocatechol (37) and 
cyclopent-2-en-1-one (38) to form Diels-Alder adduct 39 which were further 
elaborated to obtain the desired natural product 40.  
 
Scheme 4 – Synthesis of protoilludane aryl ester (+)-armillarivin (40) which 
begins with a Diels-Alder cycloaddition.155 
In the current project, the Diels-Alder cycloaddition was used to synthesise 
norbornene 33 (Scheme 5). Freshly cracked cyclopentadiene (31) was added to 
a solution of dimethyl fumarate (32) in dioxane and stirred for sixteen hours at 
room temperature. Removal of the solvent in vacuo led to the desired 
norbornene di-ester 33 in near quantitative yields. The reaction was robust and 
repeated multiple times on a scale of up to sixty grams. 
 
Scheme 5 – Synthesis of norbornene di-ester 33. 
The norbornene di-ester 33 is a known compound and its structure was 
confirmed by the comparison of NMR spectra with literature spectra.156  
2.3 Upjohn Dihydroxylation 
Catalytic use of OsO4 (41) was first employed by Hofmann for the hydroxylation 
of alkenes in the presence of secondary oxidants sodium/potassium chlorate.157-
159 Secondary oxidants regenerate the active OsO4 (VII) 41 by oxidising spent 
OsO3 44. Unfortunately, some oxidants led to the over-oxidation of the 
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unsaturated compound producing unwanted keto or carboxylic acid 
functionalities.158, 160 
Criegee then proved that OsO4 41 could be used stoichiometrically without any 
secondary oxidants.158, 161, 162 Although efficient, the stoichiometric use of OsO4 
41 had many disadvantages. There was the high cost and toxicity of OsO4 41, 
the difficult reaction conditions with low temperatures of -78 °C and a work up 
that involved treating the reaction mixture with acid for twenty-four hours. The 
disadvantages made the use of OsO4 41 unsuitable for large scale reactions.160, 
163, 164 To combat limitations, new conditions for OsO4 41 mediated 
dihydroxylations were devised by researchers at the Upjohn Chemical 
company.160 
 
Scheme 6 – Mechanism of the Upjohn dihydroxylation with 
cyclopent-1-ene (42).165 
The Upjohn dihydroxylation is now a well known reaction (Scheme 6).166, 167 
First published in 1976, by VanRheenen, Kelly and Cha (from the Upjohn 
Chemical company), they observed that using N-methylmorpholine N-oxide 
(45) (NMO) stoichiometrically oxidised OsO3 44 to OsO4 41. 160 The process 
provided high yields required only catalytic amount of OsO4 41 while 
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maintaining low costs and avoiding work up problems requiring only a simple 
aqueous wash. 
The catalytic cycle for the Upjohn dihydroxylation commences with the [3+2] 
addition of alkene 42 to the OsO4 (VII) 41 species. Water hydrolyses the cyclic 
di-ester releasing the desired cis-diol 43 and the spent OsO3 (VI) 44. Then NMO 
45, acting as the secondary oxidant, regenerates OsO4 (VII) 41 (Scheme 6).165  
Much debate surrounded the [3+2] addition of alkenes to the osmium catalyst. 
Criegee first proposed a concerted [3+2] route (Scheme 7a).162, 168 Sharpless et. 
al. more recently proposed a stepwise [2+2] addition through a metallaoxetane 
intermediate (Scheme 7b).168, 169 However by using density functional theory, a 
number of groups have showed that there is a higher energy barrier for the 
[2+2] pathway than the [3+2] pathway.170-172 Hence, the first step most likely 
proceeds by way of the [3+2] concerted route. 
 
Scheme 7 – (a): [3+2] addition. (b): [2+2] stepwise addition.162, 168, 169 
In the current project, the Upjohn dihydroxylation was used to form diol 34 
(Scheme 8). A solution of norbornene 33, NMO 45 and OsO4 41 in a 
H2O/acetone solution was allowed to stir for sixteen hours at room 
temperature. After an aqueous work up, the crude oil was purified using column 
chromatography affording diol 34 with a yield of 79% (Scheme 8). The 
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structure of diol 34 was confirmed by comparison with literature reports.145 It 
is noted that the cis-diol in 34 was formed exclusively at the exo position as 
steric interferences disfavour endo approach of OsO4 41.145, 173 
  
Scheme 8 – Dihydroxylation of norbornene di-ester 33 to obtain diol 
norbornane di-ester 34. 
With the successful installation of the diol, attention now turned to the selection 
of suitable hydrophobic residues. The choice of appropriate aldehydes and 
ketones as well as the design and synthesis of ‘boutique’ aldehydes is detailed in 
the following section. 
2.4 Hydrophobic component 
2.4.1 Selected aldehyde and ketones 
A number of aldehydes and ketones were selected for hydrophobic regions in 
the final norbornane based CAMP mimics. The aldehydes and ketones are 
shown in Figure 34 and are either alkyl, aryl or a combination thereof. 
 
Figure 34 – Collection of aldehydes and ketones selected to form the 
hydrophobic regions of the functionalised norbornane based CAMP 
mimics. Aldehydes to be synthesised are highlighted in orange. 
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The aldehydes highlighted in orange (Figure 34) represent compounds not 
commercially available. These ‘boutique’ aldehydes were chosen to explore the 
following factors: hydrophobicity (hexadecanal 46); combination of alkyl and 
aryl functionality (octynyl benzaldehyde 47, octyl benzaldehyde 48 and 
octyloxy benzaldehyde 49); flexibility of alkyl chain (octynyl benzaldehyde 47 
and octyl benzaldehyde 48); polarity (octyl benzaldehyde 48 and octyloxy 
benzaldehyde 49). The synthesis of each aldehyde using known methods is 
elaborated in the following sections.  
2.4.2 Hexadecanal 46 
Hexadecanal 46 was synthesised through oxidation of commercially available 
hexadecanol 52 using pyridinium chlorochromate (PCC) (51) as the oxidant 
(Figure 35). In 1977, Corey reported PCC 51 as an excellent, mild and stable 
alternative to the Collins reagent 50 (known to be unstable and capricious). 
Corey showed that PCC 51 could successfully oxidise a variety of alcohols to the 
corresponding carbonyl group.167, 174-176 
 
Figure 35 – (a) Structure of the Collins reagent 50 (a solution of 
chromium trioxide and pyridine in methylene chloride; (b) Structure of 
pyridinium chlorochromate (51). 
The mechanism by which PCC 51 oxidises an alcohol is first order and most 
textbooks propose that chromium (IV) first attacks the alcohol to form the 
chromate ester.165, 177 However, in the original publications by Banerji, it is the 
hydride transfer that is proposed to occur first. 172, 175 
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Scheme 9 – Mechanisms (a) and (b) proposed by Banerji et. al. in the oxidation 
of a primary alcohol by PCC 51.178 
Banerji et. al. proposed two pathways whereby chromium (IV) is reduced to 
chromium (III).174 In the first proposed mechanism, a hydride transfer occurs 
directly leading to the formation of a chromate ester (Scheme 9a).179 In the 
second proposed mechanism, the hydride transfer occurs prior to the formation 
of the chromate ester (Scheme 9b).179 Banerji concedes that there is no kinetic 
evidence confirming the proposed PCC 51 oxidation steps. However, the 
reactions show similar kinetics to chromic acid oxidations where chromate 
ester formation is well established.179  
 
Scheme 10 – PCC 51 oxidation of hexadecanol 52 to obtain hexadecanal 
46. 
In the current project, PCC 51 was used to convert hexadecanol 52 to 
hexadecanal 46 (Scheme 10). A solution of hexadecanol 52 and PCC 51 was 
dissolved in DCM and stirred for sixteen hours at room temperature. After 
filtration through silica and Celite©, the filtrate was collected and the solvent 
removed in vacuo resulting in a solid with an excellent yield of 94%. 
Hexadecanal 46 is a known compound and its structure was confirmed by 
comparison of proton NMR spectra to published data.180  
(a) 
(b) 
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2.4.3 Octynyl benzaldehyde 47 
A literature method for the synthesis of octynyl benzaldehyde 47 involved the 
Sonogashira-Hagihara cross coupling reaction.181 The first example of this cross 
coupling was published in 1975 by Sonogashira and Hagihara where they 
explored the application of copper-catalysed alkynylation of palladium 
complexes as an extension of the Stephens-Castro reaction.153, 154, 182-184 
 
Scheme 11 – Sonogashira-Hagihara cross coupling catalytic cycle.154, 185 
The accepted mechanism for the Sonogashira-Hagihara cross coupling involves 
two catalytic cycles (Cycles 1 and 2, Scheme 11).185 In Cycle 1, oxidative addition 
occurs between the palladium catalyst (0) and the R-X species (oxidative 
addition, Scheme 11).185 Next, transmetalation of the copper acetylide formed 
by Cycle 2 occurs (transmetalation, Scheme 11).184 Finally reductive elimination 
produces the desired alkyne and regenerates the palladium catalyst (reductive 
elimination, Scheme 11).185 In Cycle 2, a proposed π-alkyne copper complex 
forms which increases the acidity of the alkyne proton allowing the base greater 
ease with deprotonation (Scheme 11).185  
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There are many reasons why the Sonogashira-Hagihara cross coupling has 
become a favoured tool of synthetic chemists. Most couplings proceed at either 
room temperature or slightly above. The use of shock sensitive and explosive 
copper acetylides are avoided with the catalytic use of copper (I) salt which is 
commercially available and stable. Solvents and reagents do not need to be 
anhydrous and often the base acts as the solvent. The cross coupling works well 
(yields of 80%-90%) on small and large (>100 g) scales tolerating a wide 
variety of functional groups.153, 154 Many groups have sought to extend and 
evolve the scope of this reaction however, the conditions first stated by 
Sonogashira and Hagihara in 1975 remain most popular to this day.184  
In this project, the Sonogashira-Hagihara cross coupling was used to couple 
para-bromobenzaldehyde (53) and 1-octyne (54) to synthesise octynyl 
benzaldehyde 47. A mixture of para-bromobenzaldehyde (53), 1-octyne (54), 
bis(triphenylphosphine)palladium(II) dichloride and copper iodide in Et3N was 
stirred at 50 °C for sixteen hours.181 After work up, the desired octynyl 
benzaldehyde 47 was obtained in an excellent yield of 97% without further 
purification (> 95% purity as determined by 1H NMR spectroscopy). 
 
Scheme 12 – Sonogashira-Hagihara cross coupling between para-
bromobenzaldehyde (53) and 1-octyne (54) producing octynyl 
benzaldehyde 47.181 
The structure of octynyl benzaldehyde 47 was confirmed by comparison of 
spectral data with that in the literature.181  
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2.4.4 Octyl benzaldehyde 48 
To synthesise octyl benzaldehyde 48, catalytic hydrogenation using Pd/C was 
selected to reduce octynyl benzaldehyde 47. Catalytic hydrogenation was 
chosen as it is chemoselective for alkenes and alkynes over carbonyl groups.153  
A study conducted by Bond and Wells investigated the reductive activity of 
alumina-supported metal catalysts.186, 187 The metals examined in the study 
were palladium, rhodium, platinum, iridium and osmium. Bond and Wells found 
that palladium performed the best when conducting hydrogenations. 
In the current project, a suspension of Pd/C in a solution of octynyl 
benzaldehyde 47 in EtOAc was stirred for sixteen hours at room temperature 
under a hydrogen at 1 atm (Scheme 13).181 The crude brown oil obtained after 
filtration was analysed using proton NMR spectroscopy and was identical to 
starting material.  
 
Scheme 13 – (a) Unsuccessful hydrogenation attempt.181 
(b)Hydrogenation of octynyl benzaldehyde 47 using Pearlman’s 
catalyst. 
The first use of Pearlman’s catalyst [Pd(OH)2/C] (palladium hydroxide on 
carbon) was reported by Pearlman in 1967 and it is considered more successful 
in conditions where Pd/C fails.188, 189 A suspension of Pearlman’s catalyst in a 
solution of octynyl benzaldehyde 47 in EtOAc was stirred for sixteen hours at 
room temperature under a hydrogen atmosphere (Scheme 13). The reaction 
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mixture was filtered through Celite©, the filtrate collected and the solvent 
removed in vacuo. Octyl benzaldehyde 48 was obtained in an excellent yield of 
93%. The structure of octyl benzaldehyde 48 was confirmed by comparison 
with literature.181  
2.4.5 Octyloxy benzaldehyde 49 
Williamson ether synthesis 
The Williamson ether synthesis was first published in 1852 by Alexander W. 
Williamson where he accurately identified the formula of diethyl ether from a  
reaction using sodium ethoxide and ethyl chloride.190 The Williamson ether 
synthesis is when alkoxides react (SN2)with alkyl, allyl or benzyl halides to 
produce ethers.154, 190  
 
Scheme 14 – General mechanism of the Williamson ether 
synthesis. 145, 158 
In the current project, ethyl 4-hydroxybenzoate (56), iodooctane (55) and 
K2CO3 in a solution of DMF was stirred at room temperature for sixteen 
hours.191 After an aqueous work up, the crude oil was purified using column 
chromatography with a gradient elution system. The desired benzyl ester 58 
was isolated in an excellent yield of 85% (Scheme 15). The structure of 
compound 57 was confirmed by comparison with literature.192  
 
Scheme 15 – Williamson ether synthesis between ethyl 4-
hydroxybenzoate (56) and iodooctane (55).154 
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51 
 
58 
Reduction 
The reduction of an ester to the corresponding alcohol is commonplace and 
there are a variety of reducing agents. One example is sodium bis(2-
methoxyethoxy)aluminium hydride (58) which is commercially available as a 
solution in toluene, known as Vitride® or Red-Al® (Figure 36). 
 
Figure 36 – Structure of sodium bis(2-methoxyethoxy)aluminium 
hydride 72.193 
In the current project, Red-Al® 58 was employed to reduce octyloxy benzyl ester 
57 to the desired benzyl alcohol 59. Due to the exothermic nature of the 
reaction, the solution of ester 57 and Red-Al® 58 in toluene was stirred at 0 °C 
for two hours and then allowed to warm to room temperature and stirred for a 
further thirty-two hours. After quenching and an aqueous work up, the desired 
benzyl alcohol 59 was obtained in a yield of 89% with no requirement for 
further purification (>95% purity as determined from 1H NMR spectroscopy). 
The structure of benzyl alcohol 59 was confirmed  by comparison with 
literature.194 
 
Scheme 16 – Reduction of ester 56 to alcohol 59 using 
Red-Al® 58.195 
Oxidation 
The benzyl alcohol 59 was subjected to oxidation by PCC 51 to obtain the 
desired aldehyde 49 (Scheme 17). The principles of oxidation by PCC 51 have 
been covered in detail on page 45. 
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Scheme 17 – Oxidation of benzyl alcohol 59 to obtain desired 
aldehyde 49. 
A solution of benzyl alcohol 59 and PCC 51 was dissolved in DCM and stirred for 
sixteen hours. The reaction mixture was filtered through a frit of silica and 
Celite©. The filtrate was collected and the solvent removed in vacuo to give the 
desired ‘boutique’ aldehyde 49 in a yield of 95%. The structure of aldehyde 49 
was confirmed by comparison with literature.196  
The successful synthesis of octyloxy benzaldehyde 49 meant that all desired 
aldehydes were available. Focus now turned to the acetal formation. 
2.5 Acetal formation 
Cyclic acetals are most commonly used as protecting groups for aldehyde and 
ketones.167, 197 The acetal functional group is useful being easily introduced by 
an acid catalyst. When formed, the acetal is stable to bases, nucleophiles and 
most oxidants.197 The mechanism for the formation of a cyclic acetal is well 
established (Scheme 18). With a catalytic amount of acid present, the aldehyde 
is protonated. The resulting oxonium ion is then attacked by an alcohol group. 
Deprotonation furnishes the hemiacetal intermediate 62. The tertiary alcohol is 
then protonated which eventually generates water as a by-product (Scheme 18). 
The unstable oxonium ion 63 is then attacked by the remaining alcohol group. 
Deprotonation furnishes the desired acetal. Either a drying agent or Dean Stark 
apparatus is used to remove water ensuring the equilibrium favours the 
products. 
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Scheme 18 – Mechanism for the formation of an acetal using ethylene glycol 60.153 
In the first attempt of the current project, a suspension of MgSO4 in a solution of 
diol 34, hexadecanal 46 and a catalytic quantity (0.1 eq.) of TFA in CHCl3 was 
stirred for sixteen hours at room temperature.197 After filtration, the filtrate was 
collected and the solvent removed in vacuo. The crude brown oil was purified 
using column chromatography which afforded the desired di-ester 64 in a yield 
of 30% (Scheme 19). Confirmation of the structure of di-ester 64 was 
accomplished using proton and carbon NMR spectroscopy, IR and mass 
spectrometry. 
 
Scheme 19 – The formation of an acetal with diol 34 and hexadecanal 46. 
The low yield was unacceptable and so steps were taken to increase the 
efficiency of the reaction. Many research groups have demonstrated that 
microwave irradiation has a positive effect on the efficiency of acetal 
formations.198-201 To that effect, a number of time based optimisation reactions 
were conducted. Ultimately, the optimised reaction conditions were to subject 
two equivalents of aldehyde, diol 34 and TFA (0.1 eq.) in CHCl3 to microwave 
irradiation for twenty minutes at 80 °C. Using the microwave procedure, yields 
of di-esters ranged from 58% - 94% (Table 3). The structure of each di-ester 
was confirmed by proton and carbon NMR spectroscopy, IR and mass 
spectrometry. 
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Table 3 – Yields of di-esters 64 to 75. 
 
No.  Yield No.  Yield 
64 
 
93% 70 
 
58% 
      
65 
 
94% 71  74% 
      
66 
 
84% 72 
 
83% 
      
67 
 
75% 73  67% 
      
68 
 
79% 74  87%
* 
      
69 
 
71% 75 
 
65% 
      
* Reactions conditions: diol 34, TFA (0.1 eq.) and MgSO4 in neat acetone for twenty minutes at 
60 °C 
Figure 37 has an example of NMR spectra obtained in the confirmation of the 
structures of di-ester 64 - 75. As a result of the formation of the acetal, there is a 
distinctive signal in both proton and carbon spectrum that indicates the 
presence of the acetal proton and carbon (highlighted in Figure 37). Generally,  
the acetal proton appears around δ6.0 to δ5.0 and the acetal carbon around 
δ100.0 to δ110.0. Having confirmed the successful synthesis of each of the di-
esters, attention now turned to saponification. 
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Figure 37 – (a) Proton NMR spectrum of di-ester 66 in CDCl3. (b) Carbon NMR 
spectrum of di-ester 67 in CDCl3. 
 
2.6 Di-carboxylic acids 
In a process known as saponification, esters are hydrolysed under alkaline 
conditions to make carboxylic acids.153 The process is so named as it is the 
method traditionally used to make soap. Treating oils with sodium hydroxide 
produces the principal component of soap: sodium stearate.153 The mechanism 
of saponification is well known and described in Scheme 20. 
 
Scheme 20 – Mechanism for the saponification of an ester.153 
In this project, saponification was used to convert di-esters 64 - 75 to di-
carboxylic acids 76-86 (Table 4). Each di-ester was treated with NaOH in EtOH 
for sixteen hours. After removing EtOH in vacuo and an aqueous acidic work up, 
(a) 
(b) 
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each di-carboxylic acid was obtained as a solid with yields between 70% - 96% 
(Table 4). 
Table 4 – Yields of di-carboxylic acids 77 to 87. 
 
No.  Yield No.  Yield 
76 
 
87% 82 
 
89% 
      
77 
 
88% 83  96% 
      
78 
 
70% 84 
 
89% 
      
79 
 
88% 85  96% 
      
80 
 
89% 86  75% 
      
81 
 
92%    
      
 
Each di-carboxylic acid was fully characterised using proton and carbon NMR 
spectroscopy, IR, mass spectrometry and melting point. Figure 38 contains an 
example of proton spectra collected. No signals between δ3.25 and δ4.0 ppm 
indicated saponification was successful in cleaving the ester groups. 
Furthermore, the acetal at δ5.54 integrating for one hydrogen was still intact. 
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Figure 38 –Proton NMR spectrum of di-carboxylic acid 84 in CD3OD. 
Having attached the hydrophobic residues and prepared the scaffold for the di-
amide couplings, preparation of mono-protected EDA commenced. 
2.7 Mono-protected EDA 
For the synthesis of mono-protected EDA, two protecting groups were chosen; 
the benzyl carbamate (Cbz) and tert-butyl carbamate (Boc).197 These are 
popular amino protecting groups and are likely to be cleaved in high yields 
using acid (Boc) or hydrogenolysis (Cbz). A brief description and the process by 
which these groups are attached follows.  
2.7.1 Mono-protection of EDA (Cbz) 
The use of Cbz as a protecting group for amines was first performed in 1932 by 
Bergmann and Zervas.197, 202, 203 Since then, Cbz has been used extensively; being 
easy to install using readily available Cbz-Cl 88, stable in both aqueous base and 
acid and easily cleaved in high yield through catalytic hydrogenolysis.197  
In the current project, Cbz was used to mono-protect EDA 87. Replicating 
literature conditions, a concentrated solution of benzyl chloroformate 88 in 
DCM was added drop wise to a dilute solution of EDA 87 in DCM cooled to 0 °C 
over ninety minutes (Scheme 21).204 With a yield of 93%, Cbz-EDA 89 was 
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isolated as a pale yellow solid. No further purification was conducted and the 
structure of Cbz-EDA 89 was confirmed by comparison with literature 
spectra.204 
 
Scheme 21 – The mono-protection of EDA 87 using 
benzyl chloroformate 88.204 
2.7.2 Mono-protection of EDA (Boc) 
The Boc protecting group is also used extensively in peptide synthesis with 
stability to bases, most nucleophiles and catalytic 
hydrogenation/hydrogenolysis.197, 203, 205 The Boc group is easily cleaved by acid 
and the deprotected product generally forms a salt with the acid counter-ion 
(The importance of salt formation is elaborated later in this thesis.).197 The 
protection of a free amine with the Boc protecting group occurs by the reaction 
of a free amine with commercially available di-tert-butyl dicarbonate (90) 
(Boc2O).  
In the current project, Boc2O 90 was used to mono-protect EDA 87 (Scheme 22). 
Replicating literature conditions, a dilute solution of Boc2O 90 in DCM was 
added drop wise to a concentrated solution of EDA 87 in DCM stirring at 0 °C. 
The desired compound 91 was obtained in a yield of 90% (Scheme 22). 
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Scheme 22 – Mono-protection of EDA 87 with Boc2O (90) to 
obtain Boc-EDA 91. 
The structure of Boc-EDA 91 was confirmed by comparison with literature 
spectra.206  
2.8 Di-amide coupling 
2.8.1 Trial di-amide couplings 
The choice to use an amide bond to connect the hydrophilic sections to the 
norbornane scaffold was simple. Amide bonds are one of the most important 
chemical connections in nature being the bond that links amino acid building 
blocks to construct proteins.153, 206  
 
Scheme 23 – Di-amide coupling between mono-protected EDA and di-
carboxylic acid. 
An amide bond is built from a carboxylic acid and an amine. Although the 
reaction can occur spontaneously at high temperatures (over 200 °C and water 
is eliminated), the conditions have the potential to degrade other functional 
groups.207 To facilitate amide coupling at milder temperatures, a coupling agent 
was used: N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
(EDCI) (92) (Figure 39). Coupling agent 92 acts on the carboxylic segment 
converting the ‘hydroxyl’ moiety into a better leaving group.207 
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Figure 39 – Chemical structures for EDCI 92. 
In peptide chemistry, EDCI 92 is a popular carbodiimide coupling agent.167 The 
initial coupling agents of the carbodiimide class, such as 
dicyclohexylcarbodiimide (DCC), were first synthesised in 1955 and are still 
used today.207 Use of early DCC sometimes led to purification problems due to 
the dicyclohexylurea by-product.207 Sheehan et. al. developed water soluble 
carbodiimides EDCI 92 with a rationale that an aqueous work up would remove 
any by-products formed.167, 208, 209 The ease of work up has resulted in EDCI 92 
becoming one of the most popular carbodiimide coupling agents today. 
 
Scheme 24 – EDCI 92 mediated coupling between a carboxylic acid and an amine with 
three possible products.207 
When coupling a carboxylic acid and amine using carbodiimides, the first step 
involves the formation of the O-acylurea 93 (Scheme 24).167, 207 The reaction 
then potentially diverges into three pathways. In the first pathway, the O-
acylurea 93 is attacked by a carboxylic acid and results in carboxylic acid 
anhydride 96. The carboxylic acid anhydride 96 is susceptible to attack by the 
desired amine affording the required amide and soluble urea by-product 95 
92 
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(Pathway 1, Scheme 24). The second pathway results in the desired amide as 
well as the soluble urea by-product 95 (Pathway 2, Scheme 24).167 Finally, the 
third pathway results in the formation of an undesired N-acylurea product 94.  
To avoid the disadvantage of N-acylurea formation, additives such as 1-hydroxy-
1H-benzotriazole (97) (HOBt) were introduced (Scheme 25).210, 211 In an amide 
coupling involving EDCI 92 and HOBt 97, HOBt 97 reacts with the O-acylurea 
93 to give the O-benzotriazole ‘active’ ester 98. Nucleophilic attack by the amine 
regenerates the HOBt 97 catalyst and furnishes the desired amine (Scheme 25). 
 
Scheme 25 – Amide coupling between carboxylic acid and amine using EDCI 92 
and HOBt 97.207 
Since their development, there have been some interesting applications of EDCI 
92 and HOBt 97. One such example was in the synthesis of oxadiazoles. Das and 
Evans et. al. sought to integrate the oxadiazole moiety into Combretastatin 
derivatives. 212 Combretastatin A4 (99) is a broad spectrum anti-cancer drug 
that unfortunately loses potency when the cis double bond isomerises to the 
trans-configuration (Scheme 26a). Das and Evans determined that by 
substituting the double bond in Combrestastatin A4 (99) with an oxadiazole, the 
derivatives would not only maintain biological activity but likely increase in 
potency. To install the oxadiazole moiety, substrate 101 was coupled to 
carboxylic acid 100 using EDCI 92 and HOBt 97 (Scheme 26). After thirty 
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minutes, when the O-acylated product 102 had formed, the reaction was heated 
to reflux prompting cyclisation and affording the desired oxadiazole 103.213 
 
Scheme 26 – (a) Structure of Combretastatin A4 99. (b) Synthesis of Combretastatin 
analog 103.213 
Use of microwaves with coupling agents has been shown to give good yields.214 
In the current project the trial amide coupling reactions using Cbz-EDA 89 were 
subjected to microwave irradiation. All trial reactions were conducted at 30 
minutes, using MeCN, CHCl3 or DMF as solvent and temperatures ranging from 
50 °C to 100 °C. Other coupling agents gave lower yields and mono-coupled 
products. EDCI 92 produced the cleanest samples. 
 
Scheme 27 – Reactions conditions in trial amide couplings that 
obtained the best yield. 
After conducting a number of trial reactions, the best conditions obtained used 
microwave irradiation of di-carboxylic acid 77, Cbz-EDA 89, EDCI 92 and HOBt 
(a) 
(b) 
99 
100 101 102 
103 
89 
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97 in DMF for 30 minutes at 50 °C which gave the desired di-amide 104 in a 
yield of 41%. Although the yield was modest, it was determined sufficient for 
the synthesis of the amine functionalised norbornanes. These reaction 
conditions were applied to a selection of di-carboxylic acids.  
2.8.2 Synthesis of Cbz-protected Di-amines 
To synthesise the Cbz-protected di-amines, Cbz-EDA 89 was added to a solution 
of the relevant di-carboxylic acid, EDCI 92 and HOBt 97 in DMF. The reaction 
vessel was irradiated for 30 minutes at 50 °C. The Cbz-protected amines were 
isolated following purification by column chromatography and the yields are 
listed in Table 5. 
Table 5 – Yields of Cbz-protected amines. 
 
No.  
Isolated 
Yield No.  
Isolated 
Yield 
104 
 
41% 106  43% 
      
105 
 
65%    
      
Only modest yields were obtained in the synthesis of Cbz-protected amines 
(41% - 65%). It should be noted that when the reactions were repeated, the 
methodology lacked robustness, there were times yields were very low and 
purification proved difficult. Each compound in Table 5 was novel and 
characterised by proton and carbon NMR spectroscopy, IR, mass spectrometry 
and melting point.  
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2.8.3 Synthesis of Boc-protected Di-amines 
In the synthesis of Boc-protected amines, di-carboxylic acids 81 and 84 were 
selected for coupling with Boc-EDA 91. Di-carboxylic acid 84 was chosen 
specifically as the hydrophobic moiety present was suspected to be not 
orthogonal to the Cbz functional group. If a Cbz group were to be attached to di-
carboxylic acid 84, when faced with deprotection, the benzyl ether section of 
the hydrophobic residue would be cleaved in addition to the Cbz protecting 
groups. Hence, the Boc protecting group was the only option for this analogue. 
 
Figure 40 – Structure of di-carboxylic acids 81 and 84. 
For the amide couplings using Boc-EDA 91, each di-carboxylic acid was reacted 
according to the previously used conditions, i.e. solutions of the relevant di-
carboxylic acid, Boc-EDA 91, EDCI 92 and HOBt 97 in DMF were subjected to 
microwave irradiation for 30 minutes at 50 °C. Once again, only modest yields 
were obtained and the trend of reaction unpredictability continued. 
Table 6 – Yields of Boc-protected amines. 
 
No.  Yield No.  Yield 
107 
 
57% 108 
 
36% 
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2.9 New Strategy 
Whilst successful, the lack of reproducibility was concerning and the synthetic 
methodology was re-evaluated in light of several disadvantages. The first was 
the low yields obtained from amide couplings however, the biggest 
disadvantage was the introduction of hydrophobicity early in the synthetic 
methodology (Figure 41). Acetal formation was the trigger point for the diverse 
set of compounds most of which required column chromatography for 
purification in subsequent steps.  
 
 
 
Figure 41 – Cartoon depicting trigger point for the diverse set of compounds. 
Ideally, a new approach would have variation introduced as late in the synthetic 
pathway as possible (Scheme 28). As with the previous methodology, the 
scaffold would be assembled with a Diels-Alder cycloaddition. Different to the 
initial approach, norbornene di-ester 33 would be saponified and the di-amide 
would then be formed. Upjohn dihydroxylation would give the diol 34. Variation 
would then be introduced by the formation of an acetal with the aldehydes or 
ketones. The library of protected amines would then be ready for the final step 
of de-protection and salt formation. 
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Scheme 28 – Alternative retrosynthetic analysis. 
To construct the desired di-amines, the sequence of planned reactions was as 
follows (Scheme 28): 
x Diels-Alder cycloaddition to give norbornene di-ester 33. 
x Saponification to obtain norbornene di-carboxylic acid 109.  
x Di-amide coupling with mono-protected EDA. 
x Upjohn Dihydroxylation. 
x Formation of the acetal with either aldehydes or ketones. 
x The protected amines are then subjected to de-protection and salt 
formation to finally obtain the library of amines. 
The first reaction of the alternative approach involved the Diels-Alder 
cycloaddition between cyclopentadiene 31 and dimethyl fumarate 32. The 
cycloaddition to form di-ester 33 has already been discussed on page 39.  
2.10 Saponification 
Saponification was successful to form norbornene di-carboxylic acid 109 as a 
brittle white solid with a yield of 89% (Scheme 29). Confirmation of the 
structure of norbornene di-carboxylic 109 by comparison of spectral data.215 
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Scheme 29 – Saponification of di-ester 33 resulting 
in di-carboxylic acid 109. 
 
2.11 Di-amide couplings 
For multi-gram di-amide couplings, di-carboxylic acid 109, Boc-EDA 91, EDCI 
92 and HOBt 97 in DMF was stirred at 50 °C for sixteen hours using 
conventional heating. (Scheme 30). 
 
Scheme 30 – Di-amide coupling between di-carboxylic acid 109 
and Boc-EDA 91. 
After slow precipitation and collection, norbornene 110 was isolated as a white 
solid in excellent yield of 87%. Already, the new approach appeared more 
effective. The proton NMR spectrum of norbornene 110 clearly indicated the 
successful formation of amide bonds evidenced by the presence of the N-H 
protons at δ7.02 and δ6.84 (Figure 42). The peaks at δ6.20 assigned to the 
alkene were unaffected by the di-amide coupling. 
 
Figure 42 – Proton NMR spectrum of norbornene 110 in CDCl3. 
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Further characterisation was conducted through analysis carbon NMR 
spectroscopy, IR, mass spectrometry and melting point.  
2.12 Upjohn Dihydroxylation 
As the earlier dihydroxylation reaction conditions were conducted on a multi-
gram scale with excellent success, the same conditions were used for the 
dihydroxylation of norbornene di-amide 110 (Scheme 31). 
 
Scheme 31 – The dihydroxylation of norbornene 139. 
Compound 110 and NMO 45 were dissolved in a solution of H2O/acetone. Then 
OsO4 41 was added and the solution allowed to stir at room temperature for 
sixteen hours. After an aqueous work up, diol 111 was isolated in an excellent 
yield of 88% as beige solid. Analysis of the new compound using proton NMR 
spectroscopy confirmed the lack of alkene functionality (Figure 43). Further 
characterisation of diol 111 was performed using carbon NMR spectroscopy, IR, 
mass spectrometry and melting point. 
 
Figure 43 – Proton NMR spectrum of diol 111 in CD3OD. 
No alkene 
peaks 
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The synthesis of diol 111 represented the last step in the alternative synthetic 
strategy before the introduction of hydrophobicity. So far this methodology had 
performed very well; in the four steps thus far, there had been an overall yield 
of 68%. Each of the steps had been conducted on at least a five gram scale with 
excellent yields at each point. Very important was the lack of column 
chromatography for the purification of compounds 109 to 111. Hence, the 
formation of the acetal and the attachment of the hydrophobic moieties 
commenced. 
2.13 Acetal formation 
2.13.1 With tosic acid 
One of the important aspects of the acetal formation is that it typically occurs 
using acidic conditions.167 Unfortunately, when forming an acetal with diol 111, 
treatment with acid may lead to the deprotection of Boc groups. Trifluoroacetic 
acid is an acid regularly chosen for the deprotection of Boc, hence the previously 
optimised reaction conditions for the formation of an acetal (which employed 
TFA) were not ideal.197 It was essential therefore to select an acid that could 
catalyse the formation of the acetal but still be weak enough to preserve the Boc 
protecting groups. Consequently, p-toluenesulfonic acid (tosic acid or TsOH) 
112 was selected (Figure 44). 
 
Figure 44 – Structure of p-toluenesulfonic acid mono-hydrate (112). 
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Considered a weaker acid than TFA, Tosic acid 112 has been used for the 
formation of acetals.153 Trifluoroacetic acid has a pKa range of 0.23 in water at 
25 °C.216-218 However, Tosic acid 112 has pKa values of 6.20 and 8.5 (in MeCN 
and acetic acid respectively).219 220 With a milder acid in hand, trials of acetal 
formations were performed (Table 7). 
Table 7 – Acetal formations with tosic acid 111. 
 
No.  Yield No.  Yield 
113 
 
0% 114 
 
86% 
      
108 
 
0%    
      
The reaction solvent of choice here was CHCl3 having worked well in previous 
acetal formation reactions. The reactions were conducted using a conventional 
hotplate and not in a laboratory microwave. In each of the three trials listed in 
Table 7, a suspension of MgSO4 in a solution of the relevant aldehyde or ketone, 
tosic acid 112 and the diol 111 in CHCl3 was stirred for sixteen hours at 40 °C. 
Unfortunately, in only one instance was the desired product obtained, namely 
acetal 114. The reaction conditions were unsuccessful for products 113 and 
108 therefore further optimisation was conducted. 
2.13.2 Optimisation  
In the current set of optimisation reactions, there was a decision to concentrate 
on two solvent/acid combinations: toluene/tosic acid 112 and MeCN/oxalic 
acid. These solvent/acid combinations were the preferred conditions in 
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literature for the formation of acetals in the presence of Boc-protected 
amines.221-223 One example was published by Pandey et. al.221 In their efforts at 
devising a total synthesis of Maritidine (115), it was necessary to form an acetal 
in the presence of a boc protected amine on compound 116.  Formation of the 
acetal was achieved successfully using tosic acid 112 in benzene at reflux for ten 
hours with a yield of 80% (Scheme 32).221  
 
Scheme 32 – (a) Structure of Maritidine 115. (b) Formation of an 
acetal in the presence of a Boc protected amine.221 
In the current project, a number of reactions were attempted using CHCl3 as the 
co-solvent at different temperatures. The optimal reactions conditions were to 
stir the diol 111, aldehyde and oxalic acid in MeCN/CHCl3 for sixteen hours at 
50 °C which achieved a yield of 52%. Parallel to conducting the optimisation 
reactions, a gradient elution system was devised that allowed for the efficient 
purification of the desired product in under an hour. With the last of the issues 
surrounding the formation of the acetal solved, the synthesis of the library of 
Boc-protected amines began. 
 
115 
116 117 
(a) 
(b) 
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2.14 Synthesis of Boc-protected 
amines 
In this section of the project, each aldehyde or ketone was added to a 
suspension of MgSO4 in a solution of diol 111 and oxalic acid (1 eq.) in 
MeCN/CHCl3. The reaction mixture was allowed to stir for sixteen hours at 50 
°C. After filtration and removal of solvent, the crude solids were purified using 
column chromatography with gradient elution. All the boc-protected amines 
were obtained as solids (Table 8). 
Table 8 – Yields from the acetal formation in the synthesis of the Boc-protected amines. 
 
No.  Yield No.  Yield 
113 
 
40% 122 
 
73% 
      
118 
 
91% 123  72% 
      
119 
 
52% 108 
 
85% 
      
120 
 
51% 124  75% 
      
121 
 
91% 114  59% 
      
107 
 
25% 125 
 
61% 
The yields (Table 8) vary from 25% to 91%. Generally, the larger the 
hydrophobic region, the lower the yields as demonstrated by protected amines 
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113 and 107 whose hydrophobic moieties are a pentadeca carbon chain and a 
pyrene moiety respectively. Characterisation of each product was performed 
using proton and carbon NMR spectroscopy, IR, mass spectrometry and melting 
point. Protected di-amine 125 was selected and subjected to a thorough NMR 
analysis. The information gleaned was used for characterising the rest of the 
Boc-protected amines. 
2.15 NMR analysis of 125 
 
Figure 45 – Complete structure of protected amine 125. 
The Boc-protected amine 125 had a hydrophobic moiety comprised of fluorine 
para-substituted on the aromatic ring. The following NMR experiments were 
conducted: proton, COSY, carbon, HSQC and HMBC NMR spectroscopy and each 
are discussed in detail. 
2.15.1 Proton NMR (1D) 
 
 
Figure 46 – (a) Structure of compound 125 with labelled protons. (b) 
Proton NMR spectrum of compound 125. 
(a) 
(b) 
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The proton NMR spectrum of protected amine 125 was conducted in CDCl3 at 
500 MHz. To assist with preliminary assignments of the molecule, a publication 
by Bakkeren et. al. provided some hints. Bakkeren synthesised and 
characterised Diethyl exo,exo-5,6-dihydroxy[2.2.1]heptane-trans-2,3-
dicarboxylate (126). 
 
Figure 47 – Structure of diethyl exo,exo-5,6-dihydroxy[2.2.1]heptanes-
trans-2,3-dicarboxylate (126). 
Based on the information sourced from norbornane 126 characterised by 
Bakkeren et. al., the doublets at δ1.91 and δ1.51 correspond to the bridge head 
protons Hj and Hk. The doublets at δ4.29 and δ4.09 correspond to the protons He 
and Hi which are at a substantially higher chemical shift to the rest of the 
norbornane scaffold due to the deshielding by oxygen atoms forming the acetal. 
The rest of the norbornane scaffold corresponds to the signals in the range 
δ2.86 – δ.38. Finally, the eight ethyl protons correspond to the overlapping 
signals from δ3.37 – δ3.23. Figure 48 contains the definite assignments of the 
protons in amine 125. 
 
Figure 48 – Structure of amine 125 with some proton assignments. 
126 
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2.15.2 Correlation Spectroscopy NMR (COSY 2D) 
The COSY NMR was collected in CDCl3 at 500 MHz. In the two-dimensional COSY 
NMR, both axes and the diagonal correspond to one-dimensional proton NMR 
spectra. The mirrored cross peaks (off the diagonal) indicate couplings between 
protons that are two and three bonds apart. Long range couplings may be seen 
from interactions through π-electrons or from W-couplings.224  
Cross peaks were observed between signals δ7.40 and δ5.47. The interaction 
indicates 3JH-H coupling between Hl and Hg (Figure 49). No interaction was seen 
between δ6.99 and δ5.47 confirming that δ6.99 corresponds to Hm which is too 
far from Hg to exhibit cross peaks. 
 
Figure 49 – Cross peaks observed between δ7.40 and δ5.47 and not with δ6.99. 
Cross peaks were observed between δ1.91 and δ1.51 which confirms the bridge 
protons are responsible for these signals. The bridge protons are geminal 
protons in different chemical environments. Hj experiences greater deshielding 
from the acetal functional group and would therefore be assigned to the signal 
δ1.91. The proton Hk is assigned to δ1.51 which experiences less deshielding 
from the single exo amide. Using the geminal Karplus correlation, the 2JH-H 
coupling of 10 Hz indicates that Hk and Hj exist at angle of approximately 100 ° -
110 ° to each other (acceptable for tetrahedral carbon ≅ 109.5 °).225 
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Figure 50 – Cross peaks observed between δ1.91 and δ1.51. 
Cross peaks were observed between δ1.51 and both signals δ4.30 and δ4.09. 
The interaction confirms that Hk is a bridge head proton exhibiting W-coupling 
with both He and Hi (Figure 51a). Furthermore, cross peaks indicating more W-
coupling were observed between δ1.91 and δ2.60 but not δ2.86 proving that 
δ2.60 is Hc. Therefore Hb would be δ2.86 which would not show an interaction 
with Hj being in the exo- position (Figure 51b).   
 
Figure 51 – (a) W-coupling between δ1.51 and both δ4.30 and δ4.09. (b) 
Cross coupling between δ1.91 and δ2.60 but no with δ2.86. 
Looking at δ2.86, cross peaks were observed with δ2.60 and δ2.39 but not with 
δ2.65. The interactions therefore are 3JH-H coupling of Hb with Hc and Ha. 
Previously assigning δ2.60 to Hc, means Ha assigned to δ2.39 (Figure 52a). This 
would therefore leave Hd to be assigned to δ2.65. Cross peaks were expected 
between δ2.60 and δ2.65. However, none were observed indicating that the 
vicinal protons Hc and Hd are at approximately 90 ° angle to each other (using 
the vicinal Karplus correlation) which is as expected for the norbornane 
framework.225 
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Figure 52 – (a) Cross peaks between δ2.86 and both δ2.39 and δ2.60. (b) 
No cross peaks between δ2.60 and δ2.65. 
Cross peaks were observed between δ2.65 and δ4.09 therefore indicating that 
He is responsible for the signal at δ4.09. There were no cross peaks between 
δ4.30 and δ2.39 confirming the absence of symmetry across the norbornane 
scaffold due to the endo-, exo- orientation of the hydrophilic arms. There were 
also no cross peaks to allow for the assignment of the –NH protons. Figure 53 
details the assignments accomplished after analysis of the COSY NMR.  
 
Figure 53 – Assignments of protons of aromatic ring 
and norbornane scaffold after COSY NMR analysis. 
2.15.3 Carbon NMR and Heteronuclear Single Quantum 
Coherence NMR (HMQC) 
The carbon NMR and HMQC spectra were collected in CDCl3 at 500 MHz. The 
HMCQ NMR spectrum allows for the identification of carbons directly bonded to 
hydrogens. Figure 54 details the assignments that were made based on the 
analysis of the carbon and HMQC NMR spectra.  
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Figure 54 – (a) Structure of protected amine 125 with assigned carbons. (b) 
Carbon NMR spectrum of protected amine 125. 
The HSQC spectrum did not allow for assignments of quaternary carbons. To 
assign those carbons, analysis of the HMBC spectrum was required. 
2.15.4 Heteronuclear Multiple Bond Coherence NMR (HMBC) 
The HMBC spectrum was collected in CDCl3 at 500 MHz. The HMBC shows long 
range C-H coupling between two and three bonds and allows for quaternary 
carbons to be assigned. The first peaks considered were the carbon peaks 
δ173.9 and δ172.3. These showed interactions with proton signals δ2.86 and 
δ2.60 indicating that they were the amide carbons (Figure 55a). The next set of 
carbon peaks, δ164.4 and δ162.5 showed interactions with the aromatic 
protons, δ7.40 and δ6.99, but not with the acetal proton δ5.47. The peaks were 
therefore assigned to the quarternary carbon directly coupled to the fluorine 
atom and characterised as a doublet due to the fluorine splitting (1JF = 247 Hz) 
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(Figure 55b). Interactions between carbon δ131.9 and protons δ7.40, δ6.99 and 
δ5.47 identified the other quaternary carbon (Figure 55c). 
 
Figure 55 – (a) Cross coupling between protons (δ2.86 and δ2.60) and 
carbons (δ173.9 and δ172.3) (b) Cross coupling between doublet 
carbon δ163.5 (1JF = 247 Hz) and protons (δ7.40 and δ6.99). 
The next interaction was between carbon δ156.8 and protons δ3.37 to δ3.23. 
This was the 3JC-H coupling between the carbamate carbon and the ethyl protons. 
Another interaction between carbon δ80.0 and protons in signal δ1.37 assigned 
the tert-butyl quaternary carbon.  
 
Figure 56 – Fully assigned carbon skeleton of protected amine 125. 
Having fully assigned all carbons and hydrogens in di-protected di-amine 125, 
the deprotection of the Boc-protected amine analogues could now be 
considered. 
2.16 Salt formation 
2.16.1 Pharmaceutically useful salts 
It is necessary that new bioactive compounds are tested in a form consistent 
with that of established pharmaceuticals.148 Amines are commonly marketed in 
the form of a salt to aid; bioavailability, stability, hydroscopicity and most 
80 
 
30 
importantly, improvement in aqueous solubility.148, 149 It is important therefore 
to conduct tests on a relevant salt form of a compound as early in the 
development process as possible.148  
 
Figure 57 – Structure of compound 30 with TFA counterion.145 
In the original publication by Pfeffer et. al., the compounds (for example 30) was 
tested as TFA salts (Figure 57).145 Table 9 lists the most commonly used anionic 
counterions in pharmaceutical salts – note the absence of TFA salts. Hence, 
compounds developed in the course of this project were to be produced and 
tested in the form of the more relevant hydrochloride salt.148  
Table 9 – The fifteen most common counterions.148 
Salt Form Approximate 
frequency % 
Hydrochloride/chloride 49 
Sulfate 6 
Hydrobromide/bromide 5 
Tartrate 3 
Mesylate 3 
Citrate 3 
Phosphate 2.5 
Acetate 2 
Embonate 1.5 
Hydroiodide/iodide 1 
Nitrate 1 
Lactate 1 
Methylsulphate 1 
Fumarate 1 
 
Chloride salts represent the most common salt form of drugs approved by the 
United States Food and Drug Administration.148, 226 To form chloride salts of the 
Boc-protected amines in the current project, deprotection measures that result 
directly in the HCl salt were investigated. 
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2.16.2 The potential for acetal degradation 
To deprotect the Boc groups, the protected compound must be treated with 
acid.197 Examples of acids used are TFA, HCl and acetyl chloride in MeOH 
(creating anhydrous HCl in situ).197 Unfortunately, some conditions for the 
deprotection of Boc are similar to those required for the decomposition of an 
acetal. Hence, in this project it was necessary to devise a suitable method for 
deprotecting Boc groups while still preserving the acetal functional group.  
 
Figure 58 – Di-ester 64 subjected to studies of the 
stability of the acetal.145 
Previous work published by Pfeffer et. al. studied the stability of the acetal by 
dissolving di-ester 64 in 10% aqueous DMSO media acidified to pH 1 with HCl. 
The solution was analysed hourly by proton NMR spectroscopy for eighteen 
hours and the final proton NMR spectrum was so similar to the initial spectrum 
that no degradation of the acetal was presumed to have occurred.145 As such, 
Pfeffer et. al. proceeded to treat their protected compounds with a solution of 
20% TFA in DCM for sixteen hours at room temperature, a common procedure 
for the deprotection of boc-protected substrates to form TFA salts.227, 228 
 
Figure 59 – Structures of di-esters selected for acid trials. (a) Di-ester 68. (b) Di-
ester 75. (c) Di-ester 66. (d) Di-ester 64.  
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129 
To devise appropriate deprotection reaction conditions in the current project, a 
selection of acetal di-esters (64, 66, 68 and 75) were selected (Figure 59). The 
compounds contained the following hydrophobic functionalities: purely 
hydrocarbon (di-ester 64); aromatic rings with either no or different 
substituents (Di-esters 68, 66 and 75). Next, treatment by HCl in Dioxane was 
selected as an appropriate method for deprotecting Boc groups in the presence 
of acetals.223  
 
Scheme 33 - Deprotection of Boc group in the presence of an acetal.222 
A successful example of this was employed by GlaxoSmithKline in the synthesis 
of novel pharmaceuticals.222 In the course of synthesising compound 129, it was 
necessary to deprotected the Boc group in 127 in the presence of an acetal. 
Deprotection resulted in the chloride salt 128 (Scheme 33). Hence, treatment by 
HCl in Dioxane was the first protocol attempted at the deprotection of the Boc 
groups on the di-protected di-amines. 
Table 10 – Percentage degradation of the acetal functional group. 
 
No.  Degradation No.  Degradation 
64 
 
0% 63 
 
14% 
      
75 
 
12% 68 
 
13% 
      
The di-ester 64 with a purely aliphatic region exhibited no degradation of the 
acetal was noted confirming tests conducted by Pfeffer et. al.145 The other di-
127 128 
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68 130 
64 131 
34 
esters 66, 68 and 75 all showed slight degradation.  An example of degradation 
is illustrated in Figure 60.  
 
Figure 60 – Proton NMR spectrum of (a) di-ester 69. (b) di-ester 69 subjected to acid treatment. 
It is possible that the acetal substitutents played an important role in the extent 
(if any) of degradation. For aryl acetals, protonation may ultimately result in 
carbocation 130. The cationic charge would be stabilised over the aromatic ring 
as well as oxonium and this may eventually lead to the diol 31. This additional 
stability does not exist when the substituent of the acetal is alkyl (Scheme 34). 
 
Scheme 34 – Stabilised carbocation 130 species leading to diol 34. 
To determine which would be the least detrimental to the acetal, a number of 
deprotection protocols were trialled (Table 11). In order to calculate 
(a) 
(b) 
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68 68 
degradation, the ratios of the acetal proton (δ5.56) were compared to peaks 
corresponding to degradation as determined from proton NMR spectra (Figure 
60). 
Table 11 – Percentage degradation of acetal as a result of different deprotection 
conditions.145, 197, 229 
 
Experiment 
No. Solvent Acid Time 
Temp 
(°C) 
Degradation 
(%) Comments 
1 DCM TFA 16 h r.t. 17% - 
2 MeOH AcCl 16 h r.t 17% - 
3 Et2O 1M HCl 16 h r.t. 21% - 
4 Dioxane HCl 16 h r.t. 16% - 
5 Dioxane HCl 16 h r.t. 14% MgSO4* 
6 Dioxane HCl 7 hrs r.t. 15% Anhydrous** 
* MgSO4 added to reaction vessel. 
 ** Anhydrous solvent used. 
The use of a drying agent in the reaction vessel (Entry 5, Table 11) or anhydrous 
solvent with a reduced time (Entry 6, Table 11) resulted in less degradation. 
From the above experiments, two deprotection conditions were selected for 
further investigation: acetyl chloride in MeOH and HCl in anhydrous dioxane.  
2.17 Case Study: Protected amine 
150 
The mechanism by which a Boc deprotection occurs is well established (Scheme 
35).165 Firstly, the carbonyl oxygen, the most basic oxygen, is protonated. 
Heterolysis of the oxygen and tert-butyl bond results in carbamic acid 133 and a 
tert-butyl cation 132. In the final step carbamic acid 133 decarboxylates, 
expelling carbon dioxide and free amine. Parallel to carbamic acid 
decomposition, the tert-butyl cation 132 decomposes to isobutene. 
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Scheme 35 – Deprotection of Boc group using an acid catalyst.165 
Anhydrous HCl in Dioxane solution was prepared 24 hours prior to use and 
stored in a refrigerator over 4Å molecular sieves. To MeOH, acetyl chloride was 
added and allowed to stir for thirty minutes prior to addition of amine 120. In 
both instances, amine 120 was added and the reaction stirred vigorously for 
approximately four hours with progress monitored by TLC (Scheme 36). 
 
 
Scheme 36 – Amine 120 subjected to two deprotection protocols. 
Once the nominated treatment time was complete, the reaction solvents were 
removed in vacuo and the resulting residues analysed using proton NMR 
spectroscopy. Figure 61 shows the proton NMR spectra obtained. Comparison 
with the spectrum of the protected amine 120, there was an absence of the Boc 
peaks at δ1.30 signifying successful deprotection. Nevertheless, there were new 
signals from δ6.25 to δ5.25. In the region highlighted, where the acetal protons 
commonly appear, there were up to four different peaks indicating a mixture of 
products. The peak at δ5.53 was assigned to the fully formed acetal peak using 
the acetal peak in the proton spectrum of protected amine 120. 
132 133 
120 134 
86 
 
 
Figure 61 – Proton NMR spectrum of (a) protected amine 122; (b) crude product following 
treatment with HCl in Dioxane; (c) crude product following treatment with acetyl chloride 
in MeOH. 
Comparison of the spectra indicated that the acetyl chloride in MeOH protocol 
resulted in fewer by-products (Figure 61). Each crude residue was then 
dissolved in water, washed with EtOAc and water removed by sublimation 
(freeze drying). The resulting solids resembled a ‘floss’, and were hydroscopic 
and became viscous oils when exposed to normal atmosphere. The solids were 
again analysed using proton NMR spectroscopy (Figure 62). 
(a) 
(b) 
(c) 
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Figure 62 – Following purification, Proton NMR of compound 134 after (a) treatment with 
HCl in Dioxane (b) treatment with acetyl chloride in MeOH. 
In both instances, purification served to remove most by-products, making the 
fully formed acetal the major product. Comparing the two methods of treatment 
at this point, it was determined that the acetyl chloride in MeOH and extractive 
purification protocol produced a sample that had the highest purity. 
Having selected a deprotection and purification protocol, attention now turned 
to the characterisation of the purified amine salts. In the circumstances where 
degradation occurred, small amounts of by-products were sometimes observed 
present even in the purified salt. A strategy was devised to estimate the purity 
of the amine salts obtained. First, a pure amine salt was studied to determine 
characteristic peaks (Figure 63). 
(a) 
(b) 
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Figure 63 –Proton NMR spectrum in CD3OD of (a) diol 135. (b)  di-amine 137. 
Figure 63 shows the proton spectrum of a pure amine salt (amine 137) and the 
diol 135. Key characteristic peaks are highlighted in both spectra. The protons 
forming the norbornane scaffold were chosen as ‘landmarks’ in the spectra of 
mixed products. The acetal is highlighted as that is characteristic of the presence 
of the intact hydrophobic region of the molecule (Figure 64).  
 
Figure 64 – Proton NMR spectrum of amine salt 136 containing a mixture of products. 
(a) 
(b) 
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Percentage purity was estimated through integrations of the relevant proton 
and any adjacent by-products (Figure 64). Initially, the peaks in the region of 
δ4.3 were selected. The dominant peak (δ4.29, int.=1.00) was calculated as 
percentage of the total of the dominant peak (δ4.29, int.=1.00) and the 
degradation (δ4.18, int.=0.14) to achieve the estimated purity of 87%. 
Unfortunately, for many amine salts in the library, this region contained many 
resonances and it was difficult to select peaks to estimate purity. Hence, the 
acetal was selected to calculate estimated purity as this region remained the 
least cluttered.  
The acetal integration (δ5.66, int.=0.83) was measured against the sum of 
integrations of both the acetal and degradation (δ6.29, int.=0.17, total = 1.00) to 
obtain a percentage purity of 83%. As the purity calculated using the acetal 
region was within a close range to the purity calculated using the protons from 
the norbornane scaffold, the integrations of the peaks within the acetal region 
(clearly visible in all amine salts) were used to estimate purities of all amine 
salts.  
2.18 Deprotection and salt 
formation 
Each protected amine was treated with acetyl chloride in MeOH. Once the 
reaction was judged complete by TLC, the reaction solvent was removed in 
vacuo leaving behind crude residues. The residues were re-dissolved in EtOAc 
and extracted using H2O. The aqueous phases were combined and water 
removed by sublimation. The purity of each amine salt is indicated in Table 12.  
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Table 12 – Yields of the Boc deprotection by acetyl chloride in MeOH. 
 
No.  Mass
* Purity No.  Mass
* Purity 
137 
 
66% 100% 141 
 
72% 65% 
        
138 
 
89% 98% 142 
 
91% 79% 
        
136 
 
84% 83% 143 
 
88% 56% 
134 
       
 
99% 85% 144 
 
95% 100% 
        
139 
 
99% 67% 145 
 
99% 95% 
        
140 
 
73% 86% 146 
 
80% 70% 
        
*Mass recovered after freeze drying. 
For compounds with purities higher than 85%, proton and carbon NMR 
spectroscopy, mass spectrometry and IR were further conducted to confirm 
identity of compounds. 
2.19 Conclusion  
The aim of the current chapter was to devise a methodology to synthesise 
amphiphilic di-amines containing differing hydrophobic moieties. A revised 
synthetic pathway allowed for a robust method for the synthesis of the amine 
functionalised norbornane based CAMP mimics. The new synthetic 
methodology was suitable for large scale reactions (up to sixty grams) and its 
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most attractive features was that only once in a seven step synthetic pathway 
was purification by column chromatography required. 
Unfortunately, deprotection of the Boc groups was problematic. The acetal 
functional group proved somewhat sensitive to acid treatment. A deprotection 
protocol and purification procedure was identified that gave highly pure di-
amine di-hydrochlorides. The acetyl chloride in MeOH method produced salts 
with purities ranging from 56% - 100% (twelve compounds with 8 > 85% 
purity). For the samples in the lower range of purities, the presence of the fully 
degraded product, diol 134, was noted. 
The collection of amine salts were sent for antibacterial testing the results of 
which are discussed in chapter 5. The completion of the amine library marked 
the point where focus could be turned to the synthesis of the di-guanidine 
functionalised norbornane based CAMP mimics. 
2.20 Experimental 
2.20.1 General Experimental  
Microwave reactions were conducted using a CM Discover S-Class Explorer 48 
Microwave Reactor, operating on a frequency of 50/60 Hz and continuous 
irradiation power from 0 to 200 W. All reactions were performed in either 
10mL or 30 mL septa vials with snap caps, with the following conditions: 
pressure (17 bar); power max (on); and stirring (high).  
All 1H and 13C NMR spectra were recorded on a Jeol JNM-EX 270 MHz, Jeol JNM-
EX 400 MHz or Bruker Advance III 500 MHz FT-NMR as indicated. Samples were 
dissolved in either deuterated chloroform (CDCl3), deuterated methanol 
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(CD3OD) or deuterated water (D2O) with the residual solvent peak used as an 
internal reference (δ = 7.26 ppm for CDCl3, 3.31 ppm for CD3OD, 4.71 ppm for 
D2O). Proton spectra are reported as follows: chemical shift δ (ppm), [integral, 
multiplicity (s = singlet, br s = broad singlet, d = doublet, dd = doublet of 
doublets, t = triplet, br t = broad triplet, q = quartet, m = multiplet), coupling 
constant J (Hz), assignment]. There is the presence of an apparent triplet which 
is a true doublet of doublets in the 1H NMR spectrum of norbornane based 
compounds. Carbon spectra are reported as chemical shift δ (ppm).  
Mass Spectra (MS), including High Resolution Mass Spectra (HRMS), were 
recorded on a 6210 MSD TOF mass spectrometer (Agilent Technologies, 
Australia) or Agilent MS 6520 TOF with dual electrospray ionisation source with 
the following conditions: drying gas nitrogen (7.0 L/min, 325 °C); nebuliser gas 
nitrogen (15 psi); capillary voltage 3.0 kV; vaporiser temperature 29 °C; and 
cone voltage 40 V.  
Fourier transform infrared (FT-IR) spectra were recorded on a Bruker ALPHA 
Platinum ATR FT-IR Spectrometer. The following abbreviations apply to peak 
intensity: w = weak, m = medium, s = strong, br = broad. All melting points were 
obtained using a Bibby Stuart Scientific SMP3 melting point apparatus, version 
5.0.  
Thin Layer Chromatography (TLC) was performed using aluminium-backed 
Merck TLC Silica gel 60 F254 plates, and samples were visualised using 254 nm 
ultraviolet (UV) light, potassium permanganate/potassium carbonate oxidising 
dip (1:1:100 KMnO4:K2CO3:H2O w/w) or ceric ammonium molybdate stain.  
Column Chromatography was performed using silica gel 60 (70-230 mesh).  
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All solvents used were AR grade. Petroleum spirits refers to the fraction boiling 
between 40-60 °C. THF, CHCl3 and DMF were dried using a Pure Solv 
(Innovative Technologies) solvent drying system. Solvents are degassed, and 
passed through two drying chambers of alumina and collected under a positive 
pressure of nitrogen gas.  
All general reagents were analytical grade and used as supplied unless 
otherwise stated. Purification and/or drying of general reagents were 
performed according to Perrin et. al.230 Specialist reagents such as peptide 
coupling reagents were supplied by Aldrich Chemical Co. or A.K Scientific Inc. 
and used without further purification. 
2.20.2    Known compounds 
The following compounds are known compounds and were prepared using 
literature conditions with no modifications:  
x Dimethyl bicyclo[2.2.1]hept-5-ene-2-endo,3-exo-dicarboxylate 
(norbornene di-ester) 33.156  
x Dimethyl 5,6-dihydroxy bicyclo[2.2.1]heptane-2-endo,3-exo-
dicarboxylate (norbornane diol) 34.145 
x 1-Hexadecanal 46.145, 231 
x para-Oct-1’-ynyl benzaldehyde 47.181 
x para-Octyl benzaldehyde 48.181 
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Section 2.5 Hydrophobic component 
Ethyl 4-(octyloxy)benzoate (57)192 
Ethyl 4-hydroxybenzoate 56 (1.11 g, 6.67 mmol), 
iodooctane 55 (4.8 g, 19.9 mmol) and K2CO3 (2.76 
g, 19.9 mmol) were added to DMF (10 mL) and the reaction mixture stirred for 
16 hours at room temperature. The reaction mix was diluted with EtOAc (50 
mL), transferred to a separatory funnel and washed with H2O (2 × 50 mL) and 
brine (50 mL). The organic phase was separated, dried (MgSO4) and filtered and 
solvent was removed in vacuo resulting in clear oil. This crude oil was purified 
using column chromatography (1% EtOH in Pet 40-60). Fractions containing the 
desired compound (Rf 0.17) were combined and the solvent removed in vacuo 
to give the desired compound as viscous oil. (1.57 g, 85%); δH NMR (270 MHz, 
CDCl3): 7.97 (2H, dd, JAB’ = 2.7 Hz, JAB = 8.1 Hz, H3) 6.88 (2H, dd, JA’B = 2.7 Hz, JA’B’ 
= 8.1 Hz, H4) 4.33 (2H, q, J = 5.9 Hz, H2) 3.98 (3H, t, J = 6.4 Hz, H1) 1.83-1.27 
(14H, m, H5-11) 0.87 (3H, t, J = 5.9 Hz, H12). 
4-(octyloxy)benzyl alcohol (59)194 
Red-Al® 58 (1.25 g, 6.17 mmol) was added to a 
cooled to (0 °C) solution of ethyl 4-
(octyloxy)benzoate 57 (343 mg, 1.23 mmol) in toluene (5 mL) and then allowed 
to stir for 16 hours at room temperature. Saturated potassium sodium tartrate 
solution (6 mL) was added followed by H2O (10 mL), transferred to a separatory 
flask and extracted with EtOAc (3 × 10 mL). The organic phases were combined, 
dried (MgSO4) and filtered. Solvent removed in vacuo resulting in white viscous 
oil. (261 mg, 89%); δH NMR (270 MHz, CDCl3): 7.26 (2H, dd, JAB’ = 2.7 Hz, JAB = 
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35 
5.4 Hz, H3) 6.87 (2H, dd, JA’B = 2.7 Hz, JA’B’ = 5.4 Hz, H2) 4.60 (2H, s, H1) 3.95 (2H, 
t, J = 4.5 Hz, H4) 1.49-1.24 (12H, m, H5-10) 0.89 (3H, t, J = 4.5 Hz, H11). 
p-Octyloxy benzaldehyde (49)196 
A solution of para-octyloxy benzyl alcohol 59 (1.14 
g, 4.82 mmol) and PCC 51 (1.25 g, 5.78 mmol) in 
DCM (25 mL) was stirred for 16 hours at room temperature. The reaction 
mixture was then filtered through a silica/Celite® frit. The frit was washed with 
DCM (150 mL). The filtrate was collected and the solvent removed in vacuo 
resulting in yellow viscous oil. The oil was determined to be 98% pure by NMR 
and was used in the next step without further purification. (1.01 g, 90%); δH 
NMR (270 MHz, CDCl3): 9.86 (1H, s, H1) 7.81 (2H, dd, JAB’ = 2.7 Hz, JAB = 8.1 Hz, 
H3) 6.97 (2H, dd, JA’B = 2.7 Hz, JA’B’ = 8.1 Hz,  H2) 4.02 (2H, t, J = 6.7 Hz, H4) 1.47-
1.27 (12H, m H5-10) 0.87 (3H, t, J = 6.4 Hz, H11). 
Section 2.6 Acetal formation 
 
General methodology: A solution of aldehyde/ketone (2 eq.), norbornane diol 
35 (approx. 300 mg), TFA (approx. 222 mg, 1 mmol) and MgSO4 in CHCl3 was 
irradiated in a laboratory microwave for 20 minutes at 80 °C. The reaction 
mixture was then filtered and the solvent removed in vacuo. The crude oils were 
purified using column chromatography [EtOAc/Pet 40-60]. Fractions containing 
the desired compound were combined and the solvent removed in vacuo. 
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Dimethyl 7-[pentadecyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxylate (64) 
Hexadecanal 46 (0.88 g, 3.63 
mmol); norbornane diol 34 (0.60 
g, 2.45 mmol); column eluent 
[EtoAc/Pet 40-60 (1:19)]; Rf 0.23; brown viscous oil (1.07 g, 93%); υmax(thin 
film/cm-1) 2926(s) (methyl C-H), 2855(s) (methyl C-H), 1712(s) (ester C=O), 
1362(br) (methylene C-H), 1120(m) (acetal C-O); δH NMR (270, CDCl3): 4.64  
(1H, t, J = 4.9 Hz, H7), 4.01 (1H, d, J = 5.7 Hz, H5) 3.89 (1H, d, J = 5.7 Hz, H9) 3.69 
(3H, s, -OCH3) 3.67 (3H, s, -OCH3) 3.21 (1H, dd, J = 4.9, 4.9 Hz, H2) 2.69 (1H, d, J = 
5.4 Hz, H4) 2.62 (2H, m, H1, H3) 1.76 (1H, d, J = 9.6 Hz, H10a) 1.63-1.58 (3H, m, 
H11, H10b) 1.35-1.23 (26H, m, H12-H24) 0.86 (1H, t, J = 6.4 Hz, H25); δC NMR 
(67.5, CDCl3): 174.1, 172.8, 104.3, 81.3, 78.9, 52.4, 52.2, 45.3, 45.1, 43.7, 43.32, 
43.3, 34.1, 32.8, 32.0, 31.7, 29.7, 29.6, 29.5, 29.4, 29.3, 29.1, 24.8, 24.6, 24.3, 22.8, 
14.2; HRMS (ESI m/z): calculated for  [C27H46O6+Na]+ 489.3192, found 
489.31607. 
Dimethyl 7-[(p-phenyl)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-
endo,3-exo-dicarboxylate (65) 
para-Phenyl benzaldehyde (280 mg, 1.54 
mmol); norbornane diol 34 (250 mg, 1.02 
mmol); column eluent [EtOAc/Pet 40-60 
(1:10)]; Rf 0.18; white viscous oil (395 mg, 94%); υmax(thin film/cm-1) 2955 (m) 
(methyl C-H) 2851 (w) (methyl C-H) 1647 (s) (aromatic ring C=C) 1726 (m) 
(ester C=O) 834 (m) (para substitution on aromatic C-H); δH NMR (270 MHz, 
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CDCl3): 7.62 – 7.33 (9H, m, H11-19), 5.63 (1H, s, H7), 4.26 (1H, d, J = 5.4 Hz, H5), 
4.12 (1H, d, J = 5.4 Hz, H9), 3.74 (3H, s, -OCH3), 3.73 (3H, s, -OCH3), 3.30 (1H, dd, 
J = 4.9, 5.2 Hz, H2), 2.86 (1H, d, J = 2.7 Hz, H4) 2.80 (1H, s, H3) 2.72 (1H, dd, J = 
2.7, 5.4 Hz, H1) 2.01 (1H, dd, J = 1.49, 9.6 Hz, H10a) 1.46 (1H, dd, J = 1.49, 9.6 Hz, 
H10b); δC NMR (67.5 MHz, CDCl3): 174.0, 172.8, 142.7, 140.8, 134.7, 128.9 (2 
carbons), 127.6, 127.4 (2 carbons), 127.3 (2 carbons), 127.2 (2 carbons), 103.2, 
81.8, 79.4, 52.5, 52.3, 45.4, 45.1, 43.8, 43.5, 32.0; HRMS (ESI m/z): calculated for 
[C24H24O6+Na]+ 431.4335, found 431.4353. 
Dimethyl 7-[p-bromo-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-
endo,3-exo-dicarboxylate (66) 
Bromo benzaldehyde (156 mg, 844 μmol); 
norbornane diol 34 (103 mg, 422 μmol); column 
eluent [EtOAc/Pet 40-60 (1:10)]; Rf 0.07; brown oil 
(145 mg, 84%); υmax(thin film/cm-1) 1725 (vs) (ester C=O) 1111 (vs) (acetal C-
O) 1012 (s) (aromatic C-H) 664 (m) (bromine C-Br); δH NMR (270 MHz, CDCl3): 
7.49 (2H, dd, JAB’ = 2.7 Hz, JAB = 5.4 Hz,  H12) 7.34 (2H, dd, JA’B’ = 2.7 Hz, JA’B’ = 5.4 
Hz,  H11) 5.51 (1H, s, H7) 4.21 (1H, d, J = 3.5 Hz, H5) 4.09 (1H, d, J = 3.5 Hz, H9) 
3.72 (3H, s, -OCH3) 3.70 (3H, s, -OCH3) 3.27 (1H, dd, J = 3.5, 3.5 Hz, H2) 2.82 (1H, 
d, J = 2.7 Hz, H4) 2.76 (1H, s, H3) 2.70 (1H, d, J = 2.7 Hz, H1)  1.89 (1H, dd, J = 0.9, 
5.7 Hz, H10a) 1.42 (1H, dd, J = 0.9, 5.7 Hz, H10b); δC NMR (67.5 MHz, CDCl3): 
173.9, 172.7, 134.9, 131.9 (2 carbons), 128.4 (2 carbons), 123.8, 102.6, 81.81, 
79.4, 52.5, 52.3, 45.3, 45.2, 43.8, 43.4, 31.9; HRMS (ESI m/z): calculated for 
[C18H19BrO6+Na]+ 433.0263 and 435.0245, found 433.0300 and 435.0294. 
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Dimethyl 7-[(p-octynyl)-phenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-
endo,3-exo-dicarboxylate (67) 
Octynyl benzaldehyde 47 (551 mg, 2.57 
mmol); norbornane diol 34 (314 mg, 
1.29 mmol); column eluent [EtOAc/Pet 
40-60 (1:9)]; Rf 0.23; brown viscous oil (404 mg, 75%); υmax(thin film/cm-1) 
2932 (m) (methyl C-H) 2856 (m) (methylene C-H) 1733 (vs) (ester C=O) 1070 
(s) (acetal C-O) 832 (s) (para substitution of aromatic C-H); δH NMR (270 MHz, 
CDCl3): 7.38 (4H, s, H11-12) 5.53 (1H, s, H7) 4.21 (1H, d, J = 3.7 Hz, H5) 4.09 (1H, 
d, J = 3.7 Hz, H9) 3.72 (3H, s, -OCH3) 3.71 (3H, s, -OCH3) 3.27 (1H, dd, J = 3.2, 3.2 
Hz, H2) 2.83 (1H, d, J = 2.7 Hz, H4) 2.77 (1H, s, H3) 2.71 (1H, d, J = 2.7 Hz, H1) 
2.38 (2H, t, J = 4.7 Hz, H13) 1.94 (1H, dd, J = 0.9, 6.5Hz, H10a) 1.62-1.25 (9H, m, 
H10b, H14-17) 0.89 (3H, t, J = 4.7 Hz, H18); δC NMR (67.5 MHz, CDCl3): 173.85, 
172.70, 134.75, 131.58 (2 carbons), 126.53 (2 carbons), 125.52, 102.94, 91.40, 
81.70, 80.23, 79.29, 52.42, 52.23, 45.30, 45.15, 43.72, 43.38, 31.35, 29.70, 28.66, 
28.60, 22.56, 19.44, 14.06; HRMS (ESI m/z): calculated for [C26H32O6+H]+ 
441.22717, found 441.22741. 
Dimethyl 7-phenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxylate (68) 
Benzaldehyde (821 μL, 8.13 mmol ); norbornane diol 
34 (992.3 mg, 4.06 mmol); column eluent [EtOAc/Pet 
40-60 (1:3)]; Rf 0.68; brown viscous oil (1.13 g, 79%); 
υmax(thin film/cm-1) 1731 (s) (ester C=O), 1436 (w) (aromatic C=C), 1089 (w) 
(acetal C-O); δH NMR (270, CDCl3): 7.50-7.31 (5H, m, H11-13) 5.56 (1H, s, H7) 
4.21 (1H, d, J = 5.8 Hz, H5) 4.09 (1H, d, J = 5.8 Hz, H9) 3.71 (3H, s, -OCH3) 3.70 
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(3H, s, -OCH3) 3.27 (1H, d, J = 5.2 Hz, H2) 2.83 (1H, d, J = 5.4 Hz, H4) 2.77 (1H, s, 
H3) 2.71 (1H, d, J = 2.7 Hz, H1) 1.98 (1H, dd, J = 1.5, 9.4 Hz, H10a) 1.43 (1H, dd, J 
= 1.5, 9.4 Hz, H10b); δC NMR (67.5, CDCl3): 173.9, 172.8, 135.8, 129.7, 128.6 (2 
carbons), 126.8 (2 carbons), 103.2, 81.7, 79.3, 52.8, 52.3, 45.4, 45.2, 43.8, 43.5, 
31.9; (ESI m/z): calculated for  [C18H20O6+Na]+ 355.33, found 355.30. 
Dimethyl 7-pyrenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxylate (69) 
Pyrenecarboxaldehyde (243.6 mg, 1.06 mmol ); 
norbornane diol 34 (129.2 mg, 529 μmol); column 
eluent [EtOAc/Pet 40-60 (1:3)]; Rf 0.71; yellow 
viscous oil (170.4 mg, 71%); υmax(thin film/cm-1) 1739 (w) (ester C=O) 1647 
(vs) (aromatic C=C) 1015 (s) (acetal C-O); δH NMR (270 MHz, CDCl3): 8.38-8.03 
(9H, m, H11-19) 6.59 (1H, s, H7) 4.47 (1H, d, J = 2.7 Hz, H5) 4.36 (1H, d, J = 2.7 
Hz, H9) 3.78 (3H, s, -OCH3) 3.73 (3H, s, -OCH3) 3.33 (1H, d, J = 2.7 Hz, H2) 2.94 
(1H, d, J = 2.7 Hz, H4) 2.90 (1H, s, H3) 2.83 (1H, d, J = 2.7 Hz, H1) 2.03 (1H, dd, J = 
1.5, 9.4 Hz, H10a) 1.47(1H, dd, J = 1.5, 9.4 Hz, H10b); δC NMR (67.5 MHz, CDCl3): 
173.9, 172.8, 132.0, 131.1, 128.8, 128.5, 128.2, 127.9, 127.3, 125.9, 125.5, 125.4, 
124.6 (2 carbons), 122.8, 122.6, 122.5, 122.4, 100.8, 81.9, 79.5, 52.4, 52.3, 45.3, 
45.2, 43.7, 43.5, 31.9; (ESI m/z): calculated for [C28H24O6+H] 457.165, found 
457.1721. 
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Dimethyl 7,7-dipropyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxylate (70) 
4-Heptanone (475.3 mg, 4.16 mmol ); norbornane diol 
34 (508 mg, 2.08 mmol); column eluent [EtOAc/Pet 
40-60 (1:9)]; Rf 0.38; clear viscous oil (408 mg, 58%); 
υmax(thin film/cm-1) 1658 (w) (ester C=O) 1022 (vs) (acetal C-O); δH NMR (270 
MHz, CDCl3): 4.07 (1H, d, J = 3.5 Hz, H5) 3.92 (1H, d, J = 3.5 Hz, H9) 3.68 (3H, s, -
OCH3) 3.66 (3H, s, -OCH3) 3.18 (1H, dd, J = 2.7, 2.7 Hz, H2) 2.64-2.57 (3H, m, H1, 
H3-4) 1.80 (1H, d, J = 7.2 Hz, H10a) 1.61-1.22 (9H, m, H10b, H11-12, H14-15) 
0.89-0.84 (6H, m, H13, H16); δC NMR (67.5 MHz, CDCl3): 174.1, 172.9, 113.0, 
80.9, 78.2, 52.4, 52.2, 45.4, 45.3, 43.6, 43.5, 38.0, 37.3, 31.7, 17.9, 17.1, 14.43, 
14.40; (ESI m/z): calculated for [C17H26O6+Na]+ 349.16, found 349.19. 
Dimethyl 7-(p-octyl phenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-
exo-dicarboxylate (71) 
para-Octyl benzaldehyde 48 (309 mg, 
1.41 mmol ); norbornane diol 34 (173 
mg, 707 μmol); column eluent [EtOAc/ 
Pet 40-60 (1:9)]; Rf 0.37; brown viscous oil (232 mg, 74%); υmax(thin film/cm-1) 
2925 (vs) (methylene C-H) 2856 (s) (methyl C-H) 1697 (vs) (aromatic C=C) 
1465 (m) (ester C=O) 1104 (m) (acetal C-O); δH NMR (270 MHz, CDCl3): 7.43 
(2H, d, JAB = 5.4 Hz, H11) 7.27 (2H, d, JA’B’ = 5.4 Hz, H12) 5.53 (1H, s, H7) 4.21 
(1H, d, J = 3.7 Hz, H5) 4.09 (1H, d, J = 3.7 Hz, H9) 3.73 (3H, s, -OCH3) 3.71 (3H, s, -
OCH3) 3.27 (1H, d, J = 2.7 Hz, H2) 2.83 (1H, d, J = 2.7 Hz, H4) 2.77 (1H, s, H3) 
2.71 (1H, d, J = 2.7 Hz, H1) 1.94 (1H, dd, J = 0.7, 6.7 Hz, H10a) 1.62-1.22 (14H, m, 
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H13-19) 0.88 (3H, t, J = 4.5 Hz, H20); δC NMR (67.5 MHz, CDCl3): 173.89. 172.7. 
134.8. 131.6 (2 carbons), 126.6 (2 carbons), 125.7, 102.9, 81.7, 79.3, 52.5, 52.3, 
45.5, 45.3, 45.2, 43.8, 43.6, 43.4, 31.9, 31.4, 29.1, 28.6, 22.6, 19.5, 14.1; (ESI m/z): 
calculated for [C26H36O6+H]+ 446.26, found 446.29. 
Dimethyl 7-[3-(benzyloxy)phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-
endo,3-exo-dicarboxylate (72) 
3-Benzyloxybenzaldehyde (922 mg, 4.34 
mmol); norbornane diol 34 (531 mg, 2.17 
mmol); column eluent [EtOAc/Pet 40-60 
(1:1)]; Rf 0.46; white viscous oil (765 mg, 83%); υmax(thin film/cm-1) 1718, (m) 
(ester C=O) 1624 (m) (aromatic C=C) 1213 (w) (aromatic C-H) 1105 (w) (acetal 
C-O); δH NMR (270 MHz, CDCl3): 7.42-6.90 (9H, m, H11-14, H16-20) 5.55 (2H, s, 
H15) 5.06 (1H, s, H7) 4.22 (1H, d, J = 3.9 Hz, H5) 4.10 (1H, d, J = 3.9 Hz, H9) 3.73 
(3H, s, -OCH3) 3.71 (3H, s, -OCH3) 3.28 (1H, dd, J = 2.7, 2.7 Hz, H2) 2.83 (1H, d, J = 
2.7 Hz, H4) 2.77 (1H, s, H3) 2.72 (1H, d, J = 2.7 Hz, H1) 1.94 (1H, d, J = 7.4 Hz, 
H10a) 1.42 (1H, d, J = 6.9 Hz, H10b); δC NMR (67.5 MHz, CDCl3): 173.9, 172.8, 
158.9, 137.3, 136.9, 129.7, 128.7, 128.1 (2 carbons), 127.6, 119.4, 116.2 (2 
carbons), 113.0, 103.1, 81.7, 79.3, 70.1, 52.5, 52.3, 45.4, 45.2, 43.8, 43.5, 31.9; 
(ESI m/z): calculated for [C25H27O7+Na]+ 462.16, 462.11.  
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Dimethyl 7-heptyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxylate (73) 
Octanal (734 mg, 5.72 mmol ); norbornane diol 
34 (699 mg, 2.86 mmol); column eluent 
[EtOAc/Pet 40-60 (1:9)]; Rf 0.44; clear viscous 
oil (678 mg, 67%); υmax(thin film/cm-1) 2970 (s) (methyl C-H) 1408 (m) (ester 
C=O) 1128 (s) (acetal C-O); δH NMR (270 MHz, CDCl3): 4.64 (1H, t, J = 3.2 Hz, H7) 
4.02 (1H, d, J = 3.7 Hz, H5) 3.89 (1H, d, J = 3.7 Hz, H9) 3.71 (3H, s, -OCH3) 3.69 
(3H, s, -OCH3) 3.21 (1H, d, J = 2.7 Hz, H2) 2.71-2.31 (3H, m, H1, H3-4) 1.77 (1H, 
d, J = 7.4 Hz, H10a) 1.67-1.59 (3H, m, H10b, H11) 1.35-1.22 (10H, m, H12-16) 
0.85 (3H, t, J = 4.5 Hz, H17); δC NMR (67.5 MHz, CDCl3): 174.08, 172.8, 104.3, 
81.3, 75.9, 52.4, 52.2, 45.3, 45.1, 43.7, 43.3, 32.8, 31.8, 31.7, 29.6, 29.2, 24.3, 22.7, 
14.1; (ESI m/z): calculated for [C19H30O6+H]+ 355.21, found 355.25. 
Dimethyl 7-(dimethyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxylate (74) 
A suspension of MgSO4 (250 mg) in a solution of 
norbornane diol 34 (301 mg, 1.23 μmol) and TFA (3 
drops) in acetone (2 mL) was irradiated in a laboratory 
microwave for 20 mins at 60 °C. The reaction mixture was then filtered and the 
solvent removed in vacuo. The crude brown oil was purified using column 
chromatography with an eluent of (1:1) EtOAc/Pet 40-60. Fractions containing 
the desired compound (Rf 0.64) were combined and the solvent removed in 
vacuo resulting in clear viscous oil. (303 mg, 87%); υmax(thin film/cm-1) 2923 
(w) (methyl C-H) 1732 (vs) (ester C=O) 1069 (m) (acetal C-O); δH NMR (270 
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MHz, CDCl3): 4.12 (1H, d, J = 5.4 Hz, H5) 3.99 (1H, d, J = 5.4 Hz, H9) 3.69 (3H, s, -
OCH3) 3.68 (3H, s, -OCH3) 3.21 (1H, d, J = 5.4 Hz, H2) 2.65 (1H, d, J = 1.62 Hz, H4) 
2.63 (1H, d, J = 1.62 Hz, H3) 2.57 (1H, s, H1) 1.77 (1H, dd, J = 1.5, 9.2 Hz, H10a) 
1.41 (3H, s, methyl C-H) 1.35 (1H, dd, J = 1.5, 7.9 Hz, H10b) 1.25 (3H, s, methyl C-
H); δC NMR (67.5 MHz, CDCl3): 174.1, 172.9, 109.5, 81.0, 78.4, 52.4, 52.3, 45.3, 
45.2, 43.6, 43.4, 41.2, 31.5, 25.4; (ESI m/z): calculated for [C14H20O6+H]+ 285.11, 
found 285.15. 
Dimethyl 7-(p-fluorophenyl)6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-
exo-dicarboxylate (75) 
para-Fluorobenzaldehyde (106 mg, 856 μmol ); 
norbornane diol 34 (105 mg, 428 μmol); column 
eluent [EtOAc/Pet 40-60 (1:9)]; Rf 0.14; yellow viscous 
oil (98 mg, 65%); υmax(thin film/cm-1) 1729 (vs) (ester C=O) 1117 (vs) (acetal C-
O) 1075 (s) (fluorine C-F); δH NMR (270 MHz, CDCl3): 7.46 (2H, dd, 3JF = 2.7, 13.5 
Hz, H12) 7.04 (2H, dd, 4JF = 2.7, 16.2 Hz, H11) 5.53 (1H, s, H7) 4.20 (1H, d, J = 5.7 
Hz, H5) 4.08 (1H, d, J = 5.7 Hz, H9) 3.71 (3H, s, -OCH3) 3.70 (3H, s, -OCH3) 3.27 
(1H, dd, J = 2.7, 2.7 Hz, H2) 2.82 (1H, d, J = 2.7 Hz, H4) 2.76 (1H, s, H3) 2.70 (1H, 
d, J = 2.7 Hz, H1) 1.93 (1H, dd, J = 1.5, 9.7 Hz, H10a) 1.43 (1H, dd, J = 1.5, 9.7 Hz, 
H10b); δC NMR (67.5 MHz, CDCl3): 173.8, 172.7, 163.5 (1C, d, 1JF = 134 Hz) 131.6 
(1C, d, 4JF = 2 Hz) 128.6 (2C, d, 2JF = 4 Hz) 115.4 (2C, d, 3JF = 11 Hz),  102.6, 81.7, 
79.3, 52.4, 52.3, 45.3, 45.1, 43.7, 43.4, 31.9; HRMS (ESI m/z): calculated for 
[C18H19FO6+H]+ 351.12384, found 351.12426. 
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Section 2.7 Di-carboxylic acids 
 
General method: To a stirring solution of di-ester (100 mg to 1 g) in EtOH (5 
mL) was added 1 M NaOH (20 mL) and the reaction was stirred at room 
temperature for 16 hours. The reaction mixture was then concentrated under 
vacuum to a quarter of the volume and then acidified to a pH of 1. The diluted 
reaction mixture was transferred to a separatory flask and extracted with EtOAc 
(3 × 20 mL). The organic phases were separated, dried using MgSO4 and filtered. 
The filtrate was collected and the solvent removed in vacuo. Each product was 
checked by NMR, confirmed as pure and used in the next step without further 
purification. 
7-(pentadecyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo, 3-exo-
dicarboxylic acid (76)145 
Di-ester 64 (1.39 g, 2.98 mmol); white 
solid (1.15 g, 87%); mp 61.2 - 64.3 °C; 
υmax(thin film/cm-1) 2977 (m) 
(methyl C-H) 1685 (vs) (carboxylic acid C=O) 1458 (m) (methylene C-H) 1087 
(s) (acetal C-O); δH NMR (270 MHz, CDCl3): δH  4.67 (1H, t, J = 4.9 Hz, H7) 4.04 
(2H, m, H5, H9) 3.27 (1H, dd, J = 2.7, 2.7 Hz, H2) 2.78 (1H, d, J = 2.7 Hz, H4) 2.72 
(1H, s, H3) 2.64 (1H, d, J = 5.4 Hz, H1) 1.82 (1H, d, J = 10.2 Hz, H10a) 1.62 (6H, m, 
H12-14) 1.35-1.23 (21H, m, H10b, H15-24) 0.86 (3H, t, J = 6.7 Hz, H25); δC NMR 
(67.5 MHz, CDCl3): 178.84, 177.64, 104.43, 81.28, 78.32, 45.19, 43.62, 34.07, 
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32.00, 29.76-29.13 (12 carbons), 24.75, 24.72, 22.78, 14.20; MS (ESI m/z): 
calculated for [C25H42O6-H]- 437.29, found 437.29. 
7-[(p-phenyl)phenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo, 3-exo-
dicarboxylic acid (77) 
Di-ester 65 (703 mg, 1.72 mmol); white solid (578 
mg, 88%); mp 217.5 – 219.6 °C; υmax(thin film/cm-
1) 1693 (s) (aromatic C=C) 1451 (s) (aromatic C=C) 
1382 (m) (carboxylic acid C=O) 1089 (s) (acetal C-O); δH NMR (270 MHz, 
CD3OD): 7.50 (9H, m, H11-19) 5.62 (1H, s, H7) 4.22 (2H, m, H5, H9) 3.24 (1H, dd, 
J = 5.4, 5.4 Hz, H2) 2.78 (1H, d, J = 2.7 Hz, H4) 2.72 (1H, d, H3) 2.64 (1H, d, J = 5.4 
Hz, H1) 2.00 (1H, dd, J = 1.2, 7.7 Hz, H10a) 1.44 (1H, dd, J = 1.2, 7.7 Hz, H10b); δC 
NMR (67.5 MHz, CD3OD): 175.5, 174.2, 142.4, 140.5, 135.1, 128.6 (2 carbons), 
127.3, 127.2 (2 carbons), 126.7 (2 carbons), 126.6 (2 carbons), 102.9, 81.8, 79.4, 
45.4, 45.3, 43.8, 43.3, 31.4; MS (ESI m/z): calculated for [C22H20O6+Cl]- 415.09, 
found 415.13. 
7-(p-bromo phenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxylic acid (78) 
Di-ester 66 (1.21 g, 2.94 mmol); white solid (975.1 mg, 
87%); mp 201.2-204.6 °C; υmax(thin film/cm-1) 1712 
(vs) (aromatic C=C) 1701 (vs) (aromatic C=C) 1410 (s) 
(carboxylic acid C=O) 1070 (m) (acetal C-O) 700 (m) (bromine C-BR); δH NMR 
(270 MHz, CD3OD): 7.54 (2H, d, JAB = 5.7 Hz, H12) 7.40 (2H, d, JA’B’ = 5.7 Hz, H11) 
5.55 (1H, s, H7) 4.20 (2H, m, H5, H9) 3.22 (1H, dd, J = 2.7, 2.7 Hz, H2) 2.75 (1H, 
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d, J = 2.7 Hz, H4) 2.70 (1H, s, H3) 2.62 (1H, d, J = 2.7 Hz, H1) 1.90 (1H, d, J = 6.9 
Hz, H10a) 1.41 (1H, d, J = 6.9 Hz, H10b); δC NMR (67.5 MHz, CD3OD): 175.4, 
174.1, 135.5, 131.2 (2 carbons), 128.5 (2 carbons), 123.2, 102.3, 81.8, 79.4, 45.3, 
45.2, 43.7, 43.2, 31.4; MS (ESI m/z): calculated for [C16H13BrO6+Na]- 402.97, 
found 402.98. 
7-[(p-octynyl)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-
carboyxlic acid (79) 
Di-ester 67 (404 mg, 960 μmol); brown solid 
(348 mg, 88%); mp 168.3 – 173.1 °C; 
υmax(thin film/cm-1) 1739 (vs) (alkyne C≡C) 
1691 (vs) (aromatic C=C) 1421 (m) (carboxylic acid C=O); δH NMR (270 MHz, 
CD3OD): 7.39 (4H, s, H11-14) 5.57 (1H, s, H7) 4.23 (2H, m, H5, H9) 3.32 (1H, d, J 
= 2.7 Hz, H2) 2.91 (1h, d, J = 2.7 Hz, H4) 2.86 (1H, s, H3) 2.72 (1H, d, J = 2.7 Hz, 
H1)  2.39 (2H, t, J = 4.7 Hz, H15) 2.00 (1H, d, J = 6.9 Hz, H10a) 1.63-1.25 (9H, m, 
H10b, H16-19) 0.89 (3H, t, J = 4.7 Hz, H20); δC NMR (67.5 MHz, CD3OD): 175.5, 
174.2, 135.4, 131.0 (2 carbons), 126.6 (2 carbons), 125.5, 102.7, 90.6, 81.8, 79.9, 
79.4, 45.4, 45.2, 43.8, 43.3, 31.4, 31.2, 28.5, 28.4, 22.3, 18.7, 13.1; MS (ESI m/z): 
calculated for [C24H28O6+H]+ 413.20, found 413.20. 
 
 
 
107 
 
7-phenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo, 3-exo-dicarboxylic 
acid (80) 
Di-ester 69 (495 mg, 1.49 mmol); white solid (403 mg, 
89%); mp 81.5 – 82.9 °C; υmax(thin film/cm-1) 1541 (m) 
(carboxylic acid C=O) 1456 (m) (aromatic C=C) 1073 (w) 
(acetal C-O); δH NMR (270 MHz, CD3OD): 8.03-7.37 (5H, m, H11-15) 5.56 (1H, s, 
H7) 4.19 (2H, m, H5, H9) 3.22 (1H, dd, J = 2.7, 2.7 Hz, H2) 2.76 (1H, d, J = 2.7 Hz, 
H4) 2.71 (1H, s, H3) 2.76 (1H, d, J = 2.7 Hz, H1) 1.96 (1H, dd, J = 0.9, 6.5 Hz, 
H10a) 1.41 (1H, dd, J = 0.9, 6.5 Hz, H10b); δC NMR (67.5 MHz, CD3OD): 176.9, 
175.5, 130.7, 130.6, 129.4, 129.3, 127.9, 126.7, 104.4, 82.9, 80.6, 46.7, 46.5, 45.1, 
44.6, 32.7; MS (ESI m/z): calculated for [C16H16O6+ Cl]- 339.06, found 339.03. 
7-pyrenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-dicarboxylic 
(81) 
Di-ester 69 (117 mg, 256 μmol); yellow solid (101 mg, 
92%); mp 272.1 – 274.1 °C; υmax(thin film/cm-1) 3044 
(m) (aromatic C-H) 1728 (vs) (aromatic C=C) 1408 (m) 
(carboxylic acid C=O); δH NMR (270 MHz, CD3OD): 8.38-8.11 (9H, m, H11-19) 
6.62 (1H, s, H7) 4.45 (2H, m, H5, H9) 3.26 (1H, dd, J = 5.4, 5.4 Hz, H2) 2.87 (1H, 
d, J = 5.4 Hz, H4) 2.79 (1H, s, H3) 2.72 (1H, dd, J = 2.7, 5.4 Hz, H1) 1.99 (1H, d, J = 
9.1 Hz, H10a) 1.45 (1H, d, J = 9.1 Hz, H10b); δC NMR (67.5 MHz, CD3OD): 175.4, 
174.2, 131.9, 131.2, 130.6, 128.9, 127.6, 127.6, 127.4, 127.2, 127.0, 125.8, 125.2, 
125.1, 125.1, 125.0, 124.3, 124.2, 100.3, 45.4, 45.3, 45.2, 43.8, 43.7, 43.3, 31.4; 
MS (ESI m/z): calculated for [C26H20O6+2H]2+ 215.0, found 215.0. 
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7-[(p-octyl)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-
carboxylic acid (83) 
Di-ester 71 (232 mg, 521 μmol); brown solid 
(208 mg, 96%); mp 162.3 – 165.40 °C; 
υmax(thin film/cm-1) 2957 (s) (methyl C-H) 
1708 (vs) (aromatic C=C) 1551 (s) (carboxylic acid C=O) 1131 (s) (acetal C-O) 
831 (1,4-disubstitution of aromatic C-H); δH NMR (270 MHz, CD3OD): 7.41 (2H, 
d, JAB = 5.4 Hz, H11) 7.35 (2H, d, JA’B’ = 5.4 Hz, H12)  5.55 (1H, s, H7) 4.19-4.17 
(2H, m, H5, H9) 3.22 (1H, dd, J = 2.7, 2.7 Hz, H2) 2.75 (1H, d, J = 2.7 Hz, H4) 2.7 
(1H, s, H3) 2.62 (1H, d, J = 2.7 Hz, H1) 2.39 (2H, t, J = 4.9 Hz, H15) 1.92 (1H, d, J = 
6.9 Hz, H10a) 1.62-1.28 (13H, m, H10b, H16-21) 0.91 (3H, t, J = 4.7 H, H22); δC 
NMR (67.5 MHz, CD3OD): 175.5, 174.2, 135.3, 130.9 (2 carbons), 126.5 (2 
carbons), 125.4, 102.6, 90.5, 81.6, 79.8, 79.3, 47.8, 47.6, 47.4, 47.3, 31.3, 31.1, 
28.4, 28.3, 28.2, 22.2, 13.0; MS (ESI m/z): calculated for [C24H32O6+H]+ 417.22, 
found 417.22. 
7-[(3-benzyloxy)phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-
exo-dicarboxylic acid (84) 
Di-ester 72 (120 mg, 273 μmol); white solid (96.4 
mg, 89%); mp 246.0-247.1 °C; υmax(thin film/cm-
1) 3136 (br w) (aromatic C-H) 1645 (vs) 
(carboxylic acid C=O) 1217 (w) (oxy-phenyl C-O) 1015 (m) (acetal C-O); δH NMR 
(270 MHz, CD3OD): 7.44-7.00 (9H, m, H11-14, H16-20) 5.54 (1H, s, H7) 5.09 (2H, 
s, H15) 4.18 (2H, m, H5, H9) 3.21 (1H, dd, J = 5.4, 5.4 Hz, H2) 2.74 (1H, d, J = 2.7 
Hz, H4) 2.69 (1H, s, H3) 2.61 (1H, d, J = 2.7 Hz, H1) 1.88 (1H, d, J = 8.1 Hz, H10a) 
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1.39 (1H, d, J = 10.8 Hz, H10a); δC NMR (67.5 MHz, CD3OD): 174.24, 173.9, 158.9, 
137.6, 137.3, 129.3, 129.1, 128.2 (2 carbons), 127.6, 127.3, 127.2, 119.2, 115.8 
(2 carbons), 112.9, 102.9, 81.6, 79.3, 69.7, 45.0, 43.2, 31.4; MS (ESI m/z): 
calculated for [C23H22O7-2H]2- 204.06, found 204.06. 
7-heptyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-dicarboxylic 
acid (85) 
Di-ester 73 (678 mg, 1.91 mmol); white solid (601 
mg, 96%); mp 134.4-138.0 °C; υmax(thin film/cm-1) 
2925 (m) (methyl C-H) 1751 (vs) (carboxylic acid C=O) 1134 (s) (acetal C-O); δH 
NMR (270 MHz, CD3OD): 4.68 (1H, t, J = 2.7 Hz, H7) 4.04 (2H, br m, H5, H9) 3.26 
(1H, dd, J = 2.7, 5.4 Hz, H2) 2.79 (1H, d, J = 2.7 Hz, H4) 2.73 (1H, s, H3) 2.65 (1H, 
d, J = 2.7 Hz, H1) 1.82 (1H, d, J = 10.4 Hz, H10a) 1.64-1.59 (2H, m, H11) 1.38-1.22 
(11H, m, H10b, H12-16) 0.86 (3H, t, J = 4.7 Hz, H17); δC NMR (67.5 MHz, 
CD3OD): 179.1, 177.9, 104.5, 81.3, 78.7, 45.2, 45.1, 43.6, 43.3, 32.8, 31.8, 29.8, 
29.6, 29.2, 24.3, 22.7, 14.1; MS (ESI m/z): calculated for [C17H26O6-H]- 325.16, 
found 325.16. 
7,7-dipropyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-dicarboxylic 
acid (82) 
Di-ester 70 (506 mg, 1.49 mmol); white solid (411 mg, 
89%); mp 196.7-200.1 °C; υmax(thin film/cm-1) 2957 (w) 
(methyl C-H) 1697 (vs) (carboxylic acid C=O) 1140 (s) (acetal C-O); δH NMR 
(270 MHz, CD3OD): 4.13-4.08 (2H, m, H5, H9) 3.25 (1H, dd, J = 2.7, 2.7 Hz, H2) 
2.74 (1H, d, J = 2.7 Hz, H4) 2.69 (1H, s, H3) 2.64 (1H, d, J = 2.7 Hz, H1) 1.85 (1H, 
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d, J = 10.4 Hz, H10a) 1.61-1.2 (9H, m, H10b, H11-12, H14-15) 0.88 (6H, t, J = 6.4 
Hz, H13, H16); δC NMR (67.5 MHz, CD3OD): 178.9, 177.6, 113.2, 80.8, 78.1, 60.6, 
45.3, 43.6, 37.9, 37.3, 31.8, 21.2, 20.8, 17.9, 17.2, 14.4; MS (ESI m/z): calculated 
for [C16H24O6-H]- 311.15, found 311.15.  
7,7-dimethyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxylic acid (86) 
Di-ester 74 (414 mg, 1.46 mmol); white solid (280 mg, 75%); 
mp 197.5-197.8 °C; υmax(thin film/cm-1) 2984 (m) (methyl C-
H) 2854 (m) (methyl C-H) 1701 (vs) (carboxylic acid C=O); δH 
NMR (270 MHz, CD3OD): 4.15 (2H, m, H5, H9) 3.26 (1H, dd, J = 5.4, 5.4 Hz, H2) 
2.73 (1H, d, J = 5.4 Hz, H4) 2.67-2.64 (2H, m, H1, H3) 1.83 (1H, d, J = 10.6 Hz, 
H10a) 1.43-1.36 (4H, m, H11, H10b) 1.28 (3H, s, H12); δC NMR (67.5 MHz, 
CD3OD): 175.6, 174.3, 109.3, 80.99, 78.42, 45.3, 45.2, 43.6, 43.2, 30.8, 24.3, 22.9; 
MS (ESI m/z): calculated for [C12H16O6-H]- 255.09, found 255.09. 
Section 2.8 Mono-protected EDA 
The following compounds are known compounds and were prepared using 
literature conditions:  
x Benzyl 2-aminoethylcarbamate 89.232 
x N-Boc-Ethylenediamine 91.206 
111 
 
Section 2.9 Di-amide coupling 
 
General methodology: A solution of di-carboxylic acid (approx. 100 mg), mono-
protected EDA (3 eq.) and EDCI 92 (3 eq.) and HOBt 97 (0.1 eq) and CHCl3 (3 
mL) was irradiated in a microwave for 30 minutes at 50 °C. The reaction 
mixture was transferred to a separatory flask and washed with H2O (2 × 10 mL) 
and brine (10 mL). The aqueous layers were combined and extracted with CHCl3 
(10 mL). The organic layers were combined, dried (MgSO4), filtered and the 
solvent removed in vacuo. The resultant crude products were purified using 
column chromatography with gradient elution [(1:1)EtOAc/Pet 40-60 → 5% 
EtOH in (1:1) EtOAc/Pet 40-60]. Fractions containing the desired compound 
were combined and the solvent removed in vacuo. 
7-[(p-phenyl)phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
N2,N3-bis(benzyl 2-ethyl carbamate) dicarboxamide (104) 
 Di-carboxylic acid 77 (214 mg, 562 
μmol); Cbz-EDA 89 (327 mg, 1.68 
mmol); EDCI 92 (323 mg, 1.68mmol); 
HOBt 97 (20 mg, 148 μmol); Rf 0.24; white oil (167 mg, 41%); υmax(thin 
film/cm-1) 3306 (br m) (secondary amines N-h) 1703 (s) (aromatic C=C) 1648 
(s) (amide C=O); δH NMR (270 MHz, CDCl3): 7.57-7.28 (19H, m, H11-19, H25-27, 
H33-35) 6.93 (1H, br t, -NH) 6.85 (1H, br t, -NH) 5.64 (2H, t, J = 3.2 Hz, H20, 
H28) 5.55 (1H, s, H7) 5.07 (4H, s, H24, H32) 4.28 (1H, d, J = 3.7 Hz, H5) 4.16 (1H, 
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d, J = 3.7 Hz, H9) 3.33-3.25 (8H, m, H21-22, H29-30) 2.99 (1H, d, J = 2.7 Hz, H2) 
2.65 – 2.63 (2H, m, H3, H4) 2.54 (1H, d, J = 2.7 Hz, H1) 2.00 (1H, d, J = 6.9 Hz, 
H10a) 1.58 (1H, d, J = 6.9 Hz, H10b); δC NMR (67.5 MHz, CDCl3): 174.5, 172.6, 
157.4, 157.2, 142.6, 140.7, 136.5, 134.9, 128.86*, 128.61*, 128.59*, 128.22*, 
128.11*, 128.07*, 127.58*, 127.26*, 126.2, 103.0, 82.1, 79.3, 67.0, 66.9, 46.7, 
46.3, 44.2, 44.0, 40.9, 40.7, 40.2, 39.9, 32.6 (Figure 65); HRMS (ESI m/z): 
calculated for [C42H44N4O8+Na]+ 755.3057, found 755.30820.  
 
Figure 65 – Carbon NMR spectrum of protected amine 104. δ128.8 – δ127.3 is magnified. 
* δ128.86 – δ127.26 signifies the region in the Carbon NMR spectrum where there are 19 carbons. Unfortunately, there are multiple 
carbons associated with each peak and it is difficult to assign a specific number of carbons for each peak. 
7-[(p-bromo)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
N2,N3-bis(benzyl 2-ethyl carbamate) dicarboxamide (105) 
 Di-carboxylic acid 78 (77.5 mg, 202 
μmol); Cbz-EDA 89 (168 mg, 607 μmol); 
EDCI 92 (116 mg, 607 μmol); HOBt 97 (7 
mg, 51 μmol); Rf 0.29; white oil (96.7 mg, 65%); υmax(thin film/cm-1) 3056 (m) 
(aromatic C-H) 1639 (vs) (amide C=O) 1452 (vs) (aromatic C=C) 1068 (vs) 
(acetal C-O) 814 (vs) (para substitution of aromatic C-H) 653 (vs) (bromine C-
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Br); δH NMR (270 MHz, CDCl3): 7.46 (2H, d, JAB = 5.7 Hz, H12) 7.27 (12H, br m, 
H11, H18-20, H26-28) 6.99 (1H, br t, -NH) 6.89 (1H, br t, -NH) 5.65 (1H, br t, -
NH) 5.58 (1H, br t, -NH) 5.43 (1H, s, H7) 5.05-4.94 (4H, s, H17, H25) 4.24 (1H, br 
d, H5) 4.12 (1H, d, J = 1.7 Hz, H9) 3.32-3.25 (8H, m, H14-15, H22-23) 2.82 (1H, d, 
J = 5.4 Hz, H2) 2.63 (1H, s, H4) 2.56 (1H, d, J = 5.4 Hz, H3) 2.43 (1H, d, J = 5.4 Hz, 
H1) 1.88 (1H, d, J = 6.7 Hz, H10a) 1.54 (1H, d, J = 5.4 Hz, H10b); δC NMR (67.5 
MHz, CDCl3): 174.14, 172.35, 157.46, 157.21, 136.37, 134.99, 131.66 (2 
carbons), 128.66 (2 carbons), 128.49 (2 carbons), 128.33 (2 carbons), 128.32, 
128.20 (2 carbons), 128.16 (2 carbons), 128.07 123.75, 102.43, 82.02, 79.27, 
77.31 67.11, 66.89, 47.69, 44.67, 44.32, 43.49, 41.05, 40.64, 40.03, 36.24, 32.7; 
HRMS (ESI m/z): calculated for [C36H39BrN4O8+H]+ 735.20295 and 737.20165, 
found 735.20313 and 737.20120. 
7-[(p-octyl)-phenyl]-,6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
N2,N3-bis(benzyl 2-ethyl carbamate) dicarboxamide (106) 
Octyl phenyl di-carboxylic 
acid 83 (33.5 mg, 80.4 μmol); 
Cbz-EDA 89 (46.9 mg, 241 
μmol); EDCI 92 (46.3 mg, 241 
μmol); HOBt 97 (10 mg, 74 μmol); Rf 0.48; brown oil (26.3 mg, 43%); υmax(thin 
film/cm-1) 2971 (s) (methyl C-H) 1644 (vs) (amide C=O) 1531 (s) (aromatic 
C=C) 1487 (m) (methylene C-H) 1263 (m) (aromatic C-H) 1073 (s) (acetal C-O) 
834 (m) (para-substitution of aromatic C-H); δH NMR (270 MHz, CDCl3): 7.43-
7.30 (14H, m, H11-14, H28-30, H36-38) 6.47 (2H, br m, -NH) 5.47 (1H, s, H7) 
5.41 (1H, br t, -NH) 5.28 (1H, br t, -NH) 5.10-5.04 (4H, m, H27, H33) 4.25 (1H, d, 
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J = 3.7 Hz, H5) 4.10 (1H, d, J = 3.7 Hz, H9) 3.42-3.21 (9H, m, H2, H24-25, H32-33) 
2.76 (1H, d, J = 5.4 Hz, H4) 2.66 (1H, s, H3) 2.56 (1H, d, J = 2.7 Hz, H1) 2.39 (2H, t, 
J = 4.7 Hz, H15) 1.95 (1H, d, J = 6.9 Hz, H10a) 1.63-1.25 (13H, m, H10b, H16-21) 
0.89 (3H, t, J = 4.7 Hz, H22); δC NMR (67.5 MHz, CDCl3): 174.15, 172.38, 157.48, 
157.18, 136.58, 136.37, 134.98, 131.63 (2 carbons), 128.85, 128.65 (2 carbons), 
128.33 (2 carbons), 128.19 (2 carbons), 128.07 (2 carbons), 126.68 (2 carbons), 
125.53, 102.86, 91.44, 81.95, 80.32, 79.16, 77.29, 67.15, 66.89, 47.99, 44.40, 
43.43, 41.13, 40.82, 40.65, 40.00, 32.84, 31.42, 29.77, 28.73, 28.69, 22.64, 19.52, 
14.14; MS (ESI m/z): calculated for [C44H56N4O8+ 2K]2+ 423.17, found 423.16.  
7-pyrenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-tert-
butyl(carboxamido ethyl)carbamate (107) 
Pyrenyl di-carboxylic acid 81 (262 mg, 612 
μmol); Boc-EDA 91 (294 mg, 1.84 mmol); 
EDCI 92 (352 mg, 1.84 mmol); HOBt 97 (100 
mg, 740 μmol); Rf 0.02; yellow solid (248 
mg, 57%); mp 225.1 – 225.9 °C; υmax(thin film/cm-1) 3307 (m) (secondary 
amine N-H) 1691 (vs) (aromatic C=C) 1641 (vs) (amide C=O); δH NMR (270 
MHz, CDCl3): 8.42-8.01 (9H, m, H11-19) 6.86 (1H, br t, -NH) 6.67 (1H, br t, -NH) 
6.58 (1H, s, H7) 5.05 (1H, br t, -NH) 4.93 (1H, br t, -NH) 4.61 (1H, d, J = 3.7 Hz, 
H5) 4.40 (1H, d, J = 3.7 Hz, H9) 3.50-3.28 (8H, m, H21-22, H26-27) 2.95 (1H, br 
d, H2) 2.81 (1H, s, H4) 2.73 (1H, d, J = 5.4 Hz, H3) 2.54 (1H, d, J = 5.4 Hz, H1) 2.06 
(1H, d, J = 7.4 Hz, H10a) 1.34-1.24 (19H, m, H10b, H24, H29); δC NMR (67.5 MHz, 
CDCl3): 174.0, 172.4, 157.11 (2 carbons), 131.9, 131.2, 130.6, 128.9, 128.1 (2 
carbons), 127.9 (2 carbons), 127.4 (2 carbons) 126.0 (2 carbons) 125.4 (2 
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carbons) 124.7 (2 carbons), 100.6, 82.1, 79.4, 77.6 (2 carbons), 47.9 43.4, 40.5 
(4 carbons), 32.8, 31.9, 29.7, 28.4 (6 carbons); HRMS (ESI m/z): calculated for 
[C40H48N4O8+Na]+ 735.33644, found 735.33724.  
7-[(3-benzyloxy)-pheynyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-
exo-di-tert-butyl(carboxamido ethyl)carbamate (108) 
Benzyloxy phenyl di-carboxylic acid 84 
(68.5 mg, 167 μmol); Boc-EDA 91 (80.2 
mg, 501 μmol); EDCI 92 (96 mg, 501 
μmol); HOBt 97 (50 mg, 370 μmol); Rf 
0.02; white solid (42.2 mg, 36%); mp 145.3 – 147.5 °C; υmax(thin film/cm-1) 
2925 (m) (methyl C-H) 1688 (vs) (aromatic C=C) 1642 (vs) (amide C=O) 1251 
(vs) (aryl ether C-O) 1165 (vs) (acetal C-O); δH NMR (270 MHz, CDCl3): 7.39-
6.93 (11H, m, H11-14, H16-20 H24, H29) 5.51 (1H, s, H7) 5.40 (2H, br m, H21, 
H26) 5.01 (2H, s, H15) 4.29 (1H, br d, H5) 4.18 (1H, br d, H9) 3.35-3.16 (9H, m, 
H2, H22-23, H27-28) 2.68-2.64 (3H, m, H1, H3-4) 1.92 (1H, d, J = 6.7 Hz, H10a) 
1.57 (1H, d, J = 6.7 Hz, H10b) 1.42 (18H, m, H25, H30); δC NMR (67.5 MHz, 
CDCl3): 174.2, 172.4, 158.9, 156.8, 137.6, 136.9, 129.6, 128.6 (2 carbons), 128.1, 
127.6 (2 carbons), 119.4, 116.1, 113.0, 102.9, 82.0, 79.8, 79.7, 79.2, 70.1, 47.1, 
45.6, 44.4, 43.7, 40.8 (2 carbons), 40.4 (2 carbons), 32.6, 29.8, 28.5 (6 carbons); 
HRMS (ESI m/z): calculated for [C37H50N4O9+H]+ 695.36506, found 695.36623. 
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Section 2.10 Saponification 
Bicyclo(2.2.1]hept-5-ene-2,3-dicarboxylic acid (109)215 
To a stirring solution of norbornene di-ester 33 (57.5 g, 273 mmol) 
in EtOH (100 mL), 1M NaOH solution (300 mL) was added. The 
reaction mixture was stirred for 16 hours at room temperature, 
concentrated under vacuum to a quarter of the volume and acidified to pH 1. 
The reaction mixture was transferred to a separatory flask and extracted with 
EtOAc (3 × 100 mL). The organic phases were combined, dried with MgSO4 and 
the solvent removed in vacuo. The resulting crude solid was washed with CHCl3 
and dried under vacuum. The di-carboxylic acid was obtained as a white solid 
and determined pure by NMR spectroscopy. (44.5 g, 89%); mp 147.8 – 150.1 °C; 
υmax(thin film/cm-1) 1647 (w) (alkene C=C) 1541 (w) (carboxylic acid C=O); δH 
NMR (270 MHz, CD3OD): 6.28 (1H, m, H5) 6.10 (1H, m, H6) 3.37-3.11 (3H, m, 
H2, H3-4) 2.59 (1H, dd, J = 2.7, 2.7 Hz, H1) 1.61 (1H, dd, J = 1.5, 7.2 Hz, H7a) 1.44 
(1H, dd, J = 1.5, 7.2 Hz, H7b); δC NMR (67.5 MHz, CD3OD): 177.8, 176.8, 138.7, 
136.2, 61.7, 52.3, 46.8, 30.7, 14.5; MS (ESI m/z): calculated for [C9H10O4+Na]+ 
205.04, found 205.05. 
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Section 2.11 Di-amide coupling 
Bicyclo [2.2.1]hept-5-ene-2-endo,3-exo-di-tertbutyl(carboxamido 
ethyl)carbamate (110) 
 A solution of norbornene di-carboxylic acid 109 (2.19 
g, 12.03 mmol), EDCI 92 (6.92 mg, 36.1 mmol) and 
HOBt 97 (300 mg, 2.2 mmol) in DMF (55 mL) was 
stirred for 15 minutes at room temperature. Then Boc-
EDA 91 (5.78 mg, 36.1 mmol) was added and the reaction mixture was stirred 
for 16 hours at room temperature. The reaction solvent was then removed in 
vacuo. A small quantity of H2O was added and the reaction mixture was allowed 
to stand for several hours till a thick yellow precipitate had formed. The slurry 
was transferred to a Hirsch funnel, washed with copious amounts of H2O (500 
mL) and allowed to dry under vacuum to give the desired norbornene 110 as a 
white solid. (4.86 g, 87%); υmax(thin film/cm-1) 1683 (vs) (amide C=O);δH NMR 
(270 MHz, CDCl3): 7.02 (1H, br t, H11) 6.85 (1H, br t, H15) 6.23-6.19 (2H, m, H5-
6) 5.02 (1H, br t, H8) 4.96 (1H, br t, H12) 3.37-3.28 (8H, m, H9-10, H13-14) 3.09 
(1H, br d, H2) 3.04 (1H, br d, H4) 2.95 (1H, dd, J = 2.7, 5.4 Hz, H3) 2.32 (1H, dd, J 
= 2.7, 5.4 Hz, H1) 2.33 (1H, d, J = 2.2 Hz, H7a) 1.53 (1H, d, J = 2.2 Hz, H7b) 1.44 
(9H, s, H13) 1.43 (9H, s, H18); δC NMR (67.5 MHz, CDCl3): 175.5, 174.3, 157.2, 
156.4, 137.6, 135.1, 79.9, 79.5, 51.2, 49.1, 48.4, 45.3, 44.2, 43.1, 41.2, 40.7, 40.2, 
28.4 (6 carbons); HRMS (ESI m/z): calculated for [C23H38N4O6+H]+ 467.28641, 
found 467.28616. 
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Section 2.12 Upjohn Dihydroxylation 
6,8-dihydroxybicyclo [2.2.1]hept-5-ene-2-endo,3-exo-di-
tertbutyl(carboxamido ethyl)carbamate (111) 
To a solution of H2O: acetone (1:4) (20 mL), 
norbornene 110 (2.23 g, 4.78 mmol) and NMO 45 
(672 mg, 5.74 mmol) were added and allowed to stir 
until the solution was clear. Osmium tetroxide 41 (250 μL, 5% in t-BuOH, 49 
μmol) was then added and the mixture stirred at room temperature for 16 
hours. Sodium metabisulphite solution (8 mL, 0.53 M) was added and the 
reaction mixture allowed stirring for a further ten minutes. The mixture was 
then transferred into a separatory funnel and extracted using EtOAc (3 × 20 
mL). The combined organic phases were dried (MgSO4) and the solvent 
removed in vacuo resulting in a yellow solid. No further purification was 
performed and the sample was determined to be pure by NMR spectroscopy. 
(2.10 g, 88%); mp 171.3 – 175.2 °C; υmax(thin film/cm-1) 3305 (m) (hydroxyl O-
H) 2974 (m) (methyl C-H) 1640 (vs) (amide C=O); δH NMR (270 MHz, CD3OD): 
8.10 (1H, br t, -NH) 7.97 (1H, br t, -NH) 6.64 (1H, br t, -NH) 6.59 (1H, br t, -NH) 
3.75 (2H, m, H5, H9) 3.34 – 3.07 (9H, m, H2, H9-10, H14-15) 2.61 (1H, d, J = 2.7 
Hz, H4) 2.37 (1H, s, H3) 2.24 (1H, s, H1), 1.83 (1H, d, J = 5.4 Hz, H7a) 1.51 (1H, d, 
J = 5.4 Hz, H7b) 1.42 (18H, s, H12, H17); δC NMR (67.5 MHz, CD3OD): 175.16, 
173.21, 157.22 (2 carbons), 78.81, 73.32, 69.44, 66.05, 54.88, 49.56, 47.13, 
44.73, 39.99, 39.68, 39.54, 39.40, 31.56, 27.45 (6 carbons); MS (ESI m/z): 
calculated for [C23H40N4O8+H]+ 501.29, found 501.29. 
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112 
Section 2.14 Synthesis of Boc-protected amines 
 
General methodology: A solution of diol 111, aldehyde/ketone (2 eq.), oxalic 
acid (1 eq.) and MgSO4 in CHCl3/MeCN (20 mL) was stirred vigorously for 16 
hours at 50 °C. The reaction mixture was cooled to room temperature, filtered 
and the solvent removed in vacuo resulting in brown solids. The crude solid was 
purified using column chromatography [(1:9) EtOAc/Pet 40-60 → 5% EtOH in 
(1:1) EtOAc/Pet 40-60]. Fractions containing the desired compound were 
combined and the solvent removed in vacuo resulting in solids.  
7-pentadecyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-tert-
butyl(carboxamido ethyl)carbamate (113) 
Diol 111 (168.1 mg, 335.8 
μmol); hexadecanal 46 (161.5 
mg, 672 μmol); oxalic acid 
(42.3 mg, 335.8 μmol); Rf 0.76 
(in 5% EtOH in (1:1) EtOAc/Pet 40-60) ; brown solid (95 mg, 40%); mp 120.4 – 
125.1 °C; υmax(thin film/cm-1) 2916 (vs) (methyl C-H) 2848 (s) (methylene C-H) 
1693 (vs) (amide C=O) 1129 (m) (acetal C-O); δH NMR (270 MHz, CDCl3): 7.05 
(1H, br t, -NH) 6.86 (1H, br t, -NH) 5.19 (2H, br m, H26, H31) 4.62 (1H, t, J = 3.2 
Hz, H7) 4.10 (1H, d, J = 3.5 Hz, H5) 3.96 (1H, d, J = 3.7 Hz, H9) 3.32-3.24 (8H, m, 
H27-28, H32-33) 2.98 (1H, dd, J = 2.7, 2.7 Hz, H2) 2.55-2.54 (2H, m, H3-4) 2.46 
(1H, d, J = 2.7 Hz, H1) 1.78 (1H, d, J = 6.9 Hz, H10a) 1.47-1.23 (47H, m, H10b, 
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H11-24, H30, H35) 0.86 (3H, t, J = 4.5 Hz, H25); δC NMR (67.5 MHz, CDCl3): 
174.60, 172.70, 156.89, 156.80, 103.99, 81.56, 79.72, 79.57, 78.68, 77.32, 46.76, 
45.83, 44.15, 43.72, 40.26 (4 carbons), 34.16, 32.91, 32.26, 31.99, 29.76 (6 
carbons), 29.54, 29.44, 29.35, 29.19, 28.47 (2 carbons), 24.85, 24.30, 22.76 (2 
carbons), 14.18; HRMS (ESI m/z): calculated for [C39H70N4O8+H]+ 723.52664, 
found 723.52681. 
7-[(p-phenyl)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
di-tert-butyl(carboxamido ethyl)carbamate (118) 
Diol 111 (291 mg, 582 μmol); para-
phenyl benzaldehyde (212 mg, 1.16 
mmol); oxalic acid (73.3 mg, 582 μmol); 
Rf 0.76 (in 5% EtOH in (1:1) EtOAc/Pet 
40-60); white solid (354 mg, 91%); mp 142.1 – 144.2 °C; υmax(thin film/cm-1) 
2928 (m) (methyl C-H) 1684 (vs) (aromatic C=C) 1637 (vs) (amide C=O ) 1072 
(s) (acetal C-O) 835 (m) (aromatic 1,4-disubstitution C-H); δH NMR (270 MHz, 
CDCl3): 7.60-7.33 (9H, m, H11-19) 6.86 (1H, br t, -NH) 6.68 (1H, br t, -NH) 5.61 
(1H, s, H7) 5.04 (1H, br t, -NH) 4.96 (1H, br t, -NH) 4.38 (1H, br d, H5) 4.18 (1H, 
d, J = 3.5 Hz, H9) 3.45-3.30 (8H, m, H21-22, H26-27) 3.01 (1H, dd, J = 2.7, 2.7 Hz, 
H2) 2.71 (1H, s, H4) 2.70 (1H, d, J = 2.7 Hz, H3) 2.52 (1H, d, J = 5.4 Hz, H1)  2.04 
(1H, d, J = 7.2 Hz, H10a) 1.60-1.44 (19H, m, H10b, H24, H29); δC NMR (67.5 MHz, 
CDCl3): 174.1, 172.4, 157.1, 156.9, 140.8, 135.0, 128.8 (2 carbons), 127.5 (2 
carbons), 127.3 (2 carbons), 127.2 (2 carbons), 124.8, 122.8 103.0, 82.0, 79.2, 
77.3 (2 carbons), 49.9, 47.9, 44.5, 41.3, 40.6 (2 carbons), 40.4 (2 carbons), 32.0, 
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28.5 (6 carbons); HRMS (ESI m/z): calculated for [C36H48N4O8+Na]+ 687.33644, 
found 687.33712.  
7-dimethyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-tert-
butyl(carboxamido ethyl)carbamate (119) 
Diol 111 (300 mg, 599 μmol); para-bromo 
benzaldehyde (222 mg, 1.2mmol); oxalic acid 
(75.6 mg, 599 μmol); Rf 0.43 (in 5% EtOH in 
(1:1) EtOAc/Pet 40-60); white solid (209 mg, 
52%); mp 141.1 – 141.8 °C; υmax(thin film/cm-1) 2928 (m) (methyl C-H) 1690 
(s) (aromatic C=C) 1638 (vs) (amide C=O) 1071 (s) (acetal C-O) 821 (m) (1,4-
disubstitution of aromatic C-H) 629 (m) (bromine C-Br); δH NMR (270 MHz, 
CDCl3): 7.49 (2H, d, JAB = 5.4 Hz, H12) 7.34 (2H, d, JA’B’ = 5.4 Hz, H11) 6.90 (1H, br 
t, -NH) 6.69 (1H, br t, -NH) 5.50 (1H, s, H7) 5.03 (1H, br t, -NH) 4.97 (1H, br t, -
NH) 4.36 (1H, br d, H5) 4.16 (1H, br d, H9) 3.42-3.29 (8H, m, H14-15, H19-20) 
2.96 (1H, dd, J = 2.7, 2.7 Hz, H2) 2.68 (1H, s, H4) 2.65 (1H, d, J = 2.7 Hz, H3) 2.47 
(1H, d, J = 5.4 Hz, H1) 1.92 (1H, d, J = 7.4 Hz, H10a) 1.63-1.43 (19H, m, H10b, 
H17, H22); δC NMR (67.5 MHz, CDCl3): 174.1, 172.3, 157.1, 156.9, 135.1, 131.6 
(2 carbons) 128.5 (2 carbons) 123.7, 102.4, 82.0, 79.3, 77.3 (2 carbons), 47.5, 
44.5, 43.5, 40.3 (4 carbons), 32.7, 32.0, 28.5 (6 carbons); HRMS (ESI m/z): 
calculated for [C30H43BrN4O8+Na]+ 689.2162 and 691.21471, found 689.21629 
and 691.21492. 
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7-[(p-octynyl)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
di-tert-butyl(carboxamido ethyl)carbamate (120) 
Diol 111 (218 mg, 436 μmol); 
octynyl benzaldehyde 47 (93.4 
mg, 872 μmol); oxalic acid (55 
mg, 436 μmol); Rf 0.43 (in 5% 
EtOH in (1:1) EtOAc/Pet 40-60); brown solid (156 mg, 51%); mp 89.7 – 91.2 °C; 
υmax(thin film/cm-1) 2927 (m) (methyl C-H) 1683 (vs) (aromatic C=C) 1637 (vs) 
(amide C=O) 830 (m) (aromatic 1,4-disubstitution C-H) 693 (m) (alkyne C-H); 
δH NMR (270 MHz, CDCl3): 7.36 (4H, s, H11-12) 7.05 (1H, br t, -NH) 6.83 (1H, br 
t, -NH) 5.51 (1H, s, H7) 5.15 (1H, br t, -NH) 5.09 (1H, br t, -NH) 4.32 (1H, br d, 
H5) 4.16 (1H, br d, H9) 3.32-3.27 (8H, m, H20-21, H25-26) 3.00 (1H, br d, H2) 
2.67 (1H, m, H3-4) 2.51 (1H, d, J = 2.7 Hz, H1) 2.38 (2H, t, J = 4.5 Hz, H13) 1.95 
(1H, d, J = 6.9 Hz, H10a) 1.77-1.24 (27H, m, H10b, H14-17, H23, H28) 0.89 (3H, t, 
J = 4.5 Hz, H18); δC NMR (67.5 MHz, CDCl3): 174.2, 172.4, 156.9, 156.8, 135.1, 
131.6 (2 carbons) 126.6 (2 carbons), 125.4, 102.8, 91.4, 81.9, 80.3, 79.8, 79.7, 
79.3, 47.1, 45.6, 44.4, 43.7, 40.8 (2 carbons), 40.4 (2 carbons), 32.6, 31.4, 29.8, 
28.7, 28.6, 28.5 (6 carbons), 22.8, 22.6; HRMS (ESI m/z): calculated for 
[C38H56N4O8+H]+ 697.41709, found 697.41755. 
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7-dimethyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-tert-
butyl(carboxamido ethyl)carbamate (121) 
Diol 111 (207 mg, 414 μmol); benzaldehyde 
(83.7 μL, 828 μmol); oxalic acid (52.2 mg, 414 
μmol); Rf 0.40 (in 5% EtOH in (1:1) EtOAc/Pet 
40-60); white solid (222 mg, 91%); mp 110.5 – 
110.6 °C; υmax(thin film/cm-1) 2929 (m) (methyl C-H) 1684 (vs) (aromatic C=C) 
1638 (vs) (aromatic C=C) 1069 (m) (acetal C-O); δH NMR (270 MHz, CDCl3): 
7.45-7.34 (5H, m, H11-15) 7.14 (2H, br m, H19, H24) 5.53 (1H, s, H7) 5.36-5.34 
(2H, br m, H16, H21) 4.30 (1H, d, J = 2.2 Hz, H5) 4.18 (1H, br d, H9) 3.35-3.14 
(9H, m, H2 H17-18, H22-23) 2.69 (1H, br d, H4) 2.65 (1H, s, H3) 2.50 (1H, d, J = 
5.4 Hz, H1) 1.97 (1H, d, J = 6.9 Hz, H10a) 1.59-1.41 (19H, m, H10a, H20, H26); δC 
NMR (67.5 MHz, CDCl3): 174.1, 172.3, 156.9, 156.8, 135.9, 129.5, 128.4 (2 
carbons), 126.7 (2 carbons), 103.1, 81.9, 79.87, 79.68,  79.1, 47.4, 44.9, 44.5, 
43.5, 40.9, 40.4, 40.3, 32.6, 29.7, 28.4 (6 carbons); HRMS (ESI m/z): calculated 
for [C30H44N4O8+H]+ 589.32319, found 589.32377. 
7-pyrenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-tert-
butyl(carboxamido ethyl)carbamate (107) 
Diol 111 (310 mg, 618 μmol); 
pyrenecarboxaldehyde (285 mg, 1.24 
mmol); oxalic acid (77.9 mg, 618 μmol); Rf 
0.57 (in 5% EtOH in (1:1) EtOAc/Pet 40-60); 
yellow solid (109.6 mg, 25%); mp 215.1 – 215.9 °C; υmax(thin film/cm-1) 3307 
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(m) (secondary amine N-H) 1691 (vs) (aromatic C=C) 1641 (vs) (amide C=O); δH 
NMR (270 MHz, CDCl3): 8.42-8.01 (9H, m, H11-19) 6.86 (1H, br t, -NH) 6.67 (1H, 
br t, -NH) 6.58 (1H, s, H7) 5.05 (1H, br t, -NH) 4.93 (1H, br t, -NH) 4.61 (1H, d, J = 
3.7 Hz, H5) 4.40 (1H, d, J = 3.7 Hz, H9) 3.50-3.28 (8H, m, H21-22, H26-27) 2.95 
(1H, br d, H2) 2.81 (1H, s, H4) 2.73 (1H, d, J = 5.4 Hz, H3) 2.54 (1H, d, J = 5.4 Hz, 
H1) 2.06 (1H, d, J = 7.4 Hz, H10a) 1.34-1.24 (19H, m, H10b, H24, H29); δC NMR 
(67.5 MHz, CDCl3): 174.0, 172.4, 157.11 (2 carbons), 131.9, 131.2, 130.6, 128.9, 
128.1 (2 carbons), 127.9 (2 carbons), 127.4 (2 carbons) 126.0 (2 carbons) 125.4 
(2 carbons) 124.7 (2 carbons), 100.6, 82.1, 79.4, 77.6 (2 carbons), 47.9 43.4, 
40.5 (4 carbons), 32.8, 31.9, 29.7, 28.4 (6 carbons); HRMS (ESI m/z): calculated 
for [C40H48N4O8+Na]+ 735.33644, found 735.33724. 
7-[(p-octyl)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-
tert-butyl(carboxamido ethyl)carbamate (122) 
Diol 111 (153.7 mg, 307 
μmol); octyloxy benzaldehyde 
49 (143.9 mg, 614μmol); 
oxalic acid (38.7 mg, 307 
μmol); Rf 0.31 (in 5% EtOH in (1:1) EtOAc/Pet 40-60); white solid (160.6 mg, 
73%); mp 97.0 – 101.3 °C; υmax(thin film/cm-1) 2927 (m) (methylene C-H) 2857 
(methyl C-H) 1637 (vs) (amide C=O) 1616 (vs) (aromatic C=C) 1450 (vs) 
(aromatic C=C) 1248 (vs) (aryl ether C-O) 1168 (vs) (alkyl ether C-O) 1072 (vs) 
(acetal C-O) 829 (s) (para substitution C-H); δH NMR (270 MHz, CDCl3): 7.35 
(2H, d, JAB = 8.6 Hz, H12) 7.17 (1H, br t, -NH) 6.97 (1H, br t, -NH) 6.84 (2H, d, JA’B’ 
= 8.6 Hz, H11) 5.48 (1H, s, H7) 5.25 (2H, br m, H21, H26) 4.27 (1H, d, J = 5.5 Hz, 
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H5) 4.13 (1H, d, J = 5.5 Hz, H9) 3.91 (2H, t, J = 6.7 Hz, H13) 3.33-3.24 (8H, m, 
H22-23, H27-28) 3.00 (1H, dd, J = 2.7, 2.7 Hz, H2) 2.79 (1H, d, J = 2.7 Hz, H4) 
2.66 (1H, s, H3) 2.51 (1H, d, J = 5.4 Hz, H1) 1.99 (1H, d, J = 9.6 Hz, H10a) 1.79-
1.23 (31H, m, H10b, H14-19, H25, H30) 0.86 (3H, t, J = 6.2 Hz, H20); δC NMR 
(67.5 MHz, CDCl3): 174.1, 171.9, 163.3, 162.8, 157.0, 153.1, 128.1 (2 carbons), 
114.3 (2 carbons), 103.1, 86.4, 81.8, 79.7, 79.1, 68.1, 47.54, 45.79, 44.31, 43.76, 
40.56 (2 carbons), 40.26 (2 carbons), 33.82, 32.49, 31.92, 31.81, 29.70, 29.35 (3 
carbons), 29.23, 29.21 (3 carbons), 28.79, 28.44; HRMS (ESI m/z): calculated for 
[C38H60N4O9+H]+ 717.44331, found 717.44631. 
7-[(p-octyl)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-
tert-butyl(carboxamido ethyl)carbamate (123) 
Diol 111 (298 mg, 595 μmol); 
octyl benzaldehyde 48 (260 mg, 
1.19 mmol); oxalic acid (75.0 mg, 
595 μmol); Rf 0.29 (in 5% EtOH in 
(1:1) EtOAc/Pet 40-60); brown solid (302 mg, 72%); mp 121.8 – 121.5 °C; 
υmax(thin film/cm-1) 3066 (s) (aromatic C-H) 2952 (m) (methyl C-H) 2930 
(methylene C-H) 1636 (vs) (amide C=O) 1606 (vs) (aromatic C=C) 1456 (vs) 
(aromatic C=C) 1076 (vs) (acetal C-O) 858 (m) (para substitution of aromatic C-
H); δH NMR (270 MHz, CDCl3): 7.51 (2H, 3JAB = 5.4 Hz, H12, H14) 7.46 (2H, 3JA’B’ = 
5.4 Hz, H11, H13) 7.03 (1H, br t, H26) 6.82 (1H, br t, H31) 5.50 (1H, s, H7) 5.14-
5.09 (2H, br m, H23, H28) 4.31 (1H, d, J = 5.2 Hz, H5) 4.15 (1H, d, J = 5.2 Hz, H9) 
3.33-3.25 (8H, m, H24-25, H29-30) 3.00 (1H, dd, J = 4.7, 4.7 Hz, H2) 2.67 (2H, m, 
H3-4) 2.53 (1H, d, J = 2.7 Hz, H1) 2.38 (2H, t, J = 6.7 Hz, H15) 1.94 (1H, d, J = 9.9 
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Hz, H10a) 1.65-1.20 (31H, m, H10b, H16-21, H27, H32) 0.88 (3H, t, J = 4.9 Hz, 
H22); δC NMR (67.5 MHz, CDCl3):  174.33, 172.52, 156.88, 156.80, 131.52, 
131.42 (2 carbons), 129.81 (2 carbons), 129.44, 107.05, 81.93, 80.27, 79.59, 
79.19, 57.35, 45.20, 43.73, 40.26 (4 carbons), 32.46, 31.34, 28.67, 28.61, 28.60, 
28.56 (3 carbons), 28.41 (3 carbons), 22.55, 19.52, 19.44, 15.93, 14.05; HRMS 
(ESI m/z): calculated for [C38H60N4O8+K]+ 739.40427, found 739.40561. 
7-[(3-benzyloxy)-pheynyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-
exo-di-tert-butyl(carboxamido ethyl)carbamate (108) 
Diol 111 (207 mg, 413 μmol); 
benzyloxy benzaldehyde (175 mg, 826 
μmol); oxalic acid (104.1 mg, 826 
μmol); Rf 0.37 (in 5% EtOH in (1:1) 
EtOAc/Pet 40-60); white solid (243 mg, 85%); mp 142.3 – 147.5 °C; υmax(thin 
film/cm-1) 2925 (m) (methyl C-H) 1688 (vs) (aromatic  C=C) 1642 (vs) (amide 
C=O) 1251 (vs) (aryl ether C-O) 1165 (vs) (acetal C-O); δH NMR (270 MHz, 
CDCl3): 7.39-6.93 (11H, m, H11-14, H16-20 H24, H29) 5.51 (1H, s, H7) 5.40 (2H, 
br m, H21, H26) 5.01 (2H, s, H15) 4.29 (1H, br d, H5) 4.18 (1H, br d, H9) 3.35-
3.16 (9H, m, H2, H22-23, H27-28) 2.68-2.64 (3H, m, H1, H3-4) 1.92 (1H, d, J = 6.7 
Hz, H10a) 1.57 (1H, d, J = 6.7 Hz, H10b) 1.42 (18H, m, H25, H30); δC NMR (67.5 
MHz, CDCl3): 174.2, 172.4, 158.9, 156.8, 137.6, 136.9, 129.6, 128.6 (2 carbons), 
128.1, 127.6 (2 carbons), 119.4, 116.1, 113.0, 102.9, 82.0, 79.8, 79.7, 79.2, 70.1, 
47.1, 45.6, 44.4, 43.7, 40.8 (2 carbons), 40.4 (2 carbons), 32.6, 29.8, 28.5 (6 
carbons); HRMS (ESI m/z): calculated for [C37H50N4O9+H]+ 695.36506, found 
695.36623. 
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7-hexyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-tert-
butyl(carboxamido ethyl)carbamate (124) 
Diol 111 (73.9 mg, 148 μmol); octanal 
(37.8 mg, 295 μmol); oxalic acid (14.0 mg, 
73.8 μmol); Rf 0.43 (in 5% EtOH in (1:1) 
EtOAc/Pet 40-60); white solid (67.8 mg, 
75%); mp 123.8 – 125.3 °C; υmax(thin film/cm-1) 2928 (m) (methyl C-H) 1685 
and 1638 (vs) (amide C=O) 1172 (vs) (acetal C-O); δH NMR (270 MHz, CDCl3): 
6.87 (1H, br t, -NH) 6.70 (1H, br t, -NH) 5.08-5.02 (2H, br m, H18, H23) 4.62 (1H, 
t, J = 4.7 Hz, H7) 4.11 (1H, d, J = 5.4 Hz, H5) 3.95 (1H, d, J = 5.4 Hz, H9) 3.38-3.25 
(8H, m, H19-20, H24-25) 2.91 (1H, dd, J = 4.7, 4.7 Hz, H2) 2.55-2.50 (2H, m, H3-
4), 2.31 (1H, dd, J = 2.7, 5.4 Hz, H1) 1.79 (1H, d, J = 10.4 Hz, H10a) 1.62-1.24 
(32H, m, H10b, H11-16, H22, H27) 0.85 (3H, t, J = 6.2 Hz, H17); δC NMR (67.5 
MHz, CDCl3): 177.1, 174.2, 156.9, 156.7, 104.0, 81.5, 78.6, 77.2 (2 carbons), 44.3, 
40.2 (4 carbons), 32.8, 31.7, 31.6, 29.7, 29.5, 29.2, 29.1, 28.9, 28.4 (6 carbons) 
24.8, 24.2, 22.7; HRMS (ESI m/z): calculated for [C31H54N4O8+H]+ 611.40144, 
found 611.40129. 
7-dimethyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-tert-
butyl(carboxamido ethyl)carbamate (114) 
Diol 111 (620 mg, 639 μmol); acetone (1 mL); 
oxalic acid (80.5 mg, 639 μmol); Rf 0.26 (in 5% 
EtOH in (1:1) EtOAc/Pet 40-60); white solid (203 
mg, 59%); mp 120.9 – 123.6 °C; υmax(thin film/cm-
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1) 2977 (m) (methyl C-H) 1639 (vs) (amide C=O) 1122 (s) (acetal C-O); δH NMR 
(270 MHz, CDCl3): 7.04 (1H, br t, -NH) 6.80 (1H, br t, -NH) 5.19-5.16 (2H, br m, 
H13, H18) 4.22 (1H, d, J = 3.2 Hz, H5) 4.08 (1H, d, J = 3.2 Hz, H9) 3.39-3.23 (8H, 
m, H14-15, H19-20) 2.97 (1H, br d, H2) 2.56-2.48 (3H, m, H1, H3-4) 1.79 (1H, d, 
J = 6.9 Hz, H10a) 1.50-1.40 (19H, m, H10b, H17, H22) 1.24 (6H, t, J = 5.7 Hz, H11-
12); δC NMR (67.5 MHz, CDCl3): 174.4, 172.6, 156.9, 156.8, 109.3, 81.2, 79.9, 
79.7, 78.2, 47.3, 45.2, 44.3, 43.6, 40.8 (2 carbons), 40.3 (2 carbons), 32.2, 29.8, 
28.5 (6 carbons) 25.4; HRMS (ESI m/z): calculated for [C26H44N4O8+Na]+ 
563.30514, found 563.30589. 
7-[(p-fluoro)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-
tert-butyl(carboxamido ethyl)carbamate (125) 
Diol 111 (205.4 mg, 410 μmol); para-fluoro 
benzaldehyde (101.9 mg, 821 μmol); oxalic 
acid (51.7 mg, 410 μmol); Rf 0.11 (in 5% EtOH 
in (1:1) EtOAc/Pet 40-60); white solid (153 
mg, 61%); mp 172.2 – 174.5 °C; υmax(thin film/cm-1) 3094 (m) (aromatic C-H) 
2977 (m) (methyl C-H) 1640 (vs) (amide C=O) 1610 (vs) (amide C=O) 1451 (vs) 
(aryl C=C) 1392 (vs) (t-butyl C-H) 1366 (t-butyl C-H) 1122 (vs) (acetal C-O) 
1100 (vs) (fluoro C-F) 834 (para substitution of aromatic C-H); δH NMR (500 
MHz, CDCl3): 7.40 (2H, d, 3JAB = 5 Hz, H12) 6.99 (2H, d, 3JA’B’ = 5 Hz, H11) 6.80 
(1H, br t, -NH) 6.60 (1H, br t, -NH) 5.47 (1H, s, H7) 4.96 (1H, br t, -NH) 4.89 (1H, 
br t, -NH) 4.30 (1H, d, J = 5 Hz, H5) 4.09 (1H, d, J = 5 Hz, H9) 3.37 – 3.23 (8H, m, 
H14-15, H19-20) 2.86 (1H, dd, J = 5, 5 Hz, H2) 2.65 (1H, s, H4) 2.60 (1H, d, J = 5 
Hz, H3) 2.39 (1H, d, J = 5 Hz, H1) 1.91 (1H, d, J = 10 Hz, H10a) 1.51 (1H, d, J = 10 
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Hz, H10b) 1.37 (18H, s, H17, H22); δC NMR (67.5 MHz, CDCl3): 173.95, 172.26, 
163.46 (1C, d, 1JF = 247 Hz), 156.77 (2 carbons), 131.90 (1C, d, 4JF = 3.75 Hz), 
128.62 (2C, d, 3JF = 8.58 Hz), 115.36 (2C, d, 2JF = 21.55 Hz) 102.44, 81.87, 80.04 
(2 carbons), 79.14, 47.86, 44.54, 44.39, 43.30, 40.51 (4 carbons), 32.74, 28.40 (6 
carbons); HRMS (ESI m/z): calculated for [C30H43FNaO8+H]+ 607.31377, found 
607.31318. 
Section 2.18 Deprotection and salt formation 
 
To a 2 M acetyl chloride in MeOH solution (2 mL) was added the protected di-
amine (approx. 100 mg). The reaction mixture was allowed to stir for 16 hours 
at room temperature. The reaction solvent was removed in vacuo, re-dissolved 
in EtOAc (10 mL) and transferred to a separatory flask. Extraction was 
performed using H2O (3 × 5 mL). The aqueous phases were combined and the 
water removed through sublimation.  
7-pentadecyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethanamium chloride (137) 
Protected di-amine 113 (127 mg, 
175 μmol); white solid (90 mg, 
yield: 66%, purity: 100%); mp 
186 – 189 °C; υmax(thin film/cm-1) 2924 (m) (methyl C-H) 1640 (vs) (amide 
C=O) 1074 (s) (acetal C-O); δH NMR (270 MHz, D2O): 4.7 (2H, t, J = 5.4 Hz, H7), 
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4.14 (1H, d, J = 5.4 Hz, H9) 4.09 (1H, d, J = 5.4 Hz, H5) 3.42 – 3.18 (9H, m, H2, 
H27-28, H31-32) 2.70 – 2.54 (3H, m, H1, H3-4) 1.71 (1H, d, J = 5.4 Hz, H10a) 
1.52 (1H, d, J = 5.4 Hz, H10b) 1.38-1.24 (28H, m, H11-24) 0.84 (3H, t, J = 2.7 Hz, 
H25); δC NMR (67.5 MHz, CD3OD): 175.3, 173.5, 103.8, 81.1, 78.6, 62.7, 54.4, 
52.6, 48.13, 48.0, 46.3, 45.7, 43.7, 43.6, 41.1, 40.6, 38.4, 37.6, 32.5, 31.7, 31.4, 
29.4, 29.3, 29.1, 26.9, 23.8, 22.4, 13.1, 6.7; HRMS (ESI m/z): calculated for 
[C29H56N4O4-H]+ 523.42178, found 523.42229. 
7-[(p-phenyl)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethanamium chloride (138) 
Protected di-amine 118 (89.7 mg, 134.9 
μmol); white hydroscopic solid (64.8 mg, 
yield: 89%, purity: 98%); υmax(thin film/cm-
1)  1644 (vs) (amide C=O) 1221 (vs) (aromatic C=C) 1071 (s) (acetal C-O) 835 
(s) (para substitution C-H); δH NMR (270 MHz, CD3OD): 7.64-7.30 (9H, m, H11-
19) 5.61 (1H, s, H7) 4.26 (1H, d, J = 5.4 Hz, H9) 4.23 (1H, d, J = 5.4 Hz, H5) 3.65-
3.13 (9H, m, H2, H21-22, H25-26) 2.85-2.68 (3H, m, H1, H3-4) 2.02 (1H, d, J = 8.1 
H, H10a) 1.63 (1H, d, J = 8.1 Hz, H10b); δC NMR (67.5 MHz, CD3OD): 175.5, 
173.7, 142.4, 140.4, 135.1, 128.51 (2 carbons), 127.07 (2 carbons), 126.6 (2 
carbons), 126.5 (2 carbons), 125.93, 102.8, 81.83, 79.1, 48.06, 47.9, 46.8, 45.8, 
44.8, 43.8, 39.4, 37.2, 31.6; HRMS (ESI m/z): calculated for [C26H34N4O4-H]+ 
465.24963, found 465.24921. 
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7-(p-bromo-phenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethanamium chloride (136) 
Protected di-amine 119 (109.9 mg, 164.6 μmol); 
white hydroscopic solid (74.9 mg, yield: 84%, 
purity: 96%); υmax(thin film/cm-1) 3285 (br s) 
(primary amine N-H) 1643 (vs) (amide C=O) 1597 (vs) (aromatic C=C) 1072 
(vs) (acetal C-O) 820 (s) (para substitution C-H) 627 (vs) (bromine C-Br); δH 
NMR (270 MHz, D2O): 7.65 (2H, dd, JAB = 2.7 Hz, JAB’ = 5.4 Hz, H12) 7.46, (2H, dd, 
JA’B’ = 2.7 Hz, JA’B = 5.4 Hz, H11) 5.66 (1H, s, H7) 4.36 (1H, d, J = 2.7 Hz, H9) 4.29 
(1H, d, J = 2.7 Hz, H5) 3.66 – 3.43 (4H, m, H14, H18) 3.27 (1H, dd, J = 2.7, 2.7 Hz, 
H2) 3.18-3.14 (4H, m, H15, H19) 1.95 (1H, d, J = 8.1 Hz, H10a) 1.60 (1H, d, J = 8.1 
Hz, H10b); δC NMR (67.5 MHz, CD3OD): 175.5, 173.6, 135.5, 131.1 (2 carbons), 
128.4 (2 carbons), 123.1, 102.2, 81.88, 79.17, 48.1, 47.9 46.1, 45.8, 43.7, 39.4, 
37.2, 37.1, 31.6; HRMS (ESI m/z): calculated for [C20H29BrN4O4-H]+ 467.12884, 
found 467.12989. 
7-[(p-octynyl)phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethanamium chloride (134) 
Protected di-amine 120 (106 mg, 
152 μmol); brown hydroscopic solid 
(90 mg, yield: 99%, purity: 94%); 
υmax(thin film/cm-1) 2929 (m) (methylene C-H) 2858 (methyl C-H) 1638 (vs) 
(amide C=O) 1539 (vs) (primary amine N-H) 1124 (vs) (acetal C-O) 830 (s) 
(aromatic C-H) 774 (s) (para substitution C-H); δH NMR (270 MHz, CD3OD): 7.51 
– 7.27 (4H, m, H11-12) 5.54 (1H, s, H7) 4.25-4.19 (2H, m, H5, H9) 3.62-3.06 (9H, 
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m, H2, H20-21, H24-25) 2.77-2.62 (3H, m, H1, H3-4) 1.92 (1H, d, J = 10.8 Hz, 
H10a) 1.62 – 1.27 (H11, m, H10b, H13-17) 0.92 (3H, t, J = 5.4 Hz, H18); δC NMR 
(67.5 MHz, CD3OD): 175.5, 173.7, 131.0 (2 carbons), 129.3, 126.5 (2 carbons), 
125.4, 102.5, 81.8, 79.1, 46.8, 46.7, 46.1, 45.8, 43.7, 39.5, 37.1, 37.1, 31.6, 31.1, 
28.4, 28.3, 22.2, 18.6, 13.0, 2 carbons under solvent peak from 48.14 – 47.12; 
HRMS (ESI m/z): calculated for [C28H42N4O4-H]+ 497.31223, found 497.31397. 
7-phenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-dicarboxamido 
ethanamium chloride (139) 
Protected di-amine 121 (103.8 mg, 176.3 μmol); 
white hydroscopic solid (81.8 mg, yield: 99%, 
purity: 67%); υmax(thin film/cm-1)  3357 (br vs) 
(primary amine N-H) 1649 (vs) (amide C=O) 1212 (vs) (aromatic C=C) 1071 
(m) (acetal C-O); Characteristic peaks in the proton NMR: 5.68 (1H, s, H7) 4.34 
(1H, d, J = 2.47 Hz, H9) 4.27 (1H, d, J = 2.7 Hz, H5) (2H, dd, J = 2.7, 2.7 Hz, H2) 
1.98 (1H, d, J = 8.1 Hz, H10a) 1.59 (1H, d, J = 8.1 Hz, H10b);  MS (ESI m/z): 
calculated for [C20H30N4O4-H]+ 389.22, found 389.22. 
7-pyrenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-dicarboxamido 
ethanamium chloride (140) 
Protected di-amine 107 (76.5 mg, 107 μmol); 
yellow solid (46 mg, yield: 73%, purity: 86%); 
m.p 217 – 220 °C; υmax(thin film/cm-1) 2970 (br 
s) (aromatic C-H) 1647 (vs) (amide C=O); δH 
NMR (270 MHz, CD3OD): 8.40 – 8.01 (9H, m, H11-19) 6.61 (1H, s, H7) 4.49 (1H, 
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d, J = 5.4 Hz, H9) 4.45 (1H, d, J = 5.4 Hz, H5) 3.76 – 3.05 (9H, m, H2, H21-22, H25-
26) 2.86 – 2.62 (3H, m, H1, H3-4) 2.00 (1H, d, J = 10.8 Hz, H10a) 1.59 (1H, d, J = 
10.8 Hz, H10b); δC NMR (67.5 MHz, CD3OD): 175.6, 173.7, 132.0, 131.2, 130.6, 
128.9, 128.8, 127.6, 127.5, 127.0, 125.9, 125.3, 125.1, 124.3, 124.2, 124.1, 122.7, 
122.5, 100.22, 82.1, 79.3, 49.1, 48.5, 46.8, 45.8, 44.8, 43.8, 39.5, 37.1, 31.7; MS 
(ESI m/z): calculated for [C30H34N4O4-H]+ 513.24963, found 513.24993. 
7-[(p-octyloxy)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethanamium chloride (141) 
Protected di-mine 122 (74.2 mg, 
104 μmol); white hydroscopic 
solid (44 mg, yield: 72%, purity: 
65%); υmax(thin film/cm-1) 2964 (s) (methyl C-H) 1647 (s) (amide C=O) 1544 
(s) (primary amine N-H) 1459 (m) (methylene C-H) 1270 (s) (aryl ether C-O) 
1076 (m) (aceta C-Ol) 1039 (m) (aromatic C-H) 798 (m) (para substitution C-
H); Characteristic peaks in the proton NMR: 5.50 (1H, s, H7) 4.21 (1H, d, J = 5.4 
Hz, H9) 4.16 (1H, d, J = 5.4 Hz, H5) 1.98 (1H, d, J = 10.8 Hz, H10a) 1.56 (1H, d, J = 
10.8 Hz, H10b);  MS (ESI m/z): calculated for [C28H44N4O5+2K]2+ 297.13, found 
297.12.  
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7-[(p-octyl)phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethanamium chloride (142) 
Protected di-amine 123 (105.0 mg, 
149.8 μmol); brown hydroscopic 
solid (78.5 mg, yield: 91%, purity: 
79%); υmax(thin film/cm-1) 3307 (br m) (primary amine N-H) 2955 (vs) (methyl 
C-H) 2923 (vs) (methylene C-H) 1688 (s) (aromatic C=C) 1639 (vs) (amide C=O) 
1252 (s) (aromatic C-H) 1094 (s) (acetal C-O) 778 (m) (para substitution C-H); 
δH NMR (270 MHz, CD3OD): 7.42 – 7.32 (4H, m, H11-14) 5.54 (1H, s, H7) 4.24 – 
4.18 (2H, m, H5, H9) 2.77 – 2.62 (3H, m, H1, H3-4) 1.92 (1H, d, J = 10.8 Hz, H10a) 
0.92 (3H, t, J = 5.4 Hz, H22);  MS (ESI m/z): calculated for [C28H44N4O4 
+2(NH4)]2+ 268.20, found 268.20. 
7-[(3-benzyloxy)phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethanamium chloride (143) 
Protected di-amine 108 (101 mg, 145 
μmol); white hydroscopic solid (72.9 mg, 
yield: 88%, purity: 56%); υmax(thin 
film/cm-1) 3307 (br vs) (primary amine N-H) 1651 (vs) (amide C=O) 1615 (vs) 
(aromatic C=C) 1272 (vs) (benzyl ether C-O) 1084 (vs) (acetal C-O) 778 (vs) 
(meta substitution C-H); δH NMR (270 MHz, CD3OD): 7.43 – 6.92 (H9, m, H11-14, 
H16-20) 5.52 (1H, s, H7) 5.08 (2H, s, H15) 3.80 – 3.73 (2H, d, H5, H9) 1.88 (2H, 
d, J = 10.8 Hz, H10a) 1.49 (1H, d, J = 10.8 Hz, H10b); MS (ESI m/z): calculated for 
[C27H36N4O5-H]+ 495.26, found 495.26. 
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7-octyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-dicarboxamido 
ethanamium chloride (144) 
Protected di-amine 124 (105 mg, 172 
μmol); white hydroscopic solid s (79 mg, 
yield: 95%, purity: 100%); υmax(thin 
film/cm-1) 3292 (br s) (primary amine N-H) 2924 (vs) (methylene C-H) 2856 
(vs) (methyl C-H) 1641 (vs) (amide C=O) 1116 (s) (acetal C-O); δH NMR (270 
MHz, CD3OD): 4.70 (2H, t, J = 5.4 Hz, H7) 4.14 (1H, d, J = 2.7 Hz, H5) 4.09 (1H, d, J 
= 2.7 Hz, H9) 3.79 – 3.69 (1H, m, H2) 3.42-3.16 (8H, m, H20-21, H24-25) 2.70 
(1H, d, J = 2.7 Hz, H4) 2.67 (1H, d, J = 2.7 Hz, H3) 2.54 (1H, s, H1)  1.74 (1H, d, J = 
10.8 Hz, H10a) 1.46 (1H, d, J = 10.8 Hz, H10b) 1.28 (H10, m, H12-17) 0.89 (3H, t, 
J = 8.1 Hz, H18); δC NMR (67.5 MHz, CD3OD): 175.6, 173.7, 103.7, 81.4, 78.6, 
45.9, 45.8, 43.7, 43.6, 39.5, 39.4, 37.1, 37.1, 32.5, 31.5, 29.2, 28.93, 23.8, 22.3, 
13.0, 2 carbon under solvent peak from 48.13 – 47.11; HRMS (ESI m/z): 
calculated for [C22H40N4O4+2(NH4)]2+ 230.18630, found 230.18916. 
7,7-dimethyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethyl guanidinium chloride (145) 
Protected di-amine 114 (94.7 mg, 175 μmol); white 
solid (74 mg, yield: 99%, purity: 95%); mp 143 – 146 
°C; υmax(thin film/cm-1) 2970 (br s) (methyl C-H) 1648 
(vs) (amide C=O) 1067 (vs) (acetal C-O); δH NMR (270 MHz, CDCl3): 3.84 (1H, d, 
J = 5.4 Hz, H9) 3.76 (1H, d, J = 5.4 Hz, H5) 3.64 – 3.42 (5, m, H2, H14, H18) 3.14 
(4H, m, H15, H19) 2.39 – 2.39 (3H, m, H1, H3-4) 1.86 (1H, d, J = 5.4 Hz, H10a) 
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1.53 (1H, d, J = 5.4 Hz, H10b) 1.46 (3H, s, H11) 1.32 (3H, s, H12); δC NMR (67.5 
MHz, CD3OD): 175.9, 174.1, 109.1, 81.1, 78.1, 46.8, 45.7, 43.7, 39.4, 37.1, 31.5, 
31.1, 24.2, 22.9, 2 carbons under solvent peak from 48.1 – 47.1; HRMS (ESI 
m/z): calculated for [C16H30N4O4-H]+ 341.21833, found 341.21681. 
7-(p-fluorophenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethanamium chloride (146) 
Protected di-amine 125 (100 mg, 165 μmol); 
white hydroscopic solid (63.2 mg, yield: 80%, 
purity: 70%); υmax(thin film/cm-1) 3309 (br vs) 
(primary amine N-H) 1649 (vs) (amide C=O) 1071 (s) (acetal C-O) 1012 (s) 
(fluorine-aryl C-F) 821 (m) (para substitution C-H); Characteristic peaks in 
proton NMR: 5.56 (1H, s, H7) 4.23 (1H, d, J = 5.4 Hz, H9) 4.19 (1H, d, J = 5.4 Hz, 
H5) 2.77 – 2.62 (3H, m, H1, H3-4) 1.93 (1H, d, J = 10.8 Hz, H10a) 1.56 (1H, d, J = 
10.8 Hz, H10b); MS (ESI m/z): calculated for [C20H27FN4O4+NH4]+ 424.24, found 
424.23. 
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Chapter 3 
Amines to Guanidines 
In the current chapter, the aim was to synthesise a library of guanidine 
functionalised norbornane based CAMP mimics. Three guanylating agents were 
explored. Once the library of protected guanidines was produced, the deprotection 
protocol was re-evaluated. A number of guanidine salts were successfully formed 
and sent for antibacterial testing.  
3.1 One Step Protocol 
Scheme 37 illustrates how guanidines can be synthesised from amines. In this 
project therefore, in theory the protected guanidines may be obtained in just 
one step from the amine functionalised compounds synthesised in Chapter 2. 
 
Scheme 37 – One step from amines to protected guanidines. 
The removal of Boc groups and salt formation protocols have already been 
discussed and applied in Chapter 2, as such the step to be explored in detail in 
this chapter is the guanylation of amines. 
3.2 Guanylating agents 
A variety of guanylating agents are available. A selected few are shown in 
Scheme 38: di-Boc methyl isothiourea 147, di-Boc thiourea 148 and di-Boc 
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triflylguanidine 149 (each of these will convert amines to Boc-protected 
guanidines). A detailed discussion of each guanylating agent, their synthesis and 
application to the current project is provided in the following sections. 
 
Scheme 38 – Guanylating agents.233 
The following sections are not intended to be an authoritative review of all 
guanylating agents. For additional detail, please refer to the review by Katritzky 
and Rogovoy.233 
3.3 Di-Boc methylisothiourea 147 
 
Figure 66 – Structure of di-Boc 
methylisothiourea 147. 
Di-Boc methylisothiourea 147 is a popular guanylating agent (Figure 66) which 
is used either individually or with an ‘activating’ agent. An example of the 
individual use of di-Boc methylisothiourea 147 was published by König et. al. in 
the synthesis of receptors to selectively recognise amino acids and small 
peptides.234, 235 Reacting the amino crown ether 150 with di-Boc 
methylisothiourea 147 afforded the protected guanidine 151 in an excellent 
yield of 78% (Scheme 39). 
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Scheme 39 – Guanylation reaction to produced protected 
ether-guanidine 151.235 
Di-Boc methylisothiourea 147 has been also used with an ‘activating’ agent, the 
most common being HgCl2.236-238 Cammidge et. al. added HgCl2 to a solution of 
an amine and di-Boc methylisothiourea 147 (Scheme 40) which produced the 
desired protected guanidines within four hours. Three of the guanidines 
synthesised by Cammidge are featured in Scheme 40. Guanidine 152 was 
sterically hindered yet a high yield of 77% was obtained. Anilines were also 
successfully guanylated, for example 153 and 154.  These examples illustrate 
that with HgCl2, 147 was an efficient guanylating agent in the presence of other 
functional groups. 
 
Scheme 40 – Guanylation of secondary amines using di-Boc methyl 
isothiourea 147 and ‘activating’ agent HgCl2.237 
The mechanism by which di-Boc methyl isothiourea 147 and an ‘activating’ 
agent converts amines to guanidines is not precisely known.239 There are 
proposals that the ‘activating’ agent coordinates to di-Boc methylisothiourea 
151 
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147 and facilitates conversion to the reactive carbodiimide 155 (Scheme 41).237 
The amine nucleophile attack on the reactive carbodiimide 155 to afford the 
guanidine is believed to be the rate determining step.237 
 
Scheme 41 – Proposed mechanism for guanylations using di-Boc methylisothiourea 147 
and an ‘activating’ agent.237, 239 
The method for the synthesis of di-Boc methylisothiourea 147 is robust and 
rapid and involves two steps: methylation of thiourea 156 and protection of 
thiourea 157 (Scheme 42).236, 240, 241  
 
Scheme 42 – Two step synthesis of di-Boc methylisothiourea 147.240, 241 
3.3.1 Synthesis of di-Boc methylisothiourea 147 
In the current project, methyl iodide was chosen for the methylation of thiourea 
156. A solution of thiourea 156 and methyl iodide in MeOH was stirred at 65 °C 
for ninety minutes (Scheme 43).240, 242, 243 A white ‘crumbly’ solid was isolated in 
quantitative yield and identified as methyl isothiourea 157 by comparison of 
proton NMR spectra with literature data.243 
 
Scheme 43 – The methylation of thiourea 156 using methyl iodide to 
synthesise methyl isothiourea 157.243 
The protection of amines using Boc2O 90 has been discussed on page 58. In the 
current section of the project, Boc2O 90 was employed to protect both amines of 
methyl isothiourea 157 (Scheme 44). 
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Scheme 44 – The protection of methyl isothiourea 157 using Boc2O 90. 
A bi-phasic mixture of methyl isothiourea 157 in saturated bicarbonate solution 
and Boc2O 90 in DCM was stirred vigorously for sixteen hours at room 
temperature. After an aqueous extraction, a crude yellow solid was obtained. 
The crude solid was precipitated from hot EtOH using H2O to give di-Boc 
methylisothiourea 147 with a yield of 94% (Scheme 44).  
3.3.2 Synthesis of guanidines using di-Boc methylisothiourea 
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Scheme 45 – Unsuccessful guanylation using di-Boc methylisothiourea 147. 
In the current project, the reaction conditions first trialled was to stir amine 
139 in a solution of di-Boc methylisothiourea 147 and HgCl2 (activating agent) 
in THF at 50 °C for 3 hours.244 Unfortunately, guanylation was not successfully 
(Scheme 45). An alternative method of heating was considered since 
guanylations using di-Boc methylisothiourea 147 and conventional heating may 
take up to two days (Scheme 39).235 
 
Scheme 46 – Synthesis of boc-protected guanidine 161 using microwave irradiation.235 
159 161 
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A microwave mediated method by Sun et. al., albeit using different guanylating 
agent 160, showed the guanylating reaction between the PEG supported amine 
159 and di-Boc benzotraizole carboxamidine (160) was reduced from six hours 
to just seven minutes (Scheme 46).235 In the current project therefore, the 
guanylations with di-Boc methylisothiourea 147 were also trialled using 
microwave irradiation (Table 13). 
Table 13 – Amines subjected to guanylation using di-Boc methylisothiourea 147. 
 
No.  Yield No.  Yield 
162 
 
N/A 163  N/A 
      
158 
 
N/A    
      
Each di-amine was dissolved in a THF solution containing di-Boc 
methylisothiourea 147, HgCl2 and Et3N. The reaction mixture was irradiated in 
a microwave laboratory for fifteen minutes at 80 °C. After aqueous work up, the 
crude oils were analysed by proton NMR spectroscopy. Unfortunately, none of 
the guanylations using di-Boc methylisothiourea 147 were successful. As such, 
it was deemed an unsuitable agent for the synthesis of guanidine-functionalised 
norbornanes. Hence, another guanylating agent, di-Boc thiourea 148 was 
trialled.  
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3.4 Di-Boc thiourea 148 
 
Figure 67 – Structure of di-Boc thiourea 148. 
Another popular guanylating agent is di-Boc thiourea 148 (Figure 67). 234, 245, 246 
An example of its use was in the total synthesis of peptidic minalemine A 164 
(Scheme 47a). Munoz et. al. utilised di-Boc thiourea 148 to install the guanidine 
moieties that ‘bookend’ the peptide. Both cadaverine and putrescine were 
guanylated using di-Boc thiourea 148 in DMF at room temperature in thirty 
minutes. Both guanylated products, 165 and 166 were obtained in excellent 
yields (92% and 91% respectively). 
 
Scheme 47 – (a) Structure of minalemine A 164. (b) Guanylation 
reactions with cadaverine and putrescine using di-Boc thiourea 148.246 
Like di-Boc methylisothiourea 147, di-Boc thiourea 148 was sometimes used 
with an ‘activating’ agent such as HgCl2. Mercury salts however are extremely 
toxic. Other examples of less toxic ‘activating’ agents are carbodiimides, 1-
methyl-2-chloropyridinium iodide 167 (Mukaiyama’s reagent) and N-
iodosuccinimide 168 (NIS) (Figure 68).  
 
Figure 68 – Structures of Mukaiyama’s reagent 167 and 
NIS 168. 
(a) 
(b) 
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Again, the exact mechanism of di-Boc thiourea 148 guanylations is still 
unknown.239 However, there are a series of proposed steps similar to the 
proposed guanylation mechanism of di-Boc methylisothiourea 147. Firstly, the 
‘activating’ agents either react or coordinate to di-boc thiourea 148.247 After the 
addition of Et3N, there is a proposed electrophilic di-Boc carbodiimide 
intermediate 155.239, 248 The amine then attacks the intermediate 155 resulting 
in the desired protected guanidine (Scheme 48). 
 
Scheme 48 – Mechanism of guanylation using di-Boc thiourea 
148 and an ‘activating’ agent.239, 247, 248 
A recently discovered ‘activating’ agent of di-Boc thiourea 148 is NIS 168. 
Vasseur and Smietana et. al. were interested in replacing agents such as the 
mercury salts and also Mukaiyama’s reagent 167 as there were solubility 
problems in most stand organic solvents.247 They discovered that NIS 168 was 
an excellent replacement. By using di-Boc thiourea 148 and NIS 168, 
guanylation of a large number of amines at room temperature in DCM in 2 to 22 
hours was achieved in yields of up to 85%.247 
 
Scheme 49 – Guanidine products from the use of di-Boc thiourea 
148 and NIS 168.247 
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In this project therefore, NIS 168 was selected as the ‘activating’ agent to be 
used with di-Boc thiourea 148. First however, di-Boc thiourea 148 was 
required.245, 246 
3.4.1 Synthesis of di-Boc thiourea 148 
Following literature conditions for the synthesis of di-Boc thiourea 148, a 
solution of thiourea 156 in 150 mL of THF was cooled to 0 °C. Then NaH was 
added and allowed to stir for five minutes at room temperature to ensure 
complete deprotonation. Then, the reaction mixture was cooled back down to 0 
°C at which Boc2O 90 was added. The resulting slurry was stirred at room 
temperature for two hours and then quenched with saturated bicarbonate 
solution. The reaction mixture was then subjected to an aqueous extraction 
which furnished the desired di-Boc thiourea 148, with no requirement for 
further purification, in a yield of 53% (yields of up 86% have been reported in 
the literature).246  
 
Scheme 50 – Synthesis of di-Boc thiourea 148. 
The structure of di-Boc thiourea 148 was confirmed by comparing proton NMR 
spectra with literature data.246  
3.4.2 Synthesis of guanidines using di-Boc thiourea 148. 
The reaction of Vasseur and Smietana were used (Scheme 49).247 Each amine 
was added to a solution of di-Boc thiourea 148 and Et3N in DCM/MeOH and 
once fully dissolved, NIS 168 was added and the reaction stirred for sixteen 
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hours. After aqueous work up, the crude brown oils obtained were purified 
using column chromatography. The resulting clear viscous oils were 
characterised using proton and carbon NMR spectroscopy, IR and mass 
spectrometry. The yields of all reactions attempted are listed in Table 14. 
Table 14 – Yields of guanylations using di-Boc thiourea 147 and NIS 168. 
 
No.  Yield No.  Yield 
162 
 
34% 163  26% 
      
171 
 
18% 175 
 
21% 
      
172 
 
9% 176  20% 
173 
     
 
N/A 177 
 
28% 
      
158 
 
6% 178 
 
11% 
      
174 
 
12%    
      
While successful, the use of NIS 168 and di-Boc thiourea 148 gave low yields 
(all less than 35%) and in the case of guanidine 173 unsuccessful. It became 
clear that di-Boc thiourea 148 would not be a suitable guanylating agent for this 
project. Attention now turned to the evaluation of the last guanylating agent, di-
Boc triflylguanidine 149. 
 
148 
147 
 
149 
3.5 Di-Boc triflylguanidine 149 
Goodman et. al. had certain criteria in mind when developing their guanylating 
agent.249-251 Firstly, guanidines should be produced in high yields using mild 
conditions. Secondly, guanylation should be efficient with complex amines 
particularly during solid phase synthesis. Lastly, the reagent should be 
synthesised from relatively inexpensive starting materials. The result of their 
endeavours was di-Boc triflylguanidine 149 (Figure 69). 
 
Figure 69 – Structure of di-Boc triflylguanidine 149. 
Goodman et. al. demonstrated the efficiency of Di-Boc triflylguanidine 149 
guanylating primary amines (yields from 75% to 100%).249 Impressive 
outcomes considering the reactions were preliminary studies. Subsequent 
publications showed the ease at which di-Boc triflylguanidine 149 guanylated 
hindered secondary amines.250 Other benefits of guanylating agent 149 were its 
stability (it can be stored at room temperature for three months). Consequently, 
Goodman et. al. reasoned that if the compound was refrigerated, the chemical 
would remain stable indefinitely. 
Since, Goodman et. al. first reported di-Boc triflylguanidine 149 as an efficient 
guanylating agent in 1998, reagent 149 has proved to be the most popular and 
efficient guanylating agent and is consistently used for the late stage 
introduction of the guanidine moiety to complex molecules.227, 228, 233, 238, 249-258 
One of the best examples of how efficient di-Boc triflylguanidine 149 can be was 
provided by Hamm and Harth et. al.  
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180 
Hamm and Harth functionalised dendrimers with guanidines to target and 
control cellular delivery of bioactive cargo across the membrane of mammalian 
cells.257 With di-Boc triflylguanidine 149, installation of the guanidine moiety 
occurred at the second to last step on the already complex and hindered 
dendrimer 179. Stirring at room temperature, Hamm and Harth were able to 
install nine guanidines to form the protected guanylated dendrimer 180 in an 
excellent yield of 90% (Scheme 51). 
 
Scheme 51 – Guanylation of dendrimer using di-Boc triflylguanidine 
149 (n = 1 or 5).257  
The mechanism by which guanylation occurs with di-Boc triflylguanidine 148 is 
not specifically addressed in the literature. In order to propose a plausible 
mechanism, there must be an examination of the trifluoromethylsulfonamide 
(triflyl) functional group 181. The triflyl group 181 was first discussed in 1957 
by Gramstad and Hazeldine (Figure 70a).259 They used 
trifluoromethanesulphonic anhydride 183 for efficient installation of the triflyl 
group. 
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Figure 70 – (a) Structure of triflyl group 181. (b) 
trifluoromethanesulphonic acid 182. (c) 
trifluoromethanesulphonic anhydride 183. (d) triflamide 184.197 
Many years later in 1973, Hendrickson and Bergeron employed the triflyl group 
as a protecting group for amines and found that trifluoromethanesulfonamides 
could be synthesised quantitatively from trifluoromethanesulphonic anhydride 
183 and the products were generally stable and crystalline (Figure 70d).197, 260. 
Furthermore, Hendrickson and Bergeron discovered that in cleaving the triflyl 
group 181, two kinds of fragmentation were observed (Figure 71).261 
 
Figure 71 – (a) Cleavage of triflyl group results in the 
displacement of triflamide 184. (b) Cleavage of triflyl group 181 
results in the displacement of the triflinate anion.261 
The first type of fragmentation of the triflyl group 181 observed is the SN2 
displacement of triflamide 184, a stabilised leaving group (Figure 71a). The 
second type of fragmentation results in a trifluoromethanesulfinate anion 
(Figure 71b). According to studies conducted by Goodman et. al., during the 
process of guanylation by di-Boc triflylguanidine 149, triflamide 184 is a by-
product. Hence, the first fragmentation between carbon and nitrogen observed 
by Hendrickson and Bergeron most likely occurs in a guanylation by di-Boc 
triflylguanidine 149. Further studies by Glass confirmed that other 
nucleophiles, such as halogens, nitrogens and cyanide, attack 
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trifluoromethanesulfonamides at the expense of the carbon-nitrogen bond for 
the preferential displacement of triflamides 184.262  
 
Scheme 52 – Proposed mechanism for the synthesis of guanidine using 
di-Boc triflylguanidine 149. 
By incorporating all of the information above, a proposed mechanism for the 
guanylations of amines by di-Boc triflylguanidine 149 is shown in Scheme 52. 
The nucleophile, which is the free amine 185, attacks the ‘imine’ carbon on di-
Boc triflylguanidine 148. Following a proton shift, intermediate 186 may result. 
It is argued that since triflamide 184 would be the stable and preferred leaving 
group, the base would preferentially attack the hydrogen on a carbamate of 
intermediate 186 thereby leading to the displacement of triflamide 184 and the 
formation of the desired protected guanidine 187. 
3.5.1 Synthesis of di-Boc triflylguanidine 149 
Goodman et. al. outlined a two step methodology by which di-Boc 
triflylguanidine 149 could be synthesised. The first step was the protection of 
guanidine hydrochloride 188 using Boc2O 90 forming di-Boc guanidine 189. 
From there triflylation using triflic anhydride 183 occurs whereby di-Boc 
triflylguanidine 149 is obtained.263, 264 
 
Scheme 53 – Synthesis of di-Boc triflylguanidine 149 following 
the Goodman procedure.250 
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3.5.2 Protection of guanidine hydrochloride 188 
 
Scheme 54 – The synthesis of di-Boc guanidine 189 from 
guanidine hydrochloride 188.250 
In the current project, the method of Goodman was followed (Scheme 54) to 
give after column chromatography the desired di-Boc guanidine 189 in a yield 
of 39%. The structure of di-Boc guanidine 189 was confirmed by comparison of 
proton NMR spectra with literature.250 
 
Figure 72 – Structures of mono-Boc guanidine 190, di-Boc guanidine 
189 and tri-Boc guanidine 191. 
Yields of the di-Boc protection of guanidine hydrochloride 188 stated in 
literature range from 43% to 60%.249, 250, 264, 265 Therefore, a yield of 39% is not 
considered poor. One of the disadvantages highlighted by Goodman et. al. of his 
method of protection for guanidine hydrochloride 188 is that the reaction 
results in a mixture of products: mono-Boc guanidine 190, di-Boc guanidine 
189 and tri-Boc guanidine 191 (Figure 72). With competing products, high 
yields are not likely. Furthermore, it was found that in the current project 
purification by column chromatography was very problematic sometimes 
requiring two or three attempts. With so many difficulties, a different method of 
synthesising di-Boc guanidine 189 was explored. 
3.5.3 Amination of di-Boc methylisothiourea 147 
Whilst developing the Mitsunobu reaction for the conversion of alcohols to 
protected guanidines, Hammerschmidt and Kvaternik developed an alternative 
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method for the synthesis of di-Boc guanidine 189.266 By treating di-Boc 
methylisothiourea 147 with ammonia, they synthesised di-Boc guanidine 189 
in an excellent yield of 95%. The methodology developed by Hammerschmidt 
and Kvaternik was replicated in this project to synthesise di-Boc guanidine 189 
(Scheme 55) in 70% yield. The method using di-Boc methylisothiourea 147 had 
the advantage of higher yields and no further purification needed beyond an 
aqueous extraction during work up. 
 
Scheme 55 – Synthesis of di-Boc guanidine 189 using di-Boc 
methylisothiourea 147. 266 
3.5.4 Synthesis of di-Boc triflylguanidine 149 
To install the triflyl group 181, di-Boc guanidine 189 was treated with triflic 
anhydride 183.267 It is assumed that the imine 193 acts as a nucleophile in 
reacting with triflic anhydride 183. Trifluoromethanesulphonic acid 182 is 
eliminated leaving the protected imine 194 (Scheme 56). 
 
Scheme 56 – Proposed mechanism for the protection of an imine using triflic 
anhydride 183.165 
In the current project, a solution of di-Boc guanidine 189 and Et3N in DCM was 
cooled to -78 °C. Then triflic anhydride 183 was added drop wise over twenty 
minutes. The reaction solution was allowed to warm to -20 °C over four hours. 
After quenching with sodium bisulphite solution and column chromatography, 
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189 149 
the desired di-Boc triflylguanidine 149 was isolated in a yield of 61% (Scheme 
57). The structure of guanylating agent 149 was confirmed by comparison with 
published data.250 
 
Scheme 57 – Synthesis of di-Boc triflylguanidine 149 from di-Boc 
guanidine 189. 
3.5.5 Synthesis of guanidines using di-Boc triflylguanidine 149 
In the reaction to install the guanidine moiety, guanylating agent 149 and the 
amine are stirred in DCM at room temperature until the reaction has reached 
completion.227, 249, 250, 254, 257 Accordingly, each amine was stirred in a solution of 
di-Boc triflylguanidine 149 and Et3N in DCM at room temperature for 16 hours 
monitoring by TLC. After an aqueous work up, each crude product was purified 
using column chromatography (Table 15). The structure of each protected 
guanidine was confirmed by analysis of proton and carbon NMR spectroscopy, 
FT-IR and HRMS.The use of di-Boc triflylguanidine 149 successfully produced 
the entire library of protected guanidines. Although the lowest yield was 15% 
with respect to guanidine 178, yields ranged from 30% to 83%. The differences 
in yields are attributed to the differences in hydrophobic region; a trend also 
observed in the synthesis of the amine functionalised norbornanes (Chapter 2). 
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Table 15 – Yields of guanylation using di-Boc triflylguanidine 173. 
 
No.  Yield No.  Yield 
162 
 
28% 195  62% 
      
171 
 
59% 163  26% 
      
172 
 
75% 175 
 
83% 
      
173 
 
59% 176  54% 
      
158 
 
30% 177 
 
29% 
      
174 
 
35% 178 
 
15% 
      
The proton NMR spectrum of protected guanidine 175 as an example is 
provided (Figure 73a). The six N-H protons are present in the proton spectrum 
(δ11.5, δ8.6, δ8.5, δ8.1 and δ6.8). Furthermore, the acetal (δ5.5) and benzyl 
(δ5.0) peaks associated with the hydrophobic moiety are present indicating that 
both functionalities are intact. Using the previous NMR analysis from Chapter 2, 
the full proton assignments for protected guanidine 175 are detailed in Figure 
73. A complete analysis of protected guanidine 175 is elaborated in the 
experimental section at the end of the current chapter. 
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Figure 73 – (a) Proton NMR spectrum of protected guanidine 175. (b) Protected guanidine 175 wil 
full proton assignments. 
Having successfully synthesised the protected guanidine library, attention now 
turned to the deprotection and salt formation step. 
3.6 Case Study with Guanidine 171 
In this section, once again two deprotection protocols were compared 
(HCl/Dioxane and acetyl chloride/MeOH) (Scheme 58). 
 
Scheme 58 – Guanidine 171 subjected to two deprotection protocols. 
Once judged complete by TLC (typically 24 hours), the reaction solvents were 
removed in vacuo and the resulting residues analysed using proton NMR 
spectroscopy (Figure 74). 
171 196 
(a) 
(b) 
156 
 
 
Figure 74 – Proton NMR spectrum of (a) di-carboyxlic acid 77 in CD3OD (b) protected guanidine 
171 in CDCl3. (c) treatment with acetyl chloride in MeOH in CD3OD. (d) treatment with HCl in 
Dioxane in CD3OD. 
Once again, there were a number of signals in both spectra from δ6.25 to δ5.25, 
the region the acetal protons commonly appear (Figure 74). The acetal proton 
was assigned to peak δ5.61 based on the acetal peaks present in the spectra of 
di-carboxylic acid 77 and protected guanidine 171. Comparison of the spectra 
indicated that as a consequence of much longer treatment times, the HCl in 
dioxane protocol did not cause as much degradation as the acetyl chloride in 
MeOH protocol. Comparison of the peaks in the acetal region showed that for 
the HCl in dioxane method, the fully formed acetal remained the dominant 
species. Unfortunately, for the acetyl chloride in MeOH method, degradation 
was extensive. 
As per previous Boc deprotections, aqueous extraction was used to purify the 
mixtures of guanidine salts. The aqueous phases were combined and water 
(a) 
(b) 
(c) 
(d) 
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removed by sublimation leaving behind a white solid that were then analysed 
using proton NMR spectroscopy (Figure 75). 
 
Figure 75 - Proton NMR of 196 after purification when (a) treated with acetyl chloride in 
MeOH. (b) treated with HCl in Dioxane. 
This extraction protocol was again successful in purifying the mixtures of 
guanidine salts however based on the comparison of the two deprotection 
protocols, it was decided that treatment with HCl in Dioxane and subsequent 
aqueous extraction was the protocol to be followed. As with the previous 
deprotections, the strategy was to use analysis by proton NMR spectroscopy to 
determine sample purity. 
 
(a) 
(b) 
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Figure 76 – Proton NMR of guanidine salt 196. 
The same key characteristic peaks were chosen to estimate the purity of the 
desired guanidine. The acetal peak (δ5.61, int.=1.00) was calculated as a 
percentage of the acetal (δ5.61, int.=1.00) and the degradation (δ6.22, int.=0.19; 
δ5.42, int.=0.08) to obtain a estimated purity of 79% (Figure 76). Having settled 
on a method for deprotection and estimating purity, the formation of the library 
of guanidine salts began. 
3.7 Deprotection and Salt Formation 
Table 16 shows the yields and purities for the products obtained from the 
deprotection/salt formation of the guanidines using the HCl in Dioxane protocol. 
Each protected guanidine was dissolved in a solution of HCl/dioxane and stirred 
at room temperature for forty-eight hours. Once judged complete by TLC, the 
reaction solvent was removed in vacuo. The viscous residue was re-dissolved in 
EtOAc and extracted with H2O. The aqueous phases were combined and water 
removed through sublimation leaving behind hydroscopic solids. 
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Table 16 – Yields of guanidine salts. 
 
No.  Mass
* Purity No.  Mass
* Purity 
30 
 
45% 98% 201 
 
97% 79% 
        
196 
 
99% 79% 202 
 
63% 36% 
        
197 
 
55% 86% 203 
 
89% 41% 
        
198 
 
87% 48% 204 
 
47% 98% 
        
199 
 
72% 40% 205 
 
77% 61% 
        
200 
 
83% 40% 206 
 
76% 39% 
        
*Mass recovered after freeze drying 
Unfortunately there were a number of guanidine salt mixtures that had less than 
70% of the desired guanidine present. This may be attributed to the treatment 
times required for the deprotection of all four of the Boc protecting groups (up 
to forty-eight hours). In some cases, the degradation was particularly noticeable 
with five salts from the guanidine library being less than 50% pure.  
3.8 Conclusion 
The aim for the current chapter was to evaluate a number of guanylating agents 
in the synthesis of a library of protected guanidines. The three guanylating 
agents chosen were di-Boc methylisothiourea 147, di-Boc thiourea 148 and di-
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Boc triflylguanidine 149. Di-Boc triflylguanidine 149 was clearly the best and 
allowed for the synthesis of the entire guanidine library. Hence, di-Boc 
triflylguanidine 149 would be the guanylating agent of choice for any future 
studies. 
Once again, deprotection resulted in degradation of the acetal functional group. 
Unfortunately, in the current instance, the length of time required for the 
deprotection of the guanidines meant that only six out of twelve guanidine salts 
had purities higher than 70%. Nonetheless, all the guanidine functionalised 
norbornane based CAMP mimics were sent for antibacterial testing the results 
of which are discussed in Chapter 5. 
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3.9 Experimental 
Guanylating agents. 
The following compounds are known compounds and were prepared using 
literature conditions:  
x Methyl isothiourea 157.243 
x Di-Boc methylisothiourea 147.240 
x Di-Boc thiourea 148.246 
x Di-Boc guanidine 189.266 
x Di-Boc triflylguanidine 149. 249 
Synthesis of protected guanidines 
Method A using N-iodosuccinimide: NIS 168 was added to a solution of amine, 
di-Boc thiourea 148 and Et3N in DCM/MeOH (1:4) (5 mL) and allowed to stir for 
16 hours at room temperature. 1 M sodium thiosulphate solution (3 mL) was 
added and the reaction mixture diluted with H2O (20 mL), transferred to a 
separatory flask and extracted using EtOAc (4 × 10 mL). The organic phases 
were combined and dried using MgSO4. The MgSO4 suspension was filtered and 
the solvent removed in vacuo resulting in crude brown oils. The oils were 
purified with column chromatography using gradient elution [(1:9) EtOAc/Pet 
40-60 → 20% EtOH in (1:1) EtOAc/Pet 40-60]. Fractions containing the desired 
compound were combined and the solvent removed in vacuo resulting in a clear 
viscous oils.  
162 
 
Method B using di-Boc triflylguanidine: A solution of amine, triflylguanidine 149 
and Et3N in DCM (5 mL) was allowed to stir for 16 hours at room temperature. 
The reaction solution was diluted with DCM (10 mL), transferred to a 
separatory flask and washed with saturated bicarbonate solution (10 mL), 
saturated brine solution (10 mL) and the organic phase separated, dried with 
MgSO4, filtered and the solvent removed in vacuo. The crude brown oil was 
purified using column chromatography using gradient elution [(1:3) DCM/ Pet 
40-60 → 5% in (1:1) EtOAc/Pet 40-60]. Fractions containing the desired 
compound were combined and the solvent removed in vacuo resulting in clear 
viscous oils. 
7-(pentadecyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-{N-[2-
(N’,N’’-di-tert-butoxy carbonyl)-guanidino]-carboxamide} (162)145 
Method A: hexadeca amine 
137 (35.3 mg, 59.2 μmol); 
dibocthiourea 148 (35.9 mg, 
130 μmol); Et3N (1 mL); NIS 
168 (29.3 mg, 130 μmol); Rf 
0.36; brown viscous oil (20.5 mg, 34%); Method B: hexadeca amine 137 (86.6 
mg, 145 μmol); di-boc triflylguanidine 149 (125.2 mg, 320 μmol); Et3N (0.1 mL); 
Rf 0.65; brown viscous oil (62.2 mg, 28%); δH NMR (270 MHz, CDCl3): 11.46 (1H, 
br s, -NH) 11.44 (1H, br s, -NH) 8.62 (1H, t, J = 5.9 Hz, -NH) 8.49 (1H, t,  J = 5.4 Hz, 
-NH) 7.99 (1H, t, J = 4.2 Hz, -NH) 6.84 (1H, t, J = 5.5 Hz, -NH) 4.59 (1H, t, J  = 4.7 
Hz, H7) 4.02 (1H, d, J = 5.9 Hz, H5) 3.94 (1H, d, J = 5.5 Hz, H9) 3.57-3.36 (8H, m, 
H27-28, H32-33) 2.93 (1H, dd, J = 2.7, 5.4 Hz, H2) 2.69 (1H, d, J = 2.7 Hz, H4) 
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2.56 (1H, s, H3) 2.43 (1H, d, J = 5.47 Hz, H1) 1.77 (1H, d, J = 9.4 Hz, H10a) 1.60-
1.23 (63H, m, H10b, H11-24, H36-39) 0.86 (3H, t,  J = 6.2 Hz, H25). 
7-(4’-biphenyl)-6,8-dioxatricyclo[5.2.1.06,8] decane-2-endo,3-exo- di-{N-[2-
(N’,N’’-di-tert-butoxy carbonyl)-guanidino]-carboxamide} (171) 
Method A: Di-phenyl amine 138 (64.8 
mg, 121 μmol); dibocthiourea 148 
(73.3 mg, 265 μmol); Et3N (27 mg, 265 
mmol); NIS 168 (59.7 mg, 265 μmol); Rf 
0.36; white viscous oil (21.1 mg, 18%); 
Method B: Di-phenyl amine 138 (89.8 mg, 167 μmol); di-boc triflylguanidine 
149 (143.9 mg, 368 μmol); Et3N 0.1 mL); Rf 0.51; white viscous (92.8 mg, 59%); 
υmax(thin film/cm-1) 1977 (m) (aromatic C=C) 2926 (m) (methyl C-H) 1638 (vs) 
(amide C=O) 1563 (m) (aromatic C=C) 1131 (vs) (tertiary amine C-N) 1074 (s) 
(acetal C-O) 833 (m) (para substitution of aromatic C-H); δH NMR (270 MHz, 
CDCl3): 11.47 (1H, br s, -NH) 11.45 (1H, br s, -NH) 8.64 (1H, br t, -NH) 8.51 (1H, 
br t, -NH) 8.08 (1H, br t, -NH) 7.56-7.34 (9H, m, H11-19) 6.90 (1H, br t, -NH) 
5.58 (1H, s, H7) 4.25 (1H, d, J = 4.8 Hz, H5) 4.18 (1H, d, J = 4.8 Hz, H9) 3.58-3.39 
(8H, m, H21-22, H26-27) 3.02 (1H, dd, J = 5.4, 5.4 Hz, H2) 2.82 (1H, d, J = 2.7 Hz, 
H4) 2.69 (1H, s, H3) 2.54 (1H, d, J = 8.1 Hz, H1) 1.99 (1H, d, J = 10.2 Hz, H10a) 
1.64 (1H, d, J = 10.2 Hz, H10b) 1.48 (36H, m, H30-33); δC NMR (67.5 MHz, 
CDCl3): 173.92, 173.64, 163.33, 162.85, 157.75, 156.97, 153.11, 141.38, 140.85, 
140.79, 135.01, 128.79 (2 carbons), 127.19 (2 carbons), 127.14 (2 carbons), 
127.08 (2 carbons), 102.87, 83.61, 83.33, 79.82, 79.55, 47.49, 44.74, 44.15, 
43.21, 40.10 (3 carbons), 39.99, 29.70, 29.36, 29.09, 28.40 (3 carbons), 28.26 (3 
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carbons), 28.047 (3 carbons), 28.05 (3 carbons); HRMS (ESI m/z): calculated for 
[C48H68N8O12+2Na]2+ 497.23706, found 497.23705. 
7-(parabromophenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo- di-
{N-[2-(N’,N’’-di-tert-butoxy carbonyl)-guanidino]-carboxamide} (172) 
Method A: Bromo phenyl amine 136 (74.9 mg, 16.46 μmol); dibocthiourea 148 
(100.1 mg, 36.22 μmol); Et3N (36.9 mg, 
36.22 mmol); NIS 168 (81.5mg, 36.22 
μmol); Rf 0.74; white viscous oil (14.6 mg, 
9%); Method B: Bromo phenyl amine 136 
(82.4 mg, 153 μmol); di-boc triflylguanidine 
149 (131 mg, 336 μmol); Et3N (0.1 mL); Rf 0.65; white viscous oil (108 mg, 
75%); υmax(thin film/cm-1) 1730 (vs) (aromatic C=C) 1642 (m) (amide C=O) 
1173 (s) (tertiary amine C-N) 833 (m) (1,4-substitution of aromatic C-H) 583 
(m) (bromine C-Br); δH NMR (270 MHz, CDCl3): 11.47 (1H, br s, -NH) 11.45 (1H, 
br s, -NH) 8.65 (1H, br t, J = 3.9 Hz, -NH) 8.51 (1H, br t, J = 3.9 Hz, -NH) 8.08 (1H, 
br t, J = 3.2 Hz, -NH) 7.48 (2H, d, JAB = 5.7 Hz, H12) 7.34 (2H, d, JA’B’ = 5.4 Hz, H11) 
6.86 (1H, br t, J = 3.7 Hz, -NH) 5.48 (1H, s, H7) 4.23 (1H, d, J = 3.7 Hz, H5) 4.15 
(1H, d, J = 3.7 Hz, H9) 3.60-3.37 (8H, m, H14-15, H19-20) 3.00 (1H, dd, J = 2.7, 
5.4 Hz, H2) 2.80 (1H, d, J = 2.7 Hz, H4) 2.67 (1H, s, H3) 2.52 (1H, d, J = 2.7 Hz,. 
H1) 1.88 (1H, d, J = 7.2 Hz, H10a) 1.57-1.25 (37H, m, H10b, H23-26); δC NMR 
(67.5 MHz, CDCl3): 173.9, 171.8, 163.6, 162.9, 159.9, 157.8, 157.6, 157.0, 153.1, 
135.2, 131.5 (2 carbons), 128.5 (2 carbons), 102.3, 83.7, 83.7, 83.4, 82.1, 80.3, 
79.9, 47.5, 44.7, 43.2, 41.8, 40.4 (2 carbons), 40.1 (2 carbons), 32.5, 29.8 (3 
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carbons), 28.3 (3 carbons), 28.2 (3 carbons), 28.1 (3 carbons); HRMS (ESI m/z): 
calculated for [C42H63BrN8O12+2(NH4)]2+ 493.22127, found 493.22395.  
7-(para-octynyl-phenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo- 
di-{N-[2-(N’,N’’-di-tert-butoxy carbonyl)-guanidino]-carboxamide} (173) 
Method B: Octynyl phenyl amine 
134 (85.3 mg, 150 μmol); di-boc 
triflylguanidine 149 (128.9 mg, 
329 μmol); Et3N (0.1 mL); Rf 
0.39; brown solid (87 mg, 59%); 
mp 90.2 – 93.2 °C; υmax(thin film/cm-1) 3314 (m) (alkyne) 2957 (m) (methyl C-
H) 2924 (m) (methylene C-H) 1638 (vs) (amide C=O) 1453 (vs) (aromatic C=C) 
1154 (vs) (tertiary amine C-N) 1070 (vs) (acetal C-O) 808 (vs) (para 
substitution C-H); δH NMR (270 MHz, CDCl3): 11.45 (2H, br m, H25, H30) 8.65 
(1H, t, J = 5.5 Hz, H24) 8.52 (1H, t, J = 5.7 Hz, H29) 8.07 (1H, t, J = 4.5 Hz, H21) 
7.36 (4H, s, H11-14) 6.87 (1H, t, J = 4.47 Hz, H26) 5.49 (1H, s, H7) 4.21 (1H, d, J = 
5.5 Hz, H5) 4.13 (1H, d, J = 5.5 Hz, H9) 3.61-3.40 (8H, m, H22-23, H27-28) 2.99 
(1H, dd, J = 5.4, 5.4 Hz, H2) 2.79 (1H, d, J = 2.7 Hz, H4) 2.67 (1H, s, H3) 2.50 (1H, 
d, J = 5.4 Hz, H1) 2.38 (2H, t, J = 6.9 Hz, H15) 1.92 (1H, d, J = 9.6 Hz, H10a) 1.60-
1.20 (45H, m, H10b, H16-19, H31-34) 0.88 (3H, t, J = 4.5 Hz, H20); δC NMR (67.5 
MHz, CDCl3): 173.95, 171.85, 163.29, 162.83, 157.77, 156.99, 153.10, 135.12, 
131.48, 131.42 (2 carbons), 128.60, 128.50, 126.58 (2 carbons), 125.22, 102.70, 
91.21, 83.62, 83.36, 81.95, 47.49, 44.63, 44.14, 43.12, 42.06, 40.04, 40.00, 39.93, 
32.49, 31.35, 29.70, 28.67, 28.60, 28.25 (3 carbons), 28.33 (3 carbons), 28.06 (3 
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carbons), 28.04 (3 carbons), 27.83, 22.55, 19.44, 14.05; HRMS (ESI m/z): 
calculated for [C50H76N8O12+H]+ 981.56555, found 981.56897. 
7-phenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo- di-{N-[2-(N’,N’’-
di-tert-butoxy carbonyl)-guanidino]-carboxamide} (158) 
Method A: Phenyl amine 139 (115 mg, 249 μmol); dibocthiourea 148 (165 mg, 
597 μmol); Et3N (61 mg, 597 mmol); NIS 
168 (134 mg, 597 μmol); Rf 0.74; white 
viscous oil (121.2 mg, 6%); Method B: 
Phenyl amine 139 (61.9 mg, 134.2 μmol); di-
boc triflylguanidine 149 (115.5 mg, 295 
μmol); Et3N (0.1 mL); Rf 0.57; white viscous oil (35 mg, 30%); υmax(thin film/cm-
1) 2853 (m) (methyl C-H) 1715 (m) (aromatic C=C) 1639 (s) (amide C=O) 1229 
(s) (tertiary amine C-N) 1132 (vs) (acetal C-O); %); δH NMR (270 MHz, CDCl3): 
11.47 (1H, br s, H20) 11.45 (1H, br s, H25) 8.64 (1H, br t, H19) 8.51 (1H, br t, 
H24) 8.05 (1H, br t, H16) 7.46-7.36 (5H, m, H11-15) 6.85 (1H, br t, H21) 5.52 
(1H, s, H7) 4.23 (1H, d, J = 4.0 Hz, H5) 4.16 (1H, d, J = 4.0 Hz, H9) 3.62-3.35 (8H, 
m, H17-18, H22-23) 3.00 (1H, br d, J = 5.4 Hz, H2) 2.81 (1H, d, J = 2.7 Hz, H4) 
2.68 (1H, s, H3) 2.52 (1H, d, J = 5.4 Hz, H1) 1.97 (1H, d, J = 10.2 Hz, H10a) 1.63-
1.43 (37H, m, H10b, H26-29); δC NMR (67.5 MHz, CDCl3): 177.4, 174.0, 171.9, 
163.4, 162.9, 157.8, 157.0, 153.2, 136.1, 129.5, 128.3 (2 carbons), 126.8 (2 
carbons), 103.1, 83.7, 83.4, 79.9, 79.4, 47.6, 44.8, 44.2, 43.3, 42.0, 40.2 (2 
carbons), 40.0 (2 carbons), 32.6, 29.8, 29.8 (3 carbons), 29.7 (3 carbons), 28.5 (3 
carbons), 28.3 (3 carbons); HRMS (ESI m/z): calculated for [C42H64N8O12+H]+ 
873.4716, found 873.47608. 
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7-pyrenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-di-{N-[2-(N’,N’’-
di-tert-butoxy carbonyl)-guanidino]-carboxamide} (174) 
Method A: Pyrenyl amine 140 (46 mg, 78.6 
μmol); dibocthiourea 148 (47.8 mg, 173 
μmol); Et3N (17.6 mg, 173 mmol); NIS 168 
(38.9 mg, 173 μmol); Rf 0.25; yellow oil 
(9.5 mg, 12%); Method B: Pyrenyl amine 
140 (83.0 mg, 141.8 μmol); di-boc triflylguanidine 149 (122.1 mg, 311.9 μmol); 
Et3N (0.1 mL); Rf 0.83; yellow oil (50.1 mg, 35%); υmax(thin film/cm-1) 1718 (s) 
(aromatic C=C) 1640 (s) (amide C=O) 1230 (vs) (tertiary amine C-N) 1079 (s) 
(acetal C-O); δH NMR (270 MHz, CDCl3): 11.48 (2H, br m, H24, H29) 8.66 (1H, br 
t, J = 5.9 Hz, H23) 8.53 (1H, br t, J = 5.9 Hz, H28) 8.40-7.96 (10H, m, H11-20) 
6.96 (1H, br t, J = 4.9 Hz, H25) 6.55 (1H, s, H7) 4.48 (1H, d, J = 5.9 Hz, H5) 4.40 
(1H, d, J = 5.9 Hz, H9) 3.60-3.39 (8H, m, H21-22, H26-27) 3.10 (1H, dd, J = 2.7, 
5.4 Hz, H2) 2.89 (1H, d, J = 2.7 Hz, H4) 2.76 (1H, s, H3) 2.64 (1H, d, J = 2.7 Hz, H1) 
1.99 (1H, d, J = 9.88 Hz, H10a) 1.49-1.43 (H37, m, H10b, H30-33); δC NMR (67.5 
MHz, CDCl3): 177.64, 174.02, 171.98, 163.38, 162.94, 157.80, 157.13, 153.20, 
131.95, 131.23, 130.67, 129.06, 129.00, 128.15, 128.07, 127.87, 127.46, 126.01, 
125.50, 125.44, 124.68, 123.03, 122.92, 122.80, 100.61, 83.68, 83.42, 82.31, 
79.88, 79.69, 47.32, 45.15, 44.26, 43.48, 42.06, 40.29 (2 carbons), 40.10 (2 
carbons), 32.57, 32.00, 30.29, 29.77, 29.59, 29.44, 29.24, 29.03, 28.63, 28.49, 
28.31, 28.12, 27.91; HRMS (ESI m/z): calculated for [C52H68N8O12+H]+ 
997.50295, found 997.50329. 
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7-(para-octyloxy phenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo- 
di-{N-[2-(N’,N’’-di-tert-butoxy carbonyl)-guanidino]-carboxamide} (195) 
Method B: Octyloxy phenyl amine 
141 (78.6 mg, 134 μmol); di-boc 
triflylguanidine 149 (115.0 mg, 
294 μmol); Et3N (0.1 mL); Rf 0.83; 
white solid (82.6 mg, 62%); mp 
64.0 – 67.2 °C; υmax(thin film/cm-
1) 3310 (m) (secondary amine N-H) 2977 (m) (methyl C-H) 2856 (m) 
(methylene C-H) 1640 (vs) (amide C=O) 1614 (vs) (aromatic C=C) 1250 (s) (aryl 
ether C-O); δH NMR (270 MHz, CDCl3): 11.46 (1H, br s, H27) 11.43 (1H, br s, 
H32) 8.64 (1H, t, J = 5.9 Hz, H26) 8.51 (1H, t, J = 5.7 Hz, H31) 8.07 (1H, t, J = 3.9 
Hz, H23) 7.36 (2H, d, 3JAB = 10.8 Hz, H11-12) 6.86-6.79 (3H, m, H13-14, H28) 
5.47 (1H, s, H7) 4.19 (1H, d, J = 5.9 Hz, H5) 4.11 (1H, d, J = 5.9 Hz, H9) 3.92 (2H, t, 
J = 6.4 Hz, H15) 3.57-3.31 (8H, m, H24-25, H29-30) 3.00 (1H, dd, J = 2.7, 5.4 Hz, 
H2) 2.79 (1H, d, J = 2.7 Hz, H4) 2.66 (1H, s, H3) 2.51 (1H, d, J = 5.4 Hz, H1) 1.98 
(1H, d, J = 10.4 Hz, H10a) 1.61 (1H, d, J = 10.4 Hz, H10b) 1.49-1.20 (48H, m, H16-
21, H33-36) 0.86 (3H, t, J = 7.2 Hz, H22); δC NMR (67.5 MHz, CDCl3): 174.09, 
171.93, 163.27, 162.82, 160.08, 157.75, 156.98, 153.10, 128.08 (2 carbons), 
127.93, 114.25 (2 carbons), 103.05, 83.63, 83.38, 81.77, 79.89, 79.68, 79.13, 
68.05, 47.54, 44.70, 44.15, 43.20, 42.02, 40.05, 39.95, 32.54, 31.92, 31.80, 29.69, 
29.34, 29.23, 29.20, 28.24 (3 carbons), 28.23 (3 carbons), 28.05 (3 carbons), 
28.03 (3 carbons), 26.01, 22.65, 14.09; HRMS (ESI m/z): calculated for 
[C50H80N8O13+H]+ 1001.59176, found 1001.59451.  
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7-(para-octyl-phenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo- di-
{N-[2-(N’,N’’-di-tert-butoxy carbonyl)-guanidino]-carboxamide} (163) 
Method B: Octyl phenyl amine 142 
(81.5 mg, 142 μmol); di-boc 
triflylguanidine 149 (122.3 mg, 313 
μmol); Et3N (0.1 mL); Rf 0.36.8; 
white solid (36.8 mg, 26%); mp 79.1 
– 83.2 °C; υmax(thin film/cm-1) 2924 
(m) (-CH2-) 2854 (vs) (methyl C-H) 1637 (vs) (amide C=O) 1614 (vs) (aromatic 
C=C) 1155 (vs) (tertiary amine C-N) 1130 (vs) (acetal C-O) 859 (s) (para 
substitution); δH NMR (270 MHz, CDCl3): 11.46 (1H, br s, H27) 11.44 (1H, br s, 
H32) 8.64 (1H, br t, H26) 8.53 (1H, br t, H31) 8.08 (1H, br t, H23) 7.38 (2H, 3JAB = 
2.7 Hz, H12, H14)  7.32 (2H, 3JA’B’ = 2.7 Hz, H11, H13) 6.94 (1H, br t, H28) 5.48 
(1H, s, H7) 4.21 (1H, d, J = 5.7 Hz, H5) 4.13 (1H, d, J = 5.7 Hz, H9) 3.58-3.40 (8H, 
m, H24-25, H29-30) 3.01-2.45 (4H, m, H1-4) 2.34 (2H, t, J = 6.9 Hz, H15) 1.92 
(1H, d, J = 13.1 Hz, H10a) 1.79-1.24 (49H, m, H10b, H16-21, H33-36) 1.24 (3H, t, 
J = 3.2 Hz, H22);δC NMR (67.5 MHz, CDCl3): 174.13, 173.94, 172.09, 171.83, 
163.30, 162.83 (2 carbons) 157.01 (2 carbons), 153.11, 131.42, 126.58, 109.16, 
83.63, 79.87, 79.85, 79.63, 79.60, 44.15, 43.37, 43.34, 40.05, 39.98, 31.93, 31.35, 
29.70, 29.66, 29.36, 28.67, 28.60, 28.06 (3 carbons), 28.04 (3 carbons), 28.03 (3 
carbons), 27.90 (3 carbons), 27.83, 25.36, 24.09, 22.69, 22.55, 19.44, 14.12, 
14.05; HRMS (ESI m/z): calculated for [C50H80N8O12+H]+ 985.59685, found 
985.59313. 
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7-[(3-(beznyloxy)phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-
exo- di-{N-[2-(N’,N’’-di-tert-butoxy carbonyl)-guanidino]-carboxamide} 
(175) 
Method A: Benzyloxy phenyl amine 
143 (72.9 mg, 282.6 μmol); 
dibocthiourea 148 (156.2 mg, 565.2 
μmol); Et3N (28.8 mg, 282.6 mmol); 
NIS 168 (127.2 mg, 565.2 μmol); Rf 
0.43; white viscous oil (26.2 mg, 21%); Method B: Benzyloxy phenyl amine 143 
(94.4 mg, 166 μmol); di-boc triflylguanidine 149 (143.2 mg, 366 μmol); Et3N 
(0.1 mL); Rf 0.71; white viscous oil (135.1 mg, 83%); υmax (thin film/cm-1) 2956 
(m) (methyl C-H) 1720 (m) (aromatic C=C) 1614 (s) (amide C=O) 12518 (s) 
(tertiary amine C-N) 1229 (vs) (benzyl ether C-O) 1131 (vs) (acetal C-O) 807 
(m) (meta substitution on aromatic); δH NMR (270 MHz, CDCl3): 11.47 (1H, br s, 
H25) 11.45 (1H, br s, H30) 8.66 (1H, br t, H24) 8.55 (1H, br t, H29) 8.06 (1H, t, J 
= 2.7 Hz, H21) 7.43-6.95 (9H, m, H11-19) 6.86 (1H, br t, H26) 5.50 (1H, s, H7) 
5.05 (2H, s, H20) 4.22 (1H, d, J = 3.9 Hz, H5) 4.15 (1H, d, J = 3.9 Hz, H9) 3.60-3.36 
(8H, m, H22-23, H27-28) 3.01 (1H, d, J = 5.4 Hz, H2) 2.79 (1H, d, J = 5.4 Hz, H4) 
2.67 (1H, s, H3) 2.52 (1H, d, J = 5.4 Hz, H1) 1.93 (1H, d, J = 7.2 Hz, H10a) 1.61-
1.44 (37H, m, H10b, H31-34); δC NMR (67.5 MHz, CDCl3): 174.00, 171.89, 
163.38, 162.91, 158.83, 157.80, 157.02, 153.16, 137.60, 136.93, 129.51, 128.67, 
128.07, 127.60 (2 carbons), 119.44, 116.03, 112.96, 102.83, 83.68, 83.42, 82.00, 
79.89, 79.65, 79.42, 70.05,47.45, 44.84, 44.15, 43.28, 42.10, 40.03 (4 carbons), 
32.59, 32.02, 29.79 (3 carbons), 28.47 (3 carbons), 28.34 (3 carbons), 28.12 (3 
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carbons); HRMS (ESI m/z): calculated for [C49H70N8O13+H]+ 979.51351, found 
979.51300. 
7-heptyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo- di-{N-[2-(N’,N’’-
di-tert-butoxy carbonyl)-guanidino]-carboxamide} (176) 
Method A: Octyl amine 144 (78.7 mg, 
162.8 μmol); dibocthiourea 148 (99.0 
mg, 358.1 μmol); Et3N (36.5 mg, 358.1 
mmol); NIS 168 (80.6 mg, 358.1 μmol); 
Rf 0.25; white viscous oil (29.4 mg, 
20%); Method B: Octyl amine 144 (99.5 mg, 206 μmol); di-boc triflylguanidine 
149 (177.2 mg, 453 μmol); Et3N (0.1 mL); Rf 0.64; white viscous oil (99.8 mg, 
54%); υmax(thin film/cm-1) 2926 (m) (methylene C-H) 1131 (vs) (acetal C-O) 
1614 (s) (amide C=O) 1228 (s) (tertiary amine C-N) 2856 (m) (methyl C-H); δH 
NMR (270 MHz, CDCl3): 11.48 (1H, br s, H22) 11.45 (1H, br s, H27) 8.63 (1H, t, J 
= 3.5 Hz, H21) 8.51 (1H, t, J = 3.5 Hz, H26) 8.03 (1H, t, J = 2.7 Hz, H18) 6.84 (1H, 
t, J = 3.7 Hz, H23) 4.61 (1H, t, J = 3.2 Hz, H7) 4.03 (1H, d, J = 3.5 Hz, H5) 3.95 (1H, 
d, J = 3.5 Hz, H9) 3.59-3.33 (8H, m, H19-20, H24-25) 2.92 (1H, dd, J = 2.7, 5.4 Hz, 
H2) 2.69 (1H, d, J = 2.7 Hz, H4) 2.56 (1H, s, H3) 2.43 (1H, d, J = 5.4 Hz, H1) 1.77 
(1H, d, J = 6.9 Hz, H10a) 1.60-1.24 (37H, m, H10b, H28-31);δC NMR (67.5 MHz, 
CDCl3): 174.13, 172.03, 163.41, 162.91, 157.82, 157.01, 153.16, 104.06, 83.64, 
83.36, 81.61, 79.85, 79.58, 78.94, 47.65, 44.43, 44.17, 42.98, 42.11, 40.16, 39.95, 
32.92, 32.39, 31.80, 29.76, 29.60, 29.24, 24.46, 28.33 (6 carbons), 28.14 (6 
carbons), 24.27, 22.69, 14.15; HRMS (ESI m/z): calculated for [C43H74N8O12+Na]+ 
917.53184, found 917.53243. 
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7,7-dimethyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo- di-{N-[2-
(N’,N’’-di-tert-butoxy carbonyl)-guanidino]-carboxamide} (177) 
Method A: Di-methyl amine 145 (73.9 mg, 179 
μmol); dibocthiourea 148 (109 mg, 393 μmol); 
Et3N (40 mg, 393 mmol); NIS 168 (88.5 mg, 393 
μmol); Rf 0.25; white viscous oil (41.7 mg, 28%); 
Method B: Di-methyl amine 145 (33.2 mg, 80.3 
μmol); di-boc triflylguanidine 149 (69.2 mg, 176.7 μmol); Et3N (0.1 mL); Rf 0.41; 
white viscous oil (19.3 mg, 29%); υmax(thin film/cm-1) 2978 (m) (methyl C-H) 
1639 (s) (amide C=O) 1366 (m) (tert-butyl C-H) 1154 (s) (tertiary amine C-N) 
1130 (vs) (acetal C-O); δH NMR (270 MHz, CDCl3): 11.46 (1H, br s, H17) 11.43 
(1H, br s, H22) 8.63 (1H, br t, H16) 8.44 (1H, br t, H21) 8.01 (1H, br t, H13) 6.91 
(1H, br t, H18) 4.11 (1H, br d, H5) 4.06 (1H, br d, H9) 3.58-3.39 (8H, m, H14-15, 
H 19-20) 2.92 (1H, d, J = 2.7 Hz, H2) 2.65 (1H, d, J = 2.7 Hz, H4) 2.51 (1H, s, H3) 
2.45 (1H, d, J = 2.7 Hz, H1) 1.77 (1H, d, J = 10.3 Hz, H10a) 1.48 (36H, s, H23-26) 
1.38 (3H, s, H11) 1.24 (3H, s, H12); δC NMR (67.5 MHz, CDCl3): 173.4, 172.92, 
174.1, 172.1, 163.4, 162.9, 157.8, 157.0, 153.1, 109.2, 83.6, 83.3, 81.2, 79.8, 79.5, 
74.5, 47.5, 44.5, 44.0, 43.1, 42.2, 40.1, 39.9, 39.8, 32.1, 29.7, 28.3(6 carbons), 
28.1(6 carbons), 25.4, 24.2; HRMS (ESI m/z): calculated for [C38H64N8O12+H]+ 
825.4716, found 825.47206. 
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7-(parafluorophenyl)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo- di-
{N-[2-(N’,N’’-di-tert-butoxy carbonyl)-guanidino]-carboxamide} (178) 
Method A: Fluoro phenyl amine 146 (100.7 
mg, 210 μmol); dibocthiourea 148 (139.3 
mg, 504 μmol); Et3N (51.4 mg, 504 mmol); 
NIS 168 (113.4 mg, 504 μmol); Rf 0.25; 
white viscous oil (21.3 mg, 11%); Method B: 
Fluoro phenyl amine 146 (68.5 mg, 143 μmol); di-boc triflylguanidine 149 
(123.0 mg, 314 μmol); Et3N (0.1 mL); Rf 0.51; white viscous oil (19.4 mg, 15%); 
υmax(thin film/cm-1) 3330 (br m) (aromatic ring C=C) 1128 (m) (acetal C-O) 
1032 (vs) (fluorine C-F) 816 (m) (1,4-substitution on aromatic C-H); δH NMR 
(67.5 MHz, CDCl3): 11.48 (2H, br m, H17, H22) 8.56 (2H, t, J = 3.5 Hz, H16, H21) 
7.48-7.44 (3H, m, H12, H13) 7.44 (2H, d, 4JF = 5.4 Hz, H11) 7.03 (2H, d, 3JF = 5.4 
Hz, H12) 6.98 (1H, t, J = 3.2 Hz, H18) 5.54 (1H, s, H7) 4.14 (1H, d, J = 3.7 Hz, H5) 
4.10 (1H, d, J = 3.7 Hz, H9) 3.61-3.42 (8H, m, H14-15, H19-20) 2.99 (1H, d, J = 5.4 
Hz, H2) 2.79 (1H, d, J = 5.4 Hz, H4) 2.67 (1H, s, H3) 2.51 (1H, d, J = 5.4 Hz, H1) 
1.90 (1H, d, J = 6.4 Hz, H10a) 1.67 (1H, d, J = 6.4 Hz, H10b) 1.56-1.48 (36H, m, 
H23-26); δC NMR (67.5 MHz, CDCl3): 173.4, 173.2,  172.9, 171.40, 163.5 (1C, d, 
1JF = 246  Hz), 157.3 (4 carbons),  131.7 (1C, d, 4JF = 2.5 Hz) 128.6 (2C, d, 2JF = 7.5  
Hz) 115.4 (2C, d, 3JF = 21 Hz), 102.54, 83.54 (2 carbons), 81.90, 79.6, 77.6 (2 
carbons), 52.2, 45.5, 44.7, 42.9, 40.8 (2 carbons), 40.0 (2 carbons), 31.8, 28.3 (6 
carbons), 28.0 (6 carbons);   HRMS (ESI m/z): calculated for 
[C42H63FN8O12+2H]2+ 447.2402, found 447.24235. 
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Synthesis of guanidine salts 
 
General methodology: The protected guanidines were added to a solution of HCl 
in Dioxane(3 M, 3 mL) and stirred for 8 hours at room temperature. The 
reaction solvent was removed in vacuo, the residue re-dissolved in EtOAc (10 
mL) and transferred to a separatory flask. H2O (3 × 5 mL) was used for 
extraction. The aqueous phases were combined and the water removed through 
sublimation.  
Where analysis using carbon NMR spectroscopy was conducted, it was found 
that signals associated with carbons 1-4 of the norbornane scaffold lay under 
the CD3OD signals as verified by HSQC NMR spectroscopy. 
7-(pentadeca)-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethyl guanidinium chloride (30) 
Hexadeca protected 
guanidine 162 (30.2 mg, 
29.99 μmol); white floss (9.19 
mg, yield: 45%, purity: 98%); υmax(thin film/cm-1) 3062 (s) (methylene C-H) 
2927 (s) (methyl C-H) 1696 (vs) (guanidine·HCl) 1638 (vs) (amide C=O) 1150 
(s) (guanidine·HCl) 1074 (m) (acetal C-O); δH NMR (270 MHz, CD3OD): 5.22 (2H, 
t, J = 2.7 Hz, H7) 4.02 (1H, br d, H9) 3.99 (1H, br d, H5) 3.46 – 3.20 (9H, H2, H27-
28, H33-34) 2.62 – 2.45 (3H, m, H1, H3-4) 1.72 (1H, d, J = 8.1 Hz, H10a) 1.57 – 
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1.27 (H27, m, H10b, H12 24) 0.89 (3H, t, J = 8.1 Hz, H25); δC NMR (67.5 MHz, 
CD3OD): 157.5, 152.0, 130.0, 128.6, 103.7, 84.5, 81.5, 78.6, 62.7, 54.41, 46.3, 
46.2, 45.7, 43.7, 43.6, 41.1, 40.6, 38.4, 37.5, 32.5, 31.7, 31.4, 29.4, 26.9, 23.8, 22.4, 
13.1, 4 carbons under solvent peak from 48.2 – 47.2; HRMS (ESI m/z): 
calculated for [C31H60N8O4]2+ 304.23633, found 304.23596. 
7-[(para-phenyl)phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethyl guanidinium chloride (196) 
Di-phenyl protected guanidine 171 
(28.9 mg, 28.88 μmol); white floss 
(19.28 mg, yield: 99%, purity: 72%); 
υmax(thin film/cm-1) 1656 (vs) (amide C=O) 1591 (vs) (guanidine·HCl) 1091 (s) 
(acetal C-O) 1049 (m) (aromatic C=C); Characteristic peaks in the proton NMR: 
7.61 – 7.33 (H9, m, H11-19) 5.61 (1H, s, H7) 3.75 – 3.73 (2H, br m, H5, H9) 1.86 
(1H, d, J = 8.1 Hz, H10a) 1.49 (1H, d, J = 8.1 Hz, H10b); MS (ESI m/z): calculated 
for [C28H38N8O4-H]+ 549.29, found 549.29. 
7-[(para-bromo)phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethyl guanidinium chloride (197) 
Bromo phenyl protected guanidine 172 
(30.2 mg, 31.78 μmol); white floss (10.93 mg, 
yield: 55%, purity: 86%); υmax(thin film/cm-
1) 3304 (br vs) (primary amine N-H) 1650 
(vs) (amide C=O) 1211 (m) (aromatic C=C) 1071 (s) (acetal C-O) 633 (m) 
(bromine C-Br ); Characteristic peaks in proton NMR: 7.54 (2H, d, 3JAB = 8.1 Hz, 
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H12) 7.39 (2H, d, 3JA’B’ = 8.1 Hz, H11) 5.53 (1H, s, H7) 4.24 – 4.17 (2H, m, H5, H9) 
3.73 – 3.30 (9H, m, H2, H14-15, H20-21) 2.72-2.56 (3H, m, H1, H3-4) 1.88 (1H, d, 
J = 10.8 Hz, H10a) 1.58 (1H, d, J = 10.8 Hz, H10b); HRMS (ESI m/z): calculated 
for [C22H33BrN8O4]2+ 277.09768, found 277.09090. 
7-[(para-octynyl)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-
exo-dicarboxamido ethyl guanidinium chloride (198) 
Octynyl phenyl protected 
guanidine 173 (29.8 mg, 30.3 
μmol); brown floss (18.9 mg, 
yield: 87%, purity:  48%); 
υmax(thin film/cm-1) 1664 (m) (guanidine·HCl) 1648 (m) (amide C=O) 1637 (s) 
(aromatic C=C) 1475 (s) (methyl C-H) 1062 (m) (acetal C-O) 807 (m) (para 
substitution C-H) 733 (s) (-CH2-) 667 (m) (alkyne); Characteristic peaks in 
proton NMR: 7.47 – 7.33 (4H, m, H11-14) 5.53 (1H, s, H7) 4.24 – 4.15 (2H, m, 
H5, H9) 2.73 – 2.56 (3H, m, H1, H3-4) 1.91 (1H, d, J = 10.8 Hz, H10a); MS (ESI 
m/z): calculated for [C30H45N8O4]+ 581.36, found 581.36; [C30H46N8O4]2+ 291.19, 
found 291.18. 
7-phenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-dicarboxamido 
ethyl guanidinium chloride (199) 
Phenyl protected guanidine 158 (19.9 mg, 22.8 
μmol); white floss (18.15 mg, yield: 72% 
purity: 40%); υmax(thin film/cm-1) 1591 (vs) 
(amide C=O) 1352 (s) (aromatic) 1098 (m) (guanidine·HCl) 1078 (m) (acetal C-
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O); Characteristic peaks in proton NMR: 7.45 – 7.34 (5H, m, H11-15) 5.35 (1H, s, 
H7) 2.67 – 1.43 (3H, m, H1, H3-4) 1.85 (1H, d, J = 10.8 Hz, H10a); MS (ESI m/z): 
calculated for [C22H34N8O4-H]+ 473.26, found 473.26. 
7-pyrenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-dicarboxamido 
ethyl guanidinium chloride (200) 
Pyrenyl protected guanidine 174 (24.2 mg, 
24.3 μmol); brown floss (16.4 mg, yield: 
83%, purity: 40%); υmax(thin film/cm-1) 
1970 (s) (aromatic C=C) 1596 (s) (amide 
C=O) 1255 (m) (aromatic C-H) 1150 (m) (guanidine·HCl) 10857 (s) (acetal C-O); 
Characteristic peaks in proton NMR: 7.40-6.92 (9H, m, H11-19) 6.12 (1H, s, H7) 
4.20 – 4.15 (2H, m, H5, H9) 2.72 – 2.55 (3H, m, H1, H3-4); MS (ESI m/z): 
calculated for [C32H38N8O4]2+ 299.15, found 299.15. 
7-[(para-octyloxy)phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-
exo-dicarboxamido ethyl guanidinium chloride (201) 
Octyloxy phenyl protected 
guanidine 195 (28.9 mg, 28.9 
μmol); white floss (19.3 mg, Yield 
97%, purity:  79%); υmax(thin 
film/cm-1) 2924 (m) (methylene C-
H) 1693 (s) (aromatic C=C) 1639 (s) (amide C=O) 1252 (m) (aryl ether C-O) 
1149 (vs) (alkyl ether C-O) 1123 (vs) (guanidine·HCl) 830 (vs) (para 
substitution C-H); δH NMR (270 MHz, CD3OD): 7.38 (2H, 3JAB = 8.1 Hz, H13-14) 
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6.90 (2H, 3JA’B’ = 8.1 Hz, H11-12) 5.50 (1H, s, H7) 4.21 (1H, d, J = 5.4 Hz, H9) 4.15 
(1H, d, J = 5.4 Hz, H5) 3.77 – 3.22 (9H, m, H2, H24-25, H30-31) 2.68 – 2.56 (3H, 
m, H1, H3-4) 1.86 (1H, d, J = 10.8 Hz, H10a) 1.51 (1H, d, J = 10.8 Hz, H10b); δC 
NMR (62.5 MHz, CD3OD ): 164.0, 157.6, 157.5 (2 carbons), 154.1 (2 carbons), 
128.0 (2 carbons), 113.8 (2 carbons), 100.6, 81.7, 78.9, 62.9, 46.2, 45.6, 44.6, 
43.7, 49.5, 40.6, 38.3, 31.5, 29.0, 25.8, 22.3, 17.4, 4 carbons under solvent peak 
from 48.2 – 47.2; MS (ESI m/z): calculated for [C30H50N8O5-H]+ 601.38204, found 
601.38090. 
7-[(para-octyl)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethyl guanidinium chloride (202) 
Octyl phenyl protected guanidine 163 
(29.8 mg, 30.3 μmol); brown floss 
(20.5 mg, yield: 63%, purity: 36%); 
υmax(thin film/cm-1) 2978 (vs) 
(methyl C-H) 2940 (s) (methylene C-
H) 1648 (vs) (amide C=O) 1206 (s) (aromatic C=C) 1151 (s) (guanidine·HCl) 
1073 (m) (acetal C-O) 755 (m) (para substitution C-H); Characteristic peaks in 
proton NMR: 7.47 – 7.32 (4H, m, H11-14) 5.54 (1H, s, H7) 4.06 (1H, d, J = 5.4 Hz, 
H9) 4.00 (1H, d, J = 5.4 Hz, H5) 2.68 – 2.60 (3H, m, H1, H3-4) 1.86 (1H, d, J = 10.8 
Hz, H10a); MS (ESI m/z): calculated for [C30H50N8O4-H]+ 585.39, found 585.38. 
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7-[(meta-benzyloxy)-phenyl]-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-
exo-dicarboxamido ethyl guanidinium chloride (203) 
Benzyloxy phenyl protected guanidine 
175 (29.7 mg, 30.4 μmol); white floss 
(17.6 mg, yield: 89%, purity: 41%); 
υmax(thin film/cm-1) 3138 (s) (aromatic C=C) 1693 (vs) (aromatic C=C) 1638 (s) 
(amide C=O) 1256 (s) (aryl ether C-O) 1147 (m) (guanidine·HCl) 1074 (s) 
(acetal C-O ) 864 (meta substitution C-H); Characteristic peaks in proton NMR: 
5.32 (1H, s, H7) 5.07 (2H, s, H20) 4.19 (1H, d, J = 5.4 Hz, H5) 3.75 (1H, d, J = 5.4 
Hz, H9) 2.67 – 2.41 (3H, m, H1, H3-4)    HRMS (ESI m/z): calculated for 
[C29H40N8O5-H]+ 579.30379, found 579.30393. 
7-octyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-dicarboxamido 
ethyl guanidinium chloride (204) 
Octyl protected guanidine 176 (33.7 mg, 
37.6 μmol); white floss (15.3 mg, yield: 
47%, purity: 98%); υmax(thin film/cm-1) 
3061 (m) (methylene C-H) 2937 (m) (methyl C-H) 1589 (s) (amide C=O) 1153 
(m) (guanidine·HCl) 1124 (s) (acetal C-O); δH NMR (270 MHz, CD3OD): 4.64 (2H, 
t, J = 5.4 Hz, H7) 4.03 (1H, d, J = 2.7 Hz, H5) 3.99 (1H, d, J = 2.7 Hz, H9) 3.59 – 
3.21 (9H, m, H2, H19-20, H25-26) 2.61 – 2.44 (3H, m, H1, H3-4) 1.72 (1H, d, J = 
8.1 Hz, H10a) 1.53 (13H, m, H10b, H11-16) 0.88 (3H, t, J = 5.4 Hz, H17); δC NMR 
(62.5 MHz, CD3OD): 157.48 (2 carbons), 129.09, 128.14, 103.72, 81.46, 78.56, 
46.31, 45.54, 43.73, 40.63, 38.36, 32.48, 31.50, 29.21, 28.92, 23.80, 22.27, 13.00, 
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4 carbons under solvent peak from 48.2 – 47.2; HRMS (ESI m/z): calculated for 
[C23H44N8O4]2+ 248.17373, found 248.17438. 
7,7-dimethyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-
dicarboxamido ethyl guanidinium chloride (205) 
Di-methyl protected guanidine 177 (41.7 mg, 50.6 
μmol); white floss (24.8 mg, yield: 77%, purity: 
61%); υmax(thin film/cm-1) 2956 (vs) (methyl C-H) 
1646 (vs) (amide C=O) 1154(m) (guanidine·HCl) 1065 (m) (acetal C-O); 
Characteristic peaks in proton NMR: 3.78 (1H, d, J = 5.4 Hz, H5) 3.73 (1H, d, J = 
5.4 Hz, H9) 2.69 – 2.56 (3H, m, H1, H3-4) 1.88 (1H, d, J = 10.8 Hz, H10a) 1.49 
(1H, d, J = 10.8 Hz, H10b) 1.37 (3H, s, H11) 1.25 (3H, s, H12);  MS (ESI m/z): 
calculated for [C18H32N8O4+K]+ 463.22, found 463.21. 
7-phenyl-6,8-dioxatricyclo[5.2.1.06,8]decane-2-endo,3-exo-dicarboxamido 
ethyl guanidinium chloride (206) 
Fluoro phenyl protected guanidine 178 (19.4 
mg, 21.8 μmol); white floss (9.3 mg, yield: 
76%, purity: 39%); υmax(thin film/cm-1) 1639 
(vs) (amide C=O) 1150 (s) (guanidine·HCl) 1075 (m) (acetal C-O) 1020 (vs) 
(fluorine C-F) 829 (vs) (para substitution C-H); Characteristic peaks in proton 
NMR: 5.55 (1H, s, H7) 4.05 (1H, d, J = 5.4 Hz, H5) 4.00 (1H, d, J = 5.4 Hz, H9) 2.62 
– 2.26 (3H, m, H1, H3-4) 1.86 (1H, d, J = 10.8 Ha, H10a) 1.47 (1H, d, J = 10.8 Hz, 
H10b);  MS (ESI m/z): calculated for [C22H33Cl2FN8O4]2+ 281.10, found 281.10. 
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Chapter 4 
Convergent methodology 
In the current chapter, a ‘convergent’ methodology for the synthesis of guanidine 
functionalised norbornanes was pursued. With most reactions discussed 
previously in this manuscript, the chapter focuses on the synthesis of amino 
guanidine 208. Unfortunately, the ‘convergent’ methodology proved to be inferior 
and was not used. 
4.1 Previous work 
4.1.1 Rationale 
Before the commencement of the current project, Pfeffer et. al. synthesised and 
tested guanidine salt 31 (Figure 77).145 Compound 31 displayed antibacterial 
activity against P. aeruginosa comparable to Colistin. To synthesise compound 
31, Pfeffer et. al. utilised a convergent methodology to produce the precursor 
162 (Figure 77). 
 
Figure 77 – Structure of compound 162 and the convergent 
methodology devised by Pfeffer et. al.145 
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In the current project, the ‘convergent’ methodology was explored as an 
efficient method of producing guanidine functionalised norbornanes. The key 
requirement for this approach was ethyl amino guanidine 207. 
4.1.1 Synthesis of amino guanidine 207 
 
Scheme 59 – Synthesis of amino guanidine 207 based on 
conditions by Pfeffer et. al. 145, 244 
To synthesise amino guanidine 207, di-boc methylisothiourea 147 was 
utilised.Using the method from the publication of Pfeffer et. al., a solution of di-
boc methylisothiourea 147 in THF was added drop wise to a concentrated 
solution of EDA 87 in THF stirring at 50 °C over 3 hours. The resulting crude 
viscous oil was used in the subsequent amide coupling without further 
purification. 
4.1.2 Synthesis of protected guanidine 162 
 
Scheme 60 – Di-amide coupling with di-carboxylic acid 76 and amino guanidine 207.145 
In the current instance, EDCI 95 and HOBt 97 were used in the coupling of di-
carboxylic acid 76 with two equivalents of amino guanidine 207.145 After 
column chromatography protected guanidine 162 was isolated in a yield of only 
17%. Confirmation of the structure of protected guanidine 162 was completed 
by comparison with literature characterisation.145  
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(a) (b) 
The initial coupling was conducted on a scale of 100 mg. To explore the 
robustness of the reaction, the experiment was repeated on the larger scale of 
500 mg. The proton NMR spectrum of the crude oil from the larger scale 
reaction indicated the formation of the desired protected guanidine 162. 
Unfortunately even after several attempts at purification, the desired product 
could not be separated from the many by-products in the reaction mixture 
(Scheme 61).  
 
Scheme 61 – Failed di-amide coupling between di-carboxylic acid 76 
and amino guanidine 207. 
Having obtained a yield of only 17% on a small scale di-amide coupling and 
experienced difficulties isolating the product from the large scale reaction, 
optimisation of the amide coupling step was attempted.  
4.2 Optimisation of di-amide 
coupling 
For the optimisation studies, di-carboxylic acids 76 and 77 were chosen as test 
substrates (Figure 78). As per previous trials with amide couplings, the coupling 
agents EDCI 92, HOBt 97 were used.  
 
Figure 78 – Structure of (a) di-carboxylic acid 73; (b) di-
carboxylic acid 77. 
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A variety of experiments were conducted exploring the following variables: 
solvent, temperatures, scale (100 mg vs. 500 mg) and finally the effect of 
conventional versus microwave irradiation. Unfortunately, in every instance, 
either the coupling reaction was unsuccessful or the desired guanidines could 
not be isolated in a sufficiently pure state.  
 
Figure 79 – Reactants in di-amide couplings. Amino guanidine 
207 deemed to be the problem. 
The coupling agents and solvents were not the problem as they were purchased 
commercially recently. The amino guanidine 207 was being used crude from the 
previous guanylation reaction and as such, the substance most likely interfering 
with amide coupling was the crude amino guanidine 207. 
4.3 Di-Boc methylisothiourea 147 
In the previous section, amino guanidine 207 was used crude (Scheme 62). The 
guanylation of EDA 87 using di-boc methylisothiourea 147 was reconsidered as 
purification of amino guanidine 207 appeared difficult (amines are not 
normally well seprated using chromatography) and there was a low efficiency 
associated with the guanylation reaction.  
 
Scheme 62 – Previous synthesis of amino guanidine 207. 
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4.3.1 Purification 
Work published by Nicolaou et. al. in the synthesis of integrins (act as cell 
surface proteins facilitating cell to cell adhesion) considered the synthesis of 
amino guanidine 207 using di-boc methylisothiourea 147 and EDA 87 (Scheme 
63).234 The purification of amino guanidine 207 was reported as successfully 
accomplished by column chromatography with the very polar eluent of 20% 
MeOH in EtOAc. 
 
Scheme 63 – Synthesis of amino guanidine 207 in the methodology to produce 
integrin 208. 234 
In the current project, the 20% MeOH in EtOAc elution system was tested for 
purification for the crude amino guanidine 207. Unfortunately, even using 
Nicolaou’s elution system, purification by column chromatography still 
remained difficult with co-elution of products occurring. Several column eluent 
combinations were then trialled using a range of polar solvents such as CHCl3, 
DCM and even isopropanol The only eluent found to give reasonable separation 
was isopropanol however the procedure required lengthy purification times (10 
hours) even with medium pressure which were not ideal.  
4.3.2 Guanylation using di-Boc methylisothiourea 147 
A series of optimisation reactions were conducted to improve the efficiency of 
the guanylation reaction. Changes in solvent, reaction times, reaction 
temperatures, addition of HgCl2 and basic work ups were explored. Despite 
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numerous attempts, the efficiency of the guanylation reaction between di-Boc 
methylisothiourea 147 and EDA 87 was still not satisfactory (Scheme 64).  
 
Scheme 64 – Guanylation with di-Boc methylisothiourea 147 and 
EDA 87 detailing possible products.268 
Since EDA 87 is usually used in a five to seven fold equivalents in the 
guanylation reaction, an excess of EDA 87 was present in the crude reaction 
mixture post work up as well as un-reacted di-boc methylisothiourea 147. Di-
guanylation was a possibility (ethyl di-guanidine 209) as well as 
macrocyclisation resulting in guanidine 210.268 With many by-products, 
purification was difficult.  
 
Scheme 65 – Incorporation of protecting group strategy in guanylation reaction. 
In an effort to deal with competing by-products, a protecting group strategy was 
considered (Scheme 65). By capping one of the free amines on EDA 87, mono-
guanylation of the compound would be ensured. Purification of the protected 
amine would also become easier with a greater variety of non-polar and polar 
solvents available.  
4.3.3 Using Cbz-EDA 89  
Cbz-EDA 89 was selected as the mono-protected EDA to undergo guanylation 
with di-boc methylisothiourea 147. The purpose of using the Cbz protecting 
group was the orthogonality of Cbz to the Boc groups already present on the 
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guanidine. Hence, hydrogenolysis required to remove Cbz from the substrate 
would result in high yields and not affect the Boc groups.  
With Cbz-EDA 89 already in hand (Chapter 2), guanylation with di-boc 
methylisothiourea 147 was trialled using variety of reaction conditions. 
Variations in solvent, temperature and reaction time, microwave irradiation and 
the use of additives were explored.  
 
Scheme 66 – The most efficient conditions derived from the 
optimisation reactions conducted with di-Boc methylisothiourea 147 
and Cbz-EDA 89. 
After numerous reactions, the best yield obtained was still only 36% (Scheme 
66). The result was not surprising considering the poor performance of di-Boc 
methylisothiourea 147 previously in this project. 
Triflylguanidine 149 and di-boc thiourea 148 were selected for trials in 
installing the guanidine moiety on EDA 87 and Cbz-EDA 89 (Table 17). The first 
set of guanylating agents attempted were di-boc thiourea 148 with 
Mukaiyama’s reagent 167 (Entries 1 and 2, Table 17). Unfortunately, these 
experiments did not result in the synthesis of either guanidine 207 or 211. The 
next guanylating agent trialled was triflylguanidine 149 (Entries 3 and 4, Table 
17). The guanylation with EDA 87 was unsuccessful however using Cbz-EDA 89, 
the desired Cbz-amino guanidine 211 was isolated in an excellent yield of 90%. 
The next set of guanylating agents was di-boc thiourea 148 and NIS 168. 
Encouragingly, the di-boc thiourea 148 and NIS 168 combinations also resulted 
in the synthesis of Cbz-amino guanidine 211 albeit in a modest yield of 34%. 
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Table 17 – Trial guanylation using different guanylating agents and ‘activating’ agents. 
 
Entry 
No. Amine Solvent 
Temp 
(°C) Time 
Guanylating 
Agents Yield
* 
1 EDA  DMF r.t. 90 mins 
Mukaiyama’s 
Reagent/di-Boc 
thiourea 
0% 
2 Cbz-EDA DMF r.t. 75 mins 
Mukaiyama’s 
Reagent/di-Boc 
thiourea 
0% 
3 EDA  DCM r.t. 16 h Triflylguanidine 0% 
4 Cbz-EDA  DCM r.t. 16 h Triflylguanidine 90% 
5 Cbz-EDA  
DCM/ 
MeOH 
r.t. 30 mins NIS/di-Boc thiourea 34% 
    * Isolated yields 
The guanylating agents di-boc thiourea 148 and NIS 168 were chosen over 
triflylguanidine 149 as (unlike triflylguanidine 149) di-boc thiourea 149 is 
easily synthesised in one step and NIS 168 is commercially available. The yield 
of 34% however obtained from the use of di-boc thiourea 148 and NIS 168 was 
quite poor and so a series of optimisation reactions conditions were conducted 
in an attempt to increase the yield of the reaction. 
4.3.4 Cbz-EDA 89 and di-Boc thiourea 148 
Following the methodology outlined in the literature, the amine, di-boc thiourea 
148 and Et3N were dissolved in a solution of DCM and MeOH.247 Then NIS 168 
was added and the solution stirred at room temperature.247  
 
Scheme 67 – Optimal reaction conditions for the synthesis of Cbz-
amino guanidine 211 using di-Boc thiourea 148 and NIS 168. 
Variations in temperature time and comparing bench top heating and 
microwave irradiation were explored. The optimal reaction conditions involved 
89 
189 
 
211 207 
stirring a solution of Cbz-EDA 89, di-boc thiourea 148, Et3N and NIS 168 in a 
solution of DCM/MeOH for 16 hours at room temperature and a yield of 78% 
was obtained.  
4.5 Deprotection  
4.5.1 Deprotection  
The next step in the synthesis of the hydrophilic component was the removal of 
the Cbz protecting group from Cbz amino guanidine 211. Cleaving Cbz generally 
proceeds by catalytic hydrogenolysis which in theory is an easily achieved 
process.197 Many attempts were made to remove the Cbz protecting group 
(Table 18). 
Table 18 – Attempts at catalytic hydrogenolysis of Cbz-amino guanidine 211. 
 
Entry 
No. 
Solvent Temp Time Pd  
Species 
Additives Deprotect Ref 
1 MeOH r.t. 16 h Pd/C - No 197 
2 MeOH r.t. 16 h Pd(OH)2
/C 
- No 188 
3 MeOH r.t. 16 h Pd(OH)2
/C 
CH3CO2H No 269 
4 MeOH r.t. 16 h Pd(OH)2
/C 
HCl No 270 
5 EtOH r.t. 16 h Pd/C C6H8 No 271 
6 i-PrOH 80 °C MW 5 mins Pd/C HCO2NH4 No 272 
7 i-PrOH 80 °C MW 15 mins Pd/C HCO2NH4 No 272 
8 i-PrOH 80 °C MW 30 mins Pd/C HCO2NH4 No 272 
9 MeOH r.t. 16 h Pd black - No 273 
10 MeOH r.t. 16 h Pd/C CuCl2 No 274 
There were many unsuccessful attempts at the deprotection of the Cbz 
functional group. The solvent, temperature, reaction time, heterogeneous 
catalyst and hydrogen source were all varied and still there was no indication of 
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successful deprotection. That led to a reasoning that perhaps the guanidine 
substrate 211 was in some way interfering with the catalytic activity of the 
palladium catalyst.  
Catalysts may be deactivated by substances in the reaction vessels that act as 
‘poisons’. The effect is particular severe when the catalyst is in a finely divided 
form and when the metals are deposited on active carbon for support.273 Traces 
of sulphur, phosphorus, nitrogen or mercury are known catalyst poisons.273 In 
the current project, the boc-protected guanidine moiety on compound 211 was 
suspected to be deactivating the catalyst.  
Several groups have studied the complexes that unprotected guanidine forms 
with palladium.274, 275 Gulko et. al. sought to exploit the square planar complexes 
formed by sulphaguanidine and palladium as a method of separation of 
palladium(II) and platinum(II).275 The methodology proved successful achieving 
quantitative separation of palladium and platinum species (Scheme 68). 
 
Scheme 68 – Sulfonyl guanidine ligand on resin 212 interacting with 
PdCl2 213 forming a square planar complex 214.275 
Another group that explored the guanidine and palladium complex was El-
Sonbati et. al. An interesting result from their study was that copper appeared to 
complex with the guanidine moiety as easily as palladium. 274  
Turning back to the deprotection difficulties encountered in this project, 
perhaps protected guanidine of compound 211 could be forming a complex 
with the palladium catalyst. Since El-Sonbati et. al. showed copper could form a 
213 
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stable complex with guanidine, copper chloride was added to the 
hydrogenolysis reaction vessel. The reasoning was that if the guanidine moiety 
would complex with the copper species first, then this would prevent 
complexation with the palladium catalyst, thereby not affecting its catalytic 
activity. So, a solution of compound 211 and copper chloride in MeOH was 
stirred for an hour. Then the palladium catalyst was added and the reaction 
mixture was allowed to stir for 16 hours at room temperature under a hydrogen 
atmosphere. Unfortunately, once again, deprotection was unsuccessful.  
4.5.2 The guanidine-palladium complex hypothesis 
The hypothesis that a guanidine-palladium complex could be interfering with 
the catalytic activity of the palladium catalyst was tested. An interesting study 
conducted by Hirota et. al. involved treating the heterogeneous catalyst with 
EDA 87 for up to 48 hours and then adding protected substrates.276  Hirota et. 
al. showed that O-benzyl and N-Cbz groups were retained whilst reducing olefin, 
acetylene, nitro, benzyl ester and azido residues. Their hypothesis was that EDA 
87 Pd/C formed a rigid five-member chelate (Figure 80) that decreased the 
hydrogenolytic ability of Pd/C. 
 
Figure 80 – Five-member chelate between EDA 89 and 
Pd/C proposed by Hirota et. al.276 
Looking at compound 211, there is the two carbon linker as is present in EDA 
87. It could therefore be possible that compound 211 ‘poisons’ the palladium 
catalyst. To test the hypothesis, norbornene 215 (Figure 81) was selected 
because it contained a number of functionalities that are labile when stirred 
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215 216 217 
with palladium under a hydrogen atmosphere: the alkene and the Cbz functional 
groups.  
 
Figure 81 – Structure of norbornene di-carboxamido ethyl amine Cbz 
215. 
First, the alkene and Cbz functional groups were proved to be labile under 
normal hydrogenation reaction conditions. Hence, a suspension of Pd/C in a 
solution of compound 215 in MeOH was stirred for 16 hours at room 
temperature.  The substrate 216 was formed in a yield of 64%.  
 
Scheme 69 – Parallel hydrogenation and hydrogenolysis of 
compound 215. 
Following the reasoning by Hiruto et. al., if compound 211 ‘poisons’ in a similar 
manner to EDA 87, it should deactivate any hydrogenolytic activity while still 
allowing hydrogenation.  
 
Scheme 70 – Unsuccessful hydrogenation/hydrogenolysis 
A solution of Cbz amino guanidine 211 was stirred with a suspension of Pd/C in 
MeOH for 2 hours. Then test compound 215 was added and the reaction 
mixture was stirred 16 hours at room temperature under a hydrogen 
atmosphere. The Pd/C was removed by filtration. The filtrate was collected and 
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the solvent removed in vacuo. The crude oil obtained was analysed using proton 
NMR spectroscopy.  
 
 
Figure 82 – Proton NMR spectrum at 270 MHz in CHCl3 of (a) di-amine 216; (b) 
protected amino guanidine 211; (c) Cbz-protected norbornene 215. (d) Proton NMR 
spectrum at 500 MHz in CHCl3 of crude oil obtained from the 
hydrogenation/hydrogenolysis test reaction using compounds 211 and 215. 
The proton spectrum indicated that hydrogenolysis of the test compound was 
not successful (Scheme 70). Figure 82 lists a series of spectra for comparison.   
The Cbz protecting groups are still present (strong signals at δ7.34 and δ5.09) 
while it appeared that the alkene signals were gone. 
Furthermore, the signals associated with the amide protons are clearly present 
in the spectrum of the crude oil (δ6.79 and δ6.60). Unfortunately, the rest of the 
peaks are not either the carbamate protons or alkene protons present in test 
compound 215. For more information, analysis using mass spectrometry was 
conducted. 
(a) 
(b) 
(c) 
(d) 
? 
194 
 
217·H 217·Na 
 
Figure 83 – Mass spectrum of crude oil obtained from 
hydrogenation/hydrogenolysis reaction. 
The mass spectrum of the product indicated the presence of norbornane 217, 
where hydrogenation was successfully and hydrogenolysis not. (Figure 84). The 
experiments indicated that it is possible the Cbz-protected amino guanidine 211 
in some way interferes with the normally efficient hydrogenolytic and 
hydrogenating activity of Pd/C. 
 
Figure 84 – Structures of species found in mass spectrum of crude oil. 
Furthermore to achieve successful Cbz deprotection, related examples in 
literature either had longer carbon spacers or used high pressures and acid 
additives which were considered impractical in the current project (Scheme 
71). 277, 278 
 
537.27160 
559.25347 
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218 219 
220 221 
148 207 
 
Scheme 71 – (a) H2, Pd/C, EtOH, 45 mins, r.t., 50 psi, 100%; (b) H2, Pd/C, 
HCl, MeOH, 92%; (c) H2, Pd/C, MeOH, r.t., 16 h, 85%.277-279 
4.6 EDA 89 and di-Boc thiourea 147 
 
Scheme 72 – Synthesis of substrate 207 using EDA 87, di-Boc 
thiourea 148 and NIS 168. 
The preceding two sections led to the conclusion that to synthesise the desired 
hydrophilic substrate 207, that perhaps using an orthogonal protecting group 
may not be the answer. With NIS 168 and di-boc thiourea 148 having a better 
success rate at guanylation then di-boc methylisothiourea 147, these were used 
to synthesise the desired substrate 207 (Scheme 72). 
 
Figure 85 – Section of Proton NMR spectrum of crude sample of compound 207. Impurities 
highlighted in blue. 
After altering reaction times several times, two hours was deemed optimal to 
produce substrate 207. Figure 85 shows the proton NMR spectrum of a crude 
87 
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76 207 162 
sample of compound 207. By using literature characterisation [δ3.34-3.33(m, -
CH2), δ2.76 (t, -CH2)], the ethyl peaks were identified and used to determine the 
purity of the sample.268 Generally, purity was approximately 70% (Figure 85). 
4.7 Final di-amide coupling 
To attach compound 207 to main scaffold, an amide coupling was conducted. 
The amide coupling still resulted in low yields and as before, column 
chromatography was again difficult with impurities constantly co-eluting. 
 
Scheme 73 – Di-amide coupling. 
Having thoroughly explored all the weak steps in the convergent methodology, 
no ideal solution could be reached and thus the convergent approach was 
abandoned in favour of the methodology devised in Chapter 3. 
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4.8 Conclusion 
Chapter 4 concludes the sections concerned with the synthesis of guanidine- 
and amine functionalised norbornanes. Two methods were explored: (i) linear 
synthesis; (ii) Late stage variation. 
 
Scheme 74 – Linear method for the synthesis of amine functionalised norbornanes. 
The linear method for the synthesis of amine functionalised norbornanes 
suffered several disadvantages (Scheme 74). For instance, in the six step 
synthesis, purification by column chromatography was requires three times. 
Since the hydrophobic residues were introduced early in the synthesis, there 
were a multitude of compounds that needed handling through the different 
stages of the synthesis. Finally, the di-amide coupling gave only in poor to 
modest yields resulting in the loss of large amounts of starting material.  
 
Scheme 75 – Late variation of norbornanes. 
31 
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Re-evaluation of the synthetic methodology led to the decision to introduce the 
hydrophobic residues at late a stage as possible. The new synthetic strategy had 
many desirable characteristics. Each step had yields of higher than 85% even 
when conducted on a multi-gram scale. In the six step synthesis, purification by 
column chromatography was only required once. Unfortunately, problems were 
encountered in the deprotection and salt formation step. The acetal functional 
group was not always stable to the conditions used to cleave Boc groups. A 
protocol involving treatment with  an acetyl chloride in MeOH solution and a 
subsequent aqueous wash resulted in amine salts that had purities of 56% - 
100% (8 > 85%).  
 
Scheme 76 – Synthesis of guanidine functionalised norbornanes using amine functionalised 
norbornanes. 
The synthesis of the guanidine functionalised norbornanes proceeded first with 
the guanylation of the amine functionalised norbornanes (Scheme 76). Three 
guanylation agents were evaluated however only di-Boc triflylguanidine 149 
was successful in producing the entire library of desired guanidines. Once again, 
there were problems with the deprotection of Boc groups. Due to the lengthy 
times required for the removal of four protecting groups, purity of some 
‘products’ were as low as 40%.   
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Figure 86 – ‘Convergent’ methodology devised by Pfeffer et. al.145 
Finally attempts were made to optimise the ‘convergent’ methodology 
developed by Pfeffer et. al. (Figure 86). The incorporation of protecting groups 
in the synthesis of amino guanidine 207 appeared to interfere with the catalytic 
efficiency of Pd/C. Pursuit of the ‘convergent’ methodology ceased in light of the 
superior methods developed in Chapter 3. 
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4.9 Experimental 
Known compounds 
The following compounds are known compounds and were prepared using 
literature conditions:  
x Di-Boc methylisothiourea 147.240 
x Di-Boc thiourea 148.246 
x Di-Boc triflylguanidine 149. 249 
x Benzyl 2-aminoethylcarbamate 89 (Cbz-EDA).232 
 [(2-benzyloxycarbonylaminoethyl)carbonimidoyl]bis-, bis-(1,1-dimethyl 
ethyl)ester (211) 
Method A: A solution of di-boc methylisothiourea 
147 (50.6 mg, 174 μmol), Cbz-EDA 89 (33.8 mg, 
174 μmol) in THF (2 mL) was irradiated in a 
microwave for 15 minutes at 80 °C. The reaction 
mixture was diluted with saturated bicarbonate solution (10 mL), transferred to 
a separatory funnel and extracted with EtOAc (3 × 10 mL). The organic phases 
were combined and the solvent removed in vacuo. The crude solid was 
dissolved in hot EtOH (1 mL) and precipitated by slowly adding H2O (2 mL). The 
precipitate was collected using vacuum filtration (27.6 mg, 36%);  
Method B: A solution of Cbz-EDA 89 (862 mg, 4.44 mmol), dibocthiourea 148 
(1.02 g, 3.7 mmol), Et3N (52 μL) and NIS 168 (915 mg, 4.07 mmol) was stirred 
for 16 hours at room temperature. 1 M sodium thiosulphate solution (3 mL) was 
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added and then the mixture was diluted with H2O (10 mL), transferred to a 
separatory flask and extracted with EtOAc (3 × 10 mL) and the organic phases 
were combined and dried with MgSO4. This was filtered and the solvent 
removed in vacuo. The crude brown oil was purified using column 
chromatography [(1:39) Acetone:DCM]. Fractions containing the desired 
compound (Rf 0.41) were combined and the solvent removed in vacuo resulting 
in clear oil. (1.25 mg, 78%);  
 Method C: A solution of Cbz-EDA 8 (26.2 mg, 134 μmol), di-boc triflylguanidine 
149 (52.8 mg, 134 μmol) and Et3N (18 μL) in DCM (5 mL) was stirred for 16 
hours at room temperature. The reaction mixture was filtered by flash 
chromatography through a Celite© frit and the filter cake rinsed with an 
EtOAc/MeOH/Et3N (5:3:2) solution (50 mL). The filtrate was collected and the 
solvent removed in vacuo resulting in light brown oil. This was purified using 
column chromatography [(1:39) Acetone:DCM]. Fractions containing the 
desired compound (Rf 0.41) were combined and the solvent removed in vacuo 
resulting in clear oil. (53.2 mg, 90%); υmax(thin film/cm-1) 3336.44 (br m) 
(secondary amine N-H) 1645.10 (s) (aromatic C=C) 1456.17 (w) (aromatic C=C) 
1368.88 (m) (tert-butyl C-H) 1135.99 (vs) (tertiary amine C-N); δH NMR (270 
MHz, CDCl3): 11.42 (1H, br s, H11) 8.51 (1H, br t, H10) 7.31-7.27 (5H, m, H1-5) 
5.88 (1H, br t, H7) 5.06 (2H, s, H6) 3.53 (2H, dd, J =4.70, 5.43 Hz, H8) 3.36 (2H, 
dd, J = 4.70, 5.45 Hz, H9) 1.49-1.42 (18H, m, H12-13); δC NMR (67.5 MHz, CDCl3): 
163.1, 157.20 156.9, 153.0, 136.5, 128.4 (2 carbons), 127.9 (2 carbons), 83.3, 
79.3, 78.6, 66.6, 41.6, 40.4, 27.99 (3 carbons), 27.92 (3 carbons); HRMS (ESI 
m/z): calculated for [C21H32N4O6+H]+ 437.2395, found  437.23409. 
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Section 4.5 Deprotection difficulties  
N2,N3-bis(2-aminoethyl)bicycle[2.2.1]heptanes-2-endo,3-exo-
dicarboxamide (216) 
To a solution of nornornene 215 (50.8 mg, 192 μmol) in MeOH 
(6 mL), Pd/C (6 mg) was added. This was stirred at room 
temperature under a hydrogen atmosphere until there was a 
complete loss of starting material as judged by TLC. The reaction mixture was 
filtered through Celite®. The filtrate was collected and the solvent removed in 
vacuo. This resulted in viscous clear oil. (33.2 mg, 64%); υmax(thin film/cm-1) 
3290.47 (br s) (amine N-H) 1635.19 (vs) (amide C=O) 537.17 (vs) (amine C-
N);δH NMR (270 MHz, CD3OD): 3.40-2.71 (8H, m, H9-10, H13-14) 2.56-2.26 (4H, 
m, H1-4) 1.74-1.05 (6H, m, H5-6, H7a-b); δC NMR (67.5 MHz, CD3OD): 176.38, 
174.50, 72.22, 60.93, 56.65, 49.8, 43.94, 43.02, 40.50, 40.39, 37.9, 28.98, 23.34; 
MS (ESI m/z): calculated for [C13H24N4O2+H]+ 269.20, found 269.20. 
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Chapter 5 
Disk Diffusion Experiments 
The current chapter provides a discussion of the disk diffusion assays that were 
conducted to evaluate the antibacterial activity of amine functionalised and 
guanidine functionalised norbornane based CAMP mimics. The results from the 
disk diffusion experiments allowed for the selection of a few active candidates to 
be further evaluated in Chapter 6. 
5.1 Introduction 
 
Figure 87 – Structures of amine functionalised and guanidine 
functionalised norbornane based mimics sent for antibacterial testing. 
The next aim of the project was to subject the libraries of amine functionalised 
and guanidine functionalised norbornane salts to antibacterial testing. Figure 87 
lists the twenty-four salts sent for antibacterial testing. It should be noted that 
the samples sent were mixtures (see discussion in Chapter 2 and 3). Since the 
fully degraded product was potentially the diol 135, this compound was also 
sent for antibacterial testing. The purpose of testing diol 135 was to ensure that 
204 
 
135 
differences of antibacterial activity between compounds could be attributed to 
the differences in the hydrophobic regions.  
 
Figure 88 – Structure of diol 135. 
 The compounds were tested using disk diffusion assays at the Monash Institute 
of Pharmaceutical Sciences courtesy of Professor Jian Li. Disk diffusion was the 
method selected for screening of antibacterial activity as it was simple, cost-
effective and allowed for the testing of a large number of compounds in one 
batch.  
A number of bacteria strains, also nominated as ‘ESKAPE’, were selected for the 
antibacterial assays.7, 280 A brief description of each strain follows: 
x Pseudomonas aeruginosa ATCC 27853 
x Pseudomonas aeruginosa 19147 n/m 
x Acinetobacter baumannii ATCC 19606 
x Acinetobacter baumannii 07AC-336 
x Klebsiella pneumoniae ATCC 13883 
x Klebsiella pneumoniae #1 
x Methicillin-resistant Staphylococcus aureus ATCC 43300 
x Vancomycin-resistant Enterococcus faecium ATCC 700221 
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5.2 Bacterial strains 
5.2.1 Pseudomonas aeruginosa ATCC 27853 and Pseudomonas 
aeruginosa 19147 n/m 
The first two strains of bacteria were varieties of Pseudomonas aeruginosa (P. 
aeruginosa).  Pseudomonas aeruginosa is a Gram-negative pathogen usually 
found in soil and when grown in cultures, it has a characteristic blue-green 
colour.281, 282 The colouring of P. aeruginosa allowed for observations of the 
bacteria’s presence in the discolouration of wounds as early as 1850 and was 
first isolated by Carle Gessard in 1882.282 The ATCC 27853 strain is resistant to 
Polymyxin E however the 19147 n/m strain is classified as one of the multi-drug 
resistant variety.283 
Pseudomonas aeruginosa is an extremely hardy bacteria, being able to survive in 
a variety of non-native environments especially in hospitals.281 In fact, humans 
acquire most P. aeruginosa infections whilst staying in hospital.282 In hospitals 
in the USA, P. aeruginosa is the most common strain of bacteria found and is one 
of the leading causes of hospital-acquired pneumonia, urinary tract, surgical site 
and bloodstream infections. Causing more concern now however is the 
emergence of antibiotic resistant strains of P. aeruginosa which are severely 
limiting therapeutic options by medical practitioners.281  
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5.2.2 Acinetobacter baumannii ATCC 19606/ Acinetobacter 
baumannii 07AC-336 
The next two strains of bacteria that were tested were varieties of Acinetobacter 
baumannii (A. baumannii). Acinetobacter baumannii are Gram-negative bacteria 
covering twenty-three different species. It is found ubiquitously in nature and is 
now increasingly associated with severe infections acquired within hospitals.284, 
285 The ATCC 19606 strain is classified as multi-drug resistant still susceptible to 
Colistin. The 07AC-336 strain however is deemed to be Extensive Drug 
Resistance as it is resistant to all antibiotics effective against Gram-negative 
bacteria.286, 287 
Over the last few decades, A. baumannii has been the major cause of healthcare-
associated infections with mortality rates rising to 54% for infections acquired 
whilst in intensive care. Acinetobacter baumannii is another strain of bacteria 
causing grave concerns as antibiotic resistance isolates have been detected 
since the 1970s and infections have become increasingly difficult to treat. 
5.2.3 Klebsiella pneumoniae ATCC 13883/ Klebsiella 
pneumoniae #1 
The next two strains of bacteria that were tested were varieties of Klebsiella 
pneumoniae (K. pneumoniae). Klebsiella pneumonia are Gram-negative bacteria 
classified under the Enterobacteriaeae family and was first identified over a 
hundred years ago as the cause of pneumonia infections within the wider 
community.288 The ATCC 13883 strain is classified as multi-drug resistant while 
still susceptible to Polymyxin E.  
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Since then, K. pneumoniae has found its way into hospitals becoming a common 
pathogen causing urinary tract, bloodstream and pneumonia infection. Also 
cause for concern is that since the 1990s, more and more antibiotic resistant 
strains of K. pneumoniae have been detected making infections increasingly 
difficult to treat. 
5.2.4 Methicillin-resistant Staphylococcus aureus ATCC 43300 
Methicillin-resistant Staphylococcus aureus is by far the most notorious multi-
drug resistant bacteria in the last few decades. More commonly known as just 
MRSA, it is the leading cause of bacterial infections around the world.1, 289 MRSA 
is a Gram-positive pathogen that is resistant to methicillin (a derivative of 
penicillin). MRSA concerns public health officials most and so the development 
of an antibiotic effective against it is of utmost importance.1  
5.2.5 Vancomycin-resistant Enterococcus faecium ATCC 700221 
Enterococcus faecium is a Gram-positive bacteria that is widespread in nature 
and even counts for 1% of the bacteria found in the human intestinal tract.290 
Enterococcus faecium has the ability to survive very harsh conditions having 
stability in extreme temperatures and unaffected by chemical disinfectants.290, 
291 Since Enterococcus faecium has the ability to reside in the human 
gastrointestinal tract for long periods of time, antibiotic resistance has 
developed rapidly.292 Vancomycin-resistant Enterococcus faecium (VRE) is a 
bacterial strain that has developed resistance against the antibiotic Vancomycin. 
VRE is another bacterium that has received widespread attention over the last 
couple of decades.7 It is also the common cause of nosocomial infections ranked 
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second to only MRSA. There exists a need therefore to also develop drugs 
capable of treating infections by VRE. 
5.3 Methodology 
Each of the compounds were weighed and transported to the testing facility 
after being subjected to freeze-drying. Each test compound was dissolved in 
Milli-Q water and ethanol to make up a solution to the concentration of 5 
mg/mL. The solutions were store at 4 °C in a refrigerator. The disk diffusion 
experiments were conducted in triplicate and 50μg of sample was added to each 
disk. Once the experiments were completed, the inhibition zones were 
measured and the compounds compared. 
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5.4 Disk diffusion results 
5.4.1 Amine functionalised norbornane based CAMP mimics 
Table 19 – Disk diffusion results for amine functionalised norbornane based CAMP mimics. Zone in 
nm). Shading indicates antibacterial activity observed. 
 
No. 
 PA 
ATCC 
27853 
PA 
19147n
/m 
Ab 
ATCC 
19606 
Ab 
07AC-
336 
Kp 
ATCC 
13883 
Kp #1 
MRSA 
ATCC 
43300 
VRE 
ATCC 
700221 
137 
 
None None None None None None None 
8 mm 
very 
faint 
145 
 
None None None None None None None None 
143 
 
None None None None None None None None 
138 
 
None None None None None 
14 mm 
very 
faint 
15 mm 
18 mm 
very 
faint 
136 
 
None None None None None None None None 
146 
 
17 mm 
Very 
faint 
None None None 
17 mm 
very 
faint 
18 mm 
very 
faint 
8 mm 
quite 
faint 
None 
140 
 
11 mm 11 mm None None 7 mm None 14 mm 
16 mm 
faint 
144 
 
None None None None None None None None 
139 
 
None None None None None None None None 
134 
 
None None None None 7 mm None 9 mm 
11 mm 
faint 
142 
 
None 11 mm None None 11 mm None 10 mm 
9 mm 
faint 
141 
 
None 10 mm None None 10 mm None 10 mm 
17 mm 
faint 
135 Diol None None None None None None None None 
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5.4.2 Guanidine functionalised norbornane based CAMP mimics 
 
No. 
 Kp 
ATCC 
13883 
MRSA 
ATCC 
43300 
VRE 
ATCC 
700221 
30 
 
None None None 
205 
 
None None None 
203 
 
None None None 
196 
 
None None None 
197 
 
None None None 
206 
 
None None None 
200 
 
None 7 mm None 
204 
 
None None None 
199 
 
None None None 
198 
 
None 7 mm None 
202 
 
None None None 
201 
 
None None None 
     
 
5.5 Discussion 
In the analysis of disk diffusion data, three descriptions of antibacterial activity 
are commonly used.293 Bacteria are considered resistant to a compound if the 
culture grows to the edge of the paper disks soaked in test compound solution. 
Bacteria are classified as susceptible if there is a circular zone around the paper 
disk where the bacteria culture has not grown. Generally, the greater the zone 
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around the paper disk, the more effective a compound is against a strain of 
bacteria. Finally, the third classification is known as intermediate. This is where 
there is a faint ring surrounding the paper disk since there is a lower amount of 
culture growth surrounds the paper disk. Figure 89 shows an agar plate where 
all three classifications of growth have been identified. 
 
Figure 89 – Picture of plate showing the three classifications of activity. 
 
5.5.1 Activity of amine functionalised norbornane based CAMP 
mimics 
 
Figure 90 – Structure of amine 139 (purity: 86%) 
Of all the amine functionalised norbornane based CAMP mimics tested, amine 
140 performed the best with five strains of bacteria showing susceptibility. 
Generally the zones of inhibition were between 7 – 14 mm (Figure 91). Amine 
Resistant Intermediate 
Susceptible 
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141 
(a) (b) 
142 
134 
146 
138 
140 also showed intermediate activity with VRE having a ring approximately 16 
mm (Figure 91) 
 
Figure 91 – Disk diffusion test of (a) MRSA culture featuring the zone of 
inhibition associated with amine 139; (b) VRE featuring a zone of intermediate 
activity associated with amine 139. 
There were a number of other amines that showed activity against at least three 
bacterial strains (Figure 92). The strains of bacteria that showed susceptibility 
to many test compounds were Pseudomonas aeruginosa (multi-drug resistant 
variant) and Klebsiella pneumoniae (multi-drug resistant variant) with most 
compounds having intermediate activity against VRE. 
 
Figure 92 – Structures of other amines that showed activity. 
Amine 
162 Amine 
162 
Purity: 79% Purity: 70% 
Purity: 98% Purity: 85% 
Purity: 65% 
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5.5.2 Activity of guanidine functionalised norbornane based 
CAMP mimics 
 
Figure 93 – Structures of guanidines 198 and 200. 
Unfortunately, only two of the guanidine functionalised norbornanes 
compounds showed activity. Guanidines 198 and 200 were active against 
MRSA. Even then, the susceptibility exhibited was not as strong as some of the 
activity exhibited by the amine counterparts. The lack of activity exhibited by 
the guanidines compounds is likely due to the low purity in certain cases. The 
results obtained from the disk diffusion tests do not then accurately reflect how 
potent the guanidine functionalised norbornanes may be but they certainly do 
not indicate strong activity for the class of compounds. 
 
Figure 94 – Disk diffusion test of MRSA culture showing susceptibility to 
guanidines 200 and 198. 
 
Guanidine 198 
Guanidine 200 
Purity: 35% 
Purity: 59% 
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5.6 Conclusion 
There were a number of active compounds identified. Across both libraries; the 
compounds with the pyrenyl hydrophobic moiety exhibited the most consistent 
antibacterial activity. The rest of the compounds that did exhibit antibacterial 
activity had the common characteristic of an aromatic group as part of the 
hydrophobic region. 
One purpose of testing these compounds was to select candidates for further 
identification of their physicochemical properties (Chapter 6). 
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Chapter 6 
Physicochemical evaluation 
The physicochemical evaluation of several amphiphiles was performed to glean 
insight regarding a potential mode of action. First, the critical micelle 
concentrations of three amine functionalised norbornanes were determined. Next, 
Dynamic Light Scattering was utilised to analyse interactions with ‘human’ and 
‘bacterial’ liposomes. Finally, Isothermal Titration Calorimetry was conducted to 
determine if the compounds were interacting with lipopolysaccharides. 
6.1 Introduction 
Evaluating physicochemical properties is common in medicinal chemistry 
projects. In the current project, three techniques were selected: 
spectrophotometry to determine critical micelle concentration (CMC), Dynamic 
Light Scattering (DLS) to observe interactions with liposomes and Isothermal 
Titration Calorimetry to detect interactions with LPS. 
 
Figure 95 – Structures of amines subjected to physicochemical evaluation. 
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Four amines were selected for testing: amines 146, 142, 134 and 141 (Figure 
95). These four compounds performed the best in the disk diffusion 
experiments being active against at least four strains of bacteria (see Chapter 5).  
6.2 Critical Micelle Concentration 
The critical micelle concentration (CMC) refers to the concentration above 
which the formation of micelles is observed.294, 295 Amphiphiles traditionally 
form micelles in water and it is commonplace to determine CMCs as a number of 
physical properties change above the CMC.296 Figure 96 shows a number of 
physical properties that are concentration dependent and the CMC marks the 
point at which change in behaviour occurs. Surface tension for example steadily 
decreases and past CMC, remains constant.  
 
Figure 96 – Schematic representation of the concentration dependence 
of some physical properties for solutions of a micelle-forming 
amphiphile.296 
An example of influence that CMC exerts on antibacterial activity was observed 
when the group of Chaveriat and Gosselin tested D-galactopyranose derivatives 
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that were synthetically derived (Table 20).297 They found that a decrease in 
CMCs was related to a similar decrease in the compounds’ MICs against Gram-
positive bacteria (compare 222 to 226, Table 20). For the D-galactopyranose 
derivatives, it would seem that developing compounds with low CMCs would 
translate to lower MICs and therefore higher potencies. Furthermore, 
determining a compound’s CMC and MIC may give evidence to the mode of 
action. According to Lichtenberg, the antibacterial activity of a compound 
occurring near or at its CMC may indicate detergent-like mechanisms as part of 
its mode of action against bacteria.298 
Table 20 – CMCs and MICs for D-galactopyranose derivatives.297 
 
No. R CMC (μg/mL) 
MIC (μg/mL) 
Bacillus 
sterothermophilus 
Micrococcus 
luteus 
222 C8H17 3506 >250 >250 
223 C12H25 Did not form micelles >250 >250 
224 (CH2)4OC8H17 109 63 63 
225 (CH2)4OC12H25 10 31 16 
226 CH2C≡CCH2OC12H25 13 8 4 
 
In the current work, the CMCs of amines 146, 142 and 141 were determined. 
The CMC of a compound can be determined by measuring either the testing of 
surface tension299, reverse-phase HPLC300, x-ray and light scattering, NMR or 
spectrophotometry using fluorescent probes.295 In each of the former instances, 
the CMC is determined by plotting different concentrations of the property 
being measured by the instrument.296 In the current project, the use of 
spectrophotometry using fluorescent probes was selected as the method for the 
determination of the CMCs of amines 146, 142 and 141 as it is relatively simple 
and many examples exist where this technique has been used.301, 302 
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6.2.1 Methodology 
Pyrene, the fluorescent probe, is highly hydrophobic and insoluble in water. 
Above the amphiphile’s CMC, the pyrene molecules will be preferentially 
encapsulated in the hydrophobic micelle core.301 Solutions of varying 
concentrations (0.0001 - 5 mg/mL) of amines 146, 142 and 144 were prepared 
using Milli-Q water.302 Then pyrene was added and each suspension was 
sonicated for 30 minutes at room temperature. The suspensions were then 
allowed to stand at room temperature for 16 hours. Immediately prior to 
analysis, each suspension was filtered using a 0.45 micron nylon filter. Steady-
state fluorescence spectra were recorded at room temperature on a Cary Eclipse 
Varian spectrophotofluorimeter using 10 mm slits. Each sample solution was 
excited at 335 nm and the emission spectrum was recorded from 350 to 600 nm 
at 80 nm/min.  
 
Figure 97 – Fluorescence spectra of amine 146 for (a) below the CMC; (b) above the CMC. 
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142 
Visually, it is possible to determine when encapsulation has occurred (Figure 
97). The spectrum recorded proceeds from a ‘sawtooth’ to a ‘smooth’ signal. 
However, in order to precisely determine when encapsulation of the pyrene 
occurs, the ratio is calculated of the first vibronic band (I1) at 386 nm to that of 
the third vibronic band (I3) at 393 nm.301, 302 I1 exhibits a higher fluorescence 
signal in a polar than in a non-polar environment. I3 however is less sensitive to 
changes in the environment. Hence when the I1/I3 ratio of different 
concentrations are plotted, there should be an inflection in the graph denoting 
the point at which pyrene has moved from the hydrophilic environment of the 
aqueous solutions and has been encapsulated in the hydrophobic core of the 
newly formed micelles.302  
6.2.2 CMC calculations 
 
Figure 98 – Structure of amine 142. 
To illustrate how the CMC calculations were conducted, amine 142 was selected 
as an example. A range of concentrations were tested from 3 mg/mL to 0.0001 
mg/mL and the ration of I1 to I3 in the emission was calculated (Table 21). 
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Table 21 – Table of I1/I3 ratios for each concentration. 
Concentration 
(mg/mL) Ratio 
0.0001 0.9436 ± 0.10 
0.001 0.9552 ± 0.20 
0.01 0.9896 ± 0.17 
0.1 1.4168 ± 0.04 
1 1.4958 ± 0.03 
1.5 1.5102 ± 0.002 
2 1.5596 ± 0.01 
2.5 1.5246 ± 0.02 
3 1.6489 ± 0.05 
The data contained in Table 21 was then plotted so as to identify the point of 
inflection denoting when pyrene was encapsulated by the micelles.  
 
Figure 99 – Graph of concentration versus ratio of I1/I3 of pyrene emission. Concentrations ranged 
from 0.0001 mg/mL – 3 mg/mL. 
Data was plotted and the point of inflection identified signifying the CMC of a 
particular compound. The calculations were conducted and the CMCs are stated 
in Figure 100. 
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142 141 
 
Figure 100 – Structures of amines and the CMCs. 
Substituents in the hydrophobic region of an amphiphile will have a substantial 
influence on micelle formation. For example, an increased CMC is generally 
observed when a polar group is incorporated onto the alkyl chain of an 
amphiphile.296 In the current project, amine 141 has a higher CMC than amine 
142 and this can be attributed to presence of oxygen in the hydrophobic region. 
Furthermore, the incorporation of fluorine can have a striking effect on the CMC 
of a compound.296 In this project, this phenomenon was observed as CMC of 
amine 146 was almost fifteen times the CMCs of the other amines.  
Looking back, the disk diffusion assays were conducted at a concentration of 50 
μg per disk (Chapter 5) which works out to be at a concentration substantially 
higher than the three CMCs determined above. Preliminarily, it would therefore 
appear that the activity observed in the disk diffusion assays were based on the 
behaviour of aggregates of the amines instead of monomers. To further explore 
this theory, DLS experiments were conducted.  
 
 
CMC = 0.1008 ± 0.2 mg/mL CMC = 0.1122 ± 0.21 mg/mL 
CMC = 1.5942 ± 0.22 mg/mL 
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6.3 Dynamic Light Scattering 
Liposomes are used extensively in the evaluation of physicochemical properties 
of amphiphilic compounds and may be easily formulated to mimic the outer 
membranes of bacteria. 
 
Figure 101 – Electron micrograph of negatively stained 
phospholipids featured in seminal publication by Bangham and 
Horne.303 
Alec Bangham is credited with the discovery of liposomes having first published 
images collected by electron microscopy of multilamellar phospholipid vesicles 
(Figure 101).303 To physicochemists, Bangham’s discovery “... was the 
membrane equivalent of finding the double helix structure of DNA” (David W. 
Deamer).304 Since then, the use of liposomes has become extensive featuring in 
drug development, membrane mimicry and even cosmetics by Dior and 
Lancôme.304  
An example where liposomes were used to evaluate membrane interactions was 
published by Ramamoorthy and Bhattacharjya.305 Using DLS, they evaluated the 
diameter and polydispersity index (PDI) of solutions of LPS micelles in the 
absence and presence of antibacterial peptides. Ramamoorthy and 
Bhattacharjya correlated changes in micelle diameters and PDI to the 
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interaction of the antibacterial peptides with LPS. They found that in the 
presence of their antibacterial peptides, there was a reduction in aggregation of 
LPS.305 
 
To gain some insight into the interactions of amines 146, 142 and 161 with 
model membranes. Liposomes were assembled, one simulating ‘human’ 
membranes and one simulating ‘bacterial’ membranes. These were compared to 
the behaviour of the detergent TritonTM X-100 known to rapidly disintegrate 
liposomes.306 The two parameters that were closely observed were the 
diameter of micelles and the PDI. 
6.3.1 Sample preparation 
The size of liposomes depends heavily on the method of preparation. The two 
most common sizes are known as Small Unilamellar Vesicles (SUVs) and Large 
Unilamellar Vesicles (LUVs). SUVs are less than 50 nm in diameter and are 
obtained through sonication.307 LUVs are between 50 to 500 nm are prepared 
by extruding stock liposome solution through membranes with pore sizes 
between 50 to 500 nm.307 Although SUVs scatter less light and are more suited 
to analysis by DLS, their bilayer is very strained. Hence, as a model membrane, 
LUVs are considered better suited for the type of analysis to be conducted.307  
Two different types of LUVs were prepared, one that mimicked human cells, 
herein referred to as the ‘human’ liposomes and the other that mimicked a 
bacterial cell membrane, herein referred to as the ‘bacterial’ liposomes. 
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Figure 102 – (a) Structure of lipid POPC 227. (b) Structure of lipid POPG 228. 
To prepare the ‘human’ liposomes, 2-oleoyl-1-palmitoyl-sn-glycero-3-
phosphocholine 227 (POPC) was added to sodium phosphate buffer (10 mM, pH 
= 7.4) to obtain a lipid concentration of 1 mM (Figure 102).308, 309 The stock 
solution of the lipid dispersion was extruded three times using 450 micron 
nylon filter. A series of sample solutions were then prepared where different 
concentrations of amines were added to the ‘human’ liposomes and the samples 
allowed standing for 16 hours.  
To prepare the ‘bacterial’ liposomes, 2-oleoyl-1-palmitoyl-sn-glycero-3-
phospho-(1’-rac-glycerol) (228) (POPG) and LPS isolated from Pseudomonas 
aeruginosa was added to a minimum amount of chloroform to ensure 
dissolution. Nitrogen gas was used to evaporate most of the solvent. The 
resulting residue was then placed under vacuum for a further twenty-four hours 
to ensure all chloroform was removed. Then, Milli-Q water was added to obtain 
a lipid concentration of 1 mM. The ‘bacterial’ liposome solution was then 
extruded three times using 450 micron nylon filters. A series of sample 
solutions were then prepared where different concentrations of amines were 
added to the ‘bacterial’ liposomes and the samples allowed standing for 16 
hours.  
(a) 
(b) 
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Size diameter and size dispersion of liposomes were measured by Zetasizer 
Nano ZS (Malvern Instruments) at a light scattering angle of 173 °. Each 
experiment was conducted at 25 °C and each solution was measured in 
triplicate. The data presented in the following section is an average of the three 
measurements. 
6.3.2 Results  
6.3.2.1 Amine solutions 
Before evaluating the behaviour of the amine functionalised norbornanes with 
respect to either ‘human’ or ‘bacterial’ liposomes, each amine was subjected to 
DLS below and above their respective CMCs (Table 22). 
Table 22 – Peak diameters of particles in the amine 
solutions.  
 
  Diameter (nm) PDI 
 
Below CMC 
(0.80 mg/mL) 
Peak 1: 466 ± 31 
Peak 2: 123 ± 19 
0.81 ± 0.06 
Above CMC 
(3.19 mg/mL) 
611 ± 33 0.27 ± 0.01 
    
 
Below CMC 
(0.015 mg/mL) 
577 ± 35 0.49 ± 0.04 
Above CMC 
(0.33 mg/mL) 
164 ± 46 
 
0.48 ± 0.02 
    
 
Below CMC 
(0.056 mg/mL) 
714 ± 50 0.51 ± 0.2 
 Above CMC 
(1 mg/mL) 
Peak 1: 118 ± 11 
Peak 2: 21 ± 2 
0.32 ± 0.09 
For amine 146, homogeneity increased in the solution above CMC with only one 
population and a decrease in PDI. For amine 142, the diameter of the micelles 
decreased above CMC but PDI remained fairly consistent below and above CMC. 
For amine 141, micelle sizes decreased substantially when above CMC with a 
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decrease in PDI as well. With some information of how the amines behave in 
water below and above CMC, the evaluation of their behaviour with respect to 
liposomes began. 
6.3.2.2 ‘Human’ liposomes 
In the evaluation of physicochemical activity using liposomes, two control 
solutions were tested. The first contained just the relevant liposome and the 
second contained liposome and the known membrane disrupting agent TritonTM 
X-100. Then each amine in concentrations below and above their respective 
CMCs was mixed with the liposomes. Table 23 details the data obtained. 
Table 23 – Peak diameters obtained from testing with ‘human’ liposomes. 
 
  Peak diameter* 
(nm) 
PDI 
 Liposomes with 
no additive 
133 ± 29 0.48 ± 0.1 
    
TritonTM X-100 9.7 ± 0.9 0.33 ± 0.02 
    
 
Below CMC 
(0.80 mg/mL) 
Peak 1: 108 ± 3 
Peak 2: 620 ± 80 
0.32 ± 0.09 
Above CMC 
(3.19 mg/mL) 650 ± 63 0.21 ± 0.08 
    
 
Below CMC 
(0.015 mg/mL) 
Peak 1: 832 ± 60 
Peak 2: 133 ± 27 
0.40 ± 0.1 
Above CMC 
(0.33 mg/mL) 778 ± 10 0.24 ± 0.01 
    
 
Below CMC 
(0.056 mg/mL) 152 ± 9 0.47 ± 0.05 
Above CMC 
(1 mg/mL) 
758 ± 84 
0.49  0.06 
* Peak diameter referes to diameter of liposomes in the measured population. 
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The control solutions of ‘human’ liposomes showed that particle sizes were 
around 133 nm. The test solution using TritonTM X-100 displayed drastically 
reduced particle sizes, an indication that the liposomes had been disassembled. 
 
Figure 103 – Graph detailing the peak diameters obtained from experiments 
involving ‘human’ liposomes with amine 141. 
Selecting amine 141 as an example, Figure 103 compares the peak diameters of 
the control experiments and the solutions containing liposomes and amines. 
From the control experiment, the ‘human’ liposome size is approximately 133 
nm. TritonTM X-100, a known detergent, disintegrates the liposomes and results 
in particles sized around 9.7 nm. Considering the solutions of just amine 141 in 
water, particle sizes are approximately 714 nm below CMC and 118 nm above 
CMC. The solution containing the amine below CMC and the ‘human’ liposome 
shows a particle size of approximately 152 nm. It could be argued that this 
would be the measurement of just the ‘human’ liposomes and not an indication 
of the interaction with the amine. However, in the solution with the amine 
above CMC and the ‘human’ liposomes, a substantial increase of particle size is 
observed with a population of 758 nm observed. It may be argued that the 
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particle size change is evidence of aggregates of amine 141 interacting with the 
‘human’ liposomes by swelling particle size. Nevertheless, no drastic reduction 
in size was noted, tentatively indicating little disruptive effect. 
6.3.2.3 ‘Bacterial’ liposomes 
In the evaluation of the amines with ‘bacterial’ liposomes, once again two 
control solutions were tested. The first contained just ‘bacterial’ liposomes. The 
second contained TritonTM X-100 and ‘bacterial’ liposomes. Then each amine 
solution was tested with ‘bacterial’ liposomes above and below their respective 
CMCs.  
Table 24 – Peak diameters obtained from the testing of ‘bacterial’ liposomes. 
 
  Peak diameter* 
(nm) 
PDI 
 Liposomes with 
no additive 
177 ± 15 0.31 ± 0.07 
    
TritonTM X-100 9.3 ± 0.7 0.58 ± 0.08 
    
 
Below CMC 
(0.80 mg/mL) 147 ± 40 0.23 ± 0.03 
Above CMC 
(3.19 mg/mL) 178 ± 27 0.59 ± 0.1 
    
 
Below CMC 
(0.015 mg/mL) 165 ± 33 0.32 ± 0.05 
Above CMC 
(0.33 mg/mL) 161 ± 10 0.35 ± 0.05 
    
 
Below CMC 
(0.056 mg/mL) 181 ± 23 0.32 ± 0.07 
Above CMC 
(1 mg/mL) 
Peak 1: 316 ± 10 
Peak 2: 135 ± 57 
0.35 ± 0.06 
* Peak diameter referes to diameter of liposomes in the measured population. 
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Figure 104 – Graph detailing peak diameters obtained from experiments involving 
‘bacterial’ liposomes and amine 141. 
Once again, amine 141 was selected as an example compound of liposome 
interaction. Figure 104 compares the diameters of the control solutions and the 
solutions with amines and liposomes. In the solution of amine below CMC and 
‘bacterial’ liposomes, particle size is approximately the same as the control. 
However, the solution containing above the CMC of the amine and ‘bacterial’ 
liposomes show two populations of micelles. The changes in peak diameters 
possibly indicate that some interaction between the ‘bacterial’ liposomes and 
the amine micelles occurred.  
So far the experiments using DLS indicate that the amines interact with 
liposomes primarily above the CMC of the respective compounds. The 
interactions however do not conclusively indicate the amines binding 
preferentially to LPS. For more information about the specific interactions with 
LPS, ITC experiments were conducted. 
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134 146 
6.5 Isothermal Titration 
Calorimetry 
Isothermal Titration Calorimetry (ITC) is an analytical method used to evaluate 
the thermodynamics and kinetics of the interactions between molecular entities 
(host-guest and enzyme substrates).310-314 By accurately measuring the heat 
flow that occurs as one molecule interacts with another using titration, the 
stoichiometry of binding sites (n), the association-binding constant (K), 
enthalpy (H) and entropy (S) may all be determined. Furthermore, using the 
experimental values obtains, the Gibb’s Free energy of the system may be 
calculated. 
 
Figure 105 – Structures of amines that were subjected to ITC analysis. 
For analysis by ITC, two amines were selected: amine 134 and 146. It would be 
interesting to observe behavioural changes between the two molecules. Amine 
134 contains a hydrophobic region that has alkyl and aryl functionality. Amine 
146 however only has aryl functionality. Using ITC, the beneficial effect of the 
larger hydrophobic regions might be confirmed.  
6.5.1 Methodology 
Although there are a variety of ITC instruments, there are core components 
common to all apparatus. An ITC instrument has two cells: a sample cell and a 
reference cell are both encased in cases allowing for a highly regulated 
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environment.315 In the sample cell, there is a stirring syringe (Figure 106). 
When a known concentration of a solution of the compound is added to the 
vigorously stirred solution containing the appropriate ligand, the instrument 
measures the heat signal with respect to the reference cell and plots the signals 
versus time (an isotherm). 
 
Figure 106 – Common core components of ITC instruments.315 
Having already selected the two amines that would be evaluated using ITC, it 
was necessary to choose an appropriate ligand. Since the behaviour of the 
amine functionalised norbornane based CAMPs were evaluated using liposomes 
doped with LPS from Pseudomonas aeruginosa, it was decided that the 
previously used LPS would be the ligand in the ITC experiments. 
Microcalorimetry measurements of the amines either binding or not binding to 
LPS were performed on a MicroCal VP-ITV isothermal titration calorimeter. A 
solution of 0.1 mM LPS in 5 mM HEPES buffer (pH 7.03) filled the 
microcalorimetric cell (volume: 300 μL). Titrations were conducted at 25 °C and 
Stirring syringe containing 
solution of compound 
Reference cell 
containing Milli-Q water 
Inner shield 
Measurement cell  
Outer shield 
Adiabatic 
jacket 
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involved 30 × 2 μL injections at intervals of 120 seconds from a 40 μL syringe. 
The contents of the cell were stirred constantly at 600 RPM.  
In each experiment, it was ensured that the systems equilibrate and a stable 
baseline recorded before titrations commenced. The heat of interaction was 
recorded by the ITC instrument and plotted versus time. Furthermore, the total 
heat signal of each injection was calculated as the area under individual peaks 
and plotted against amine/LPS molar concentration ratio. All ITC experiments 
were conducted in duplicate. 
6.5.2 Results and Discussion 
 
Figure 107 – Structure of amine 134. 
The first compound subjected to ITC analysis was amine 134 (Figure 107). As a 
control, the amine solution was titrated into the 5 mM HEPES buffer (pH 7.0). 
The heats of dilution obtained from the experiment were subtracted from the 
experimental data of the heats of interaction between amine 134 and LPS. The 
corrected data was then subjected to nonlinear least square regression 
analysis(Figure 108).316  
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Figure 108 – Isothermal calorimetric titration of LPS from 
Pseudomonas aeruginosa (0.1 mM) with amine 134 (4.4 mM).  
Experiments found that at an amine concentration of 4.4 mM, the binding 
affinity constant for amine 134 was 8 × 104 M-1 while Polymyxin B (9) exhibits a 
binding affinity of 5.77 × 106 M-1.317 The attraction between Polymyxin B and 
LPS is 100 times stronger than the attraction between amine 134 and LPS. 
Furthermore, binding stoichiometry (n) was approximately 2:1 which indicated 
two amine 134 molecules adhering to the LPS molecule (shown in Figure 109). 
In comparison, the binding stoichiometry of Polymyxin B (9) to LPS is only 
1:1.318  
 
Figure 109 – Schematic representation of amine 133 binding to phosphate groups on LPS molecule. 
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The experiment showed that the potential mode of action in the antibacterial 
activity of amine 134 involved weak interaction with the LPS molecule. The 
information went towards validating the overall project approach of mimicking 
CAMPs. 
 
Figure 110 – Structure of amine 146. 
The next amine subjected to ITC analysis was amine 146. Unfortunately ITC 
experiments indicated there was little or no interaction between LPS and amine 
146.  
 
Figure 111 - Isothermal calorimetric titration of LPS from 
Pseudomonas aeruginosa (0.1 mM) with amine 146 (5.2 mM). 
Both amine 134 and 146 exhibited antibacterial activity in the disk diffusion 
assays. However, according to ITC analysis, the mode of action of amine 134 
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CMC = 1.5942 ± 0.22 mg/mL 
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involves an interaction with LPS in the outer membrane of Gram-negative 
bacteria. Amine 146 did not exhibit interaction with LPS indicating that the 
mode of action responsible for its antibacterial activity must involve other 
interactions. Due to the structural differences of amine 134 and 146, there is a 
tentative observation that perhaps both alkyl and aryl constituents are 
necessary for the interaction with LPS.  
6.6 Conclusion 
The current chapter sought to evaluate the physicochemical activity of a 
number of amine functionalised norbornane based CAMP mimics. 
 
Figure 112 – Structures of amines that underwent physicochemical evaluation. 
The CMCs of three amines (141, 142 and 146) were determined. While the 
CMCs of amine 142 and 141 were approximately 0.1 mg/mL, amine 146 was 
found to have a CMC of 1.6 mg/mL. The larger CMC value was attributed to the 
presence of the fluorine atom in the hydrophobic region of amine 146. 
Next, DLS experiments were conducted evaluating the behaviours of amine 141, 
142 and 146. Unfortunately, only amine 141 exhibited significant interaction 
with the ‘human’ and ‘bacterial’ liposomes. Amine 141 caused significant 
CMC = 0.1008 ± 0.2 mg/mL CMC = 0.1122 ± 0.21 mg/mL 
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swelling of ‘human’ liposomes at concentrations above CMC. Amine 141 was 
also responsible altering particle sizes of the ‘bacterial’ liposomes.  
Finally, ITC confirmed that amine 134 interacted with LPS in a 2:1 ratio. 
Interestingly, amine 134 showed no binding affinity to LPS which confirms 
results from the DLS experiments where there were no interactions of amine 
146 with liposomes. Antibacterial activity was still observed of amine 146 in 
the disk diffusion assays. Hence, the data received in the physicochemical tests 
indicate while amine 146 may act on the Gram-negative bacterial membrane 
through interaction with LPS, amine 146 may elicit antibacterial activity 
through a different mode of action. 
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Chapter 7 
Conclusion and future work 
7.1 Thesis conclusion 
In conclusion, this thesis details the syntheses of novel norbornane based CAMP 
mimics. Preliminary attempts at the synthesis of amine functionalised 
norbornanes lacked robustness and reproducibility. By assembling the common 
sections of the targets first and then introducing hydrophobic groups, a 
methodology for the synthesis of amine functionalised norbornane based 
mimics was developed. The methodology was robust, had high yields at every 
step and did not require chromatography for purification. The methodology also 
allowed for the easy synthesis of a range of amine functionalised norbornane 
based CAMP mimics that varied in the hydrophobic region.  
Unfortunately, in the deprotection and salt formation step, the acetal functional 
group proved to be sensitive to deprotecting conditions. A number of 
deprotection conditions were trialled and some purification was attempted. 
Ultimately, although mixtures were obtained, the amine salts were nonetheless 
determined to be of sufficient purity (8 samples > 85%) to be subjected to 
further analysis.  
The synthesis of the guanidine functionalised norbornanes was accomplished in 
one step from the previously synthesised amine library. Although three 
guanylating agents were evaluated, only di-Boc triflylguanidine 149 allowed for 
the synthesis of the complete guanidine library. Once again, during deprotection 
and salt formation procedures, the acetal functional group was found to be 
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susceptible to degradation. In this instance, degradation proved to be more 
extensive as protected guanidines required longer treatment times. Guanidines 
salts had purities above 70% and all salt mixtures were sent for disk diffusion 
assays.  
In the last section of the synthetic work for this project, a ‘convergent’ 
methodology was explored. Unfortunately, the ‘convergent’ methodology 
proved to be inferior. 
A series of compounds were tested for antibacterial activity using disk diffusion 
assays. Encouragingly, a large number of amines and a few guanidines exhibited 
antibacterial activity. The disk diffusion assays proved a valuable tool for 
selecting ‘hits’ to be further evaluated for their physicochemical activity. The 
candidates were subjected to CMC evaluation, DLS and ITC testing. 
Critical Micelle Concentration analysis demonstrated that the amines were 
capable of forming micelles in water at fairly low concentrations (0.1 – 1.5 mg 
per mL). Dynamic Light Scattering analysis of ‘human’ and ‘bacterial’ liposomes 
indicated interactions occurred between the amines and the membranes. 
Isothermal Titration Calorimetry showed that perhaps some compounds 
exhibited anti-bacterial activity through interaction with LPS and others did not. 
The differences in modes of action were attributed to differences in the 
hydrophobic region of the molecules. 
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7.2 Future work 
There are a number of ways in which the direction of the current project may 
proceed in the future.  
 
Figure 113 – Structure of amine 139. 
The first would be to explore a different link between the hydrophobic region 
and the norbornane scaffold (Figure 113). Since the acetal proved to be 
sensitive to Boc deprotection reaction conditions, other potential linkages 
should be explored, preferably a linkage not sensitive to acidic media and would 
therefore not suffer during the Boc deprotecting reaction conditions (Figure 
114a).  
         
Figure 114 – (a) An alternative linkage to the acetal functional group. 
(b) Greater divide between aromatic functionality and the acetal. 
Degradation only occurred for aryl acetals so if there was a greater separation 
between the aromatic functionality and the acetal, and then compounds would 
not suffer degradation (Figure 114b). 
A future direction of this project would be to subject the hydrophilic region to 
greater variation. One attempt may be to functionalise the guanidine functional 
group (Figure 115). The group of Ōmura et. al. discovered that methylated 
guanidines exhibited greater antibacterial or antifungal activity than non-
(a) (b) 
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methylated guanidines.319, 320 Hence it would be interesting to see the influence 
that functionalisation of the guanidine group may have on the overall 
antibacterial activity of the substrate. 
 
Figure 115 - Structure of future guanidine analogues. 
Finally it may be interesting to pursue more studies to irrefutably establish the 
mode of action. More extensive DLS and ITC testing may aid in elucidation of 
potential modes of action. 
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